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 Abstract 
Injectable Hydrogels for Nucleus Pulposus Replacement 
and Repair of the Damaged Intervertebral Disc 
 
Jennifer Vernengo  
Anthony Lowman, Ph.D. 
 
 
 
 
Researchers have begun to realize the potential benefits of treating intervertebral disc 
degeneration by replacing the nucleus pulposus.  One of the material classes being 
studied for nucleus replacement is the hydrogel, a three-dimensional, hydrated polymer 
network. The development of an injectable hydrogel nucleus replacement would have 
important clinical consequences because it could be injected non-invasively using a 
needle.  Aqueous solutions of poly(N-isopropylacrylamide), or PNIPAAm, have a lower 
critical solution temperature (LCST) between room and body temperature, making it 
suitable for an injectable implant material.  Aqueous polymer solutions could be injected 
as a free flowing liquid at 25°C and solidify to a gel within the body at 37ºC.   
 
At physiological temperatures, PNIPAAm homopolymer gels hold little water and show 
poor elastic recovery. In the work, the swelling and mechanical properties of PNIPAAm 
gels are tailored by polymerizing NIPAAm in the presence of poly(ethylene) glycol 
dimethacrylate (PEGDM), thereby creating PNIPAAm-PEG branched copolymers. The 
effect of PEG molecular weight and NIPAAm/PEG molar ratio on the water content, 
stiffness, and elasticity of the hydrogels was determined.  In addition, a suitable material 
candidate for nucleus pulposus replacement was chosen from this class of hydrogels.  The 
copolymer formulation was optimized to minimize implant water loss following 
 xi 
implantation into the intradiscal environment, allowing the implant to remain space 
filling in the nuclear cavity.  Bioadhesive properties were then imparted to the hydrogel 
system by blending it with the amine containing polymer poly(ethylene imine) (PEI).  
After gelation in the disc, the implant will be crosslinked with itself and with the 
surrounding tissues by the injection of a dialdehyde.  This approach will help secure the 
implant in place, reducing the risk of implant migration or extrusion.  The bioadhesive 
material also has the potential to function as tissue adhesive for the repair of the damaged 
annulus fibrosis. 
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Chapter 1 - Introduction 
 
Lower back pain, one of the most common pain conditions in the western world, is 
responsible for significant economic and social costs.  In the United States alone, it 
accounts for more than sixty billion dollars annually in health care costs 1.  One of the 
major causes of lower back pain is intervertebral disc degeneration 2.  Disc degeneration 
is the result of damage to or dehydration of the nucleus pulposus, which reduces its 
hydrostatic pressure on the internal surface of the annulus fibrosis. This reduced 
hydrostatic pressure results in abnormal compressive stresses on the annulus, potentially 
causing tears, cracks and fissures after repeated loads.  Back pain can develop as a result 
of nucleus tissue migrating through the annulus and impinging on nerve roots 2,3.  
 
Currently, the most common surgical treatment for the degenerative disc is spinal fusion 
4
, but this causes loss of spinal mobility and increases stress on adjacent discs, 
accelerating degeneration of these joints 3,4.  Total disc arthroplasty is emerging as a 
viable alternative to fusion because more spinal motion is retained 4.  However, because 
these treatments involve highly invasive surgeries, a promising alternative is the 
replacement of the nucleus pulposus alone.  There are several pre-formed polymeric 
implants currently under investigation for nucleus pulposus replacement. While some of 
these materials are promising, using an in situ forming nucleus replacement could have 
important clinical consequences, because it can be injected non-invasively using a small 
gauge needle.  
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In situ gel formation can be achieved using the thermo-responsive polymer poly(N-
isopropylacrylamide) (PNIPAAm).  Aqueous solutions of PNIPAAm undergo a phase 
transformation at its lower critical solution temperature (LCST), typically around 32ºC, 
allowing it to form a free flowing solution in water at ambient temperatures and a gel at 
body temperature 5. This property makes it ideal for an injectable nucleus pulposus 
replacement.  
 
This work focuses on designing an in situ forming PNIPAAm-based polymeric nucleus 
pulposus replacement.  Because the PNIPAAm homopolymer holds little water and 
shows poor elastic recovery, the swelling and mechanical properties of PNIPAAm gels 
are tailored by polymerizing NIPAAm in the presence of a small amount of 
poly(ethylene) glycol macromers, thereby creating PNIPAAm-PEG branched 
copolymers.  It is hypothesized that a suitable candidate from this class of materials can 
be developed, which upon implantation, could prevent or postpone the annular 
degeneration process by restoring the healthy biomechanics of the intervertebral disc and 
alleviate the pain associated with degenerative disc disease. 
 
The work will begin with the synthesis of a class of hydrogels composed of PNIPAAm 
and PEG.  The molecular weight of the PEG chains and the relative proportions of 
NIPAAm and PEG units will be varied.  Then, the range of pertinent material behavior 
for the PNIPAAm-PEG family of copolymers, and how it varies with polymeric structure 
will be examined.  Based on these characterization studies, a material candidate which 
exhibits suitable, stable material properties will move on for further evaluation as a 
 3 
material candidate for nucleus pulposus replacement.  The copolymer formulation will 
then be optimized to minimize water loss and subsequent volume loss, following 
injection into the intradiscal environment due to the de-swelling of the polymer network.  
Finally, the copolymer chemistry will be modified to impart bioadhesive properties to the 
hydrogel system.  This will help secure the implant in place, reducing the risk of implant 
migration or extrusion.  With these bioadhesive characteristics, the material will also 
have the potential to perform as a closure material for the repair of annular defects. 
 4 
 
Chapter 2 - BACKGROUND 
 
2.1 Anatomy of the Spine 
 
The back, or dorsum, is the posterior part of the body and includes the skin, muscles, 
vertebral column, spinal cord, nerves, and blood vessels 6.  The vertebral column consists 
of 24 moveable vertebrae (Figure 2.1), 7 cervical, 12 thoracic, and 5 lumbar.  Below the 
lumbar vertebrae are 5 sacral vertebrae, which in the adult body, fuse to form the sacrum.  
The three to five lowermost vertebrae fuse in late adult life to form the coccyx.  These 
bones are joined together by a series of joints to form the vertebral column 7.   
 
The main functions of the human spine are to support the body, protect the spinal cord 
and spinal nerve roots, and allow for movement of the trunk.  These functions are carried 
out not only by the vertebrae, but the soft tissues surrounding them.  The adult vertebral 
column has several visible curves.  The cervical and lumbar regions are anteriorly 
convex, and the thoracic and sacral areas are posteriorly convex.  The spinal curves are 
able to dissipate loads more efficiently than if the spine were a straight column 7. 
 
A typical vertebra may be divided into three main regions: the vertebral body, the 
pedicles, and the posterior elements (Figure 2.2) 8.  The anterior part of each vertebra is a 
large block of bone called the vertebral body.  The pedicles connect the back of the 
vertebral body to the posterior elements 8.  The posterior elements consist of the lamina, 
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superior articular arch, inferior articular, transverse, and spinous processes (Figure 2.3) 7.  
The lamina are formed from projections of bone extending from the pedicles.  Two 
lamina meet one another to form the neural arch, which houses the neural elements of the 
vertebral column.  The right and left inferolateral corners of each lamina extend 
downwards to form a large mass of bone called the inferior articular process.  Similarly, 
the superior right and left portions of the lamina extends upwards to form the superior 
articular process.  Each of these four processes possess a smooth region on the surface 
covered by articular cartilage, known as the articular facet of each process.  Projecting 
posteriorly from the junction of the two lamina is a blade of bone called the spinous 
process.  These bones form visual projections under the skin.  Extending laterally from 
the junction of the pedicle and the lamina is a flat bar of bone called the transverse 
process8.   
 
The vertebral body is designed to impart load-bearing characteristics to the vertebrae.  
The flat superior and inferior surfaces of the vertebral bodies contribute to the stability of 
the vertebrae under longitudinal, or compressive, loads.  Its internal architecture also 
contributes to its ability to support weight.  The bone in this region is composed of an 
outer layer of dense cortical bone and a core of spongy cancellous bone.  While the 
cortical bone allows the bone to sustain static loads, the cancellous bone makes the 
vertebral body resilient, or able to withstand sudden and dynamic loading.  The 
cancellous bone is composed of thin rods of bone called trabeculae that extend in the 
vertical and transverse directions.  Applied compressive loads are first supported by the 
vertical trabeculae and are then transferred to the horizontal trabeculae in transverse 
 6 
tension 8.  Both the vertical and transverse trabeculae increase in numbers after prolonged 
or increased compressive loading.  Also, the transverse diameter of the vertebral bodies 
increases from the cervical to the lumbar regions of the spine, resulting from the fact that 
the latter carries a greater load.  The width then diminishes from the first sacral segment 
to the tip of the coccyx 7.   
 
The spaces between the trabeculae serve as channels for blood supply 8.  Small veins are 
present in the superior and inferior parts of the vertebral body.  These smaller veins enter 
into larger tributaries in the center of the vertebral body, forming a dense network of 
veins.  The cortical bone also contains small veins and nutrient arties, as well as some 
nerve endings 7.   
 
Because there are no mechanisms on the surfaces of the vertebral bodies that prevent 
sliding and twisting motion, the vertebral bodies are dependent on the posterior elements 
for stabilization in the horizontal direction.  The inferior articular processes form hooks 
that lock into the superior articular process of the vertebra below, forming a locking 
mechanism that prevents sliding.  The posterior elements are designed to receive the 
dynamic forces placed on the spine.  Loads on the processes are eventually transmitted to 
the pedicles and, eventually, the vertebral bodies. In addition, the posterior elements 
provide areas for muscle attachments, so muscle forces are transmitted to the posterior 
elements and then to the vertebral bodies through the pedicles 8. 
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Because the pedicles play such an important role in transmitting all forces to the vertebral 
bodies, they must possess a structure which enables them to resist bending, tension, and 
compression 8.  Interestingly, the amount of cortical bone on the pedicles varies from one 
region of the spine to the other, being higher in regions which are subjected to more 
motion.  The middle cervical and upper lumbar pedicle regions contain more cortical 
bone than the thoracic regions.  The pedicles in the thoracic region are composed mostly 
of cancellous bone 9.  These trends may be explained by the fact that there is less spinal 
motion in the thoracic region. 
 
Adjacent vertebral bodies are separated by a layer of strong yet flexible soft tissue, called 
the intervertebral disc.  This tissue is strong enough to sustain weight yet can deform to 
accommodate rocking motions 8.  It also helps to carry compressive loads placed on the 
spine 7 and transfer loads to the vertebral bodies 8. It has been suggested that its 
mechanical efficiency improves with use 10.  Applied stresses affect cellular activity, so 
the disc can remodel itself to minimize that stress 11.  However, the extent to which 
remodeling is possible may be limited, and high stresses are also thought to lead to disc 
degeneration 12.  The shape of the disc is determined by the shape of the adjacent 
vertebral bodies.  Also, the thickness of the discs varies with spinal level.  The discs are 
thickest in the lumbar region and thinnest in the thoracic region.  The discs of the cervical 
and lumbar regions are thicker anteriorly than posteriorly, while thoracic discs have a 
constant thickness throughout 13. 
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The main components of the disc are water, proteoglycans, and collagen 7.  Proteoglycans 
are molecules consists of several glycosaminoglycan (GAG) chains covalently linked a 
core protein.  GAGs are a class of chemicals present in most forms of connective tissue, 
such as skin, bone, cartilage, and tendons.  They are long chains of polysaccharides, 
which consist of a repeating sequence of two molecules, a sugar and a sugar with an 
amine attached.  The GAGs found in the intervertebral disc are principally chondroitin-6-
sulphate, chondroitin-4-sulphate, keratin sulphate, and hyaluronic acid.  As many as 60 
GAGs can be attached to the core protein.  Proteoglycans can aggregate when several of 
them link to a chain of hyaluronic acid.  However, proteoglycans that do not aggregate 
with hyaluronic acid are the major proteoglycans that occur in the disc.  These 
proteoglycans play a key role in allowing the disc tissues to attract and retain water 8. 
 
The fundamental unit of collagen is the tropocollagen molecule 8.  A tropocollagen 
molecule consists of three polypeptide chains that are twisted around one another in a 
helical fashion and held together by hydrogen bonding 8.  When these molecules align 
side by side, a collagen fibril is formed.  Aggregates of collagen fibrils form a collage 
fibre 7.  There are 19 different types of collagen, differing in chemical composition and 
structural arrangement.  The types of collagen found in the disc are predominantly type I 
and II, which have the helical structure described above 8.  These rope-like molecules 
give the disc its ability to withstand forces and loads 7. 
 
The disc is composed of three basic structures: a central nucleus pulposus, a peripheral 
annulus fibrosis, and two layers of cartilage covering the top and bottom called vertebral 
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endplates (Figure 2.4) 8.  These components differ in the arrangement of proteoglycans 
and collagen in the tissue, as well as the relative concentrations of each.  In healthy discs, 
the nucleus is a fluid like mass of mucoid material 8.  The nucleus is thickest in the 
lumbar region and thinnest in the thoracic region.  It is most centrally placed in the 
cervical region and is more posteriorly placed in the lumbar region 10.  The nucleus 
pulposus is approximately 80% water in youth and gradually dehydrates beginning 
between ages 20 and 30 2.  Proteoglycans comprise about 65% of the dry weight of the 
nucleus 14.  Only about 25% of these proteoglycans exist in the aggregate form.  About 
20% of the dry weight of the nucleus is composed of collagen.  Bundles of type II 
collagen help to hold the proteoglycan matrix together 15.   
 
The main component of the annulus fibrosis is water, accounting for 70% of its weight.  
About 60% of the dry weight of the annulus is composed of type I and type II collagen 
fibres, arranged in concentric sheets called lamellae. The lamellae are thickest toward the 
center of the disc 16.  Posteriorly, they are finer and more tightly packed, so the posterior 
of the annulus is thinner that the anterior 17.  In the lumbar region, the fibres run parallel 
to one other at a 65º angle with the vertical plane, although the direction of the lamella 
can vary from person to person 10.  The spaces between lamellae are filled with 
proteoglycan gel which binds the collagen fibres together 8.  These proteoglycans make 
up about 20% of the dry weight of the annulus.   
 
The vertebral endplates are attached to both the disc and the adjacent vertebral body.  
They are approximately 1mm thick peripherally and 3mm thick centrally 7.  The chemical 
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structure of these plates resembles that of the nucleus pulposus and the annulus fibrosis 
because they are composed of proteoglycans and collagen fibers.  Directly above the 
nucleus, the endplate contains more proteoglycans than collagen.  However, at the 
periphery of the endplates, the opposite is true 8.  The inner lamellae of the annulus attach 
to the vertebral endplate and the outer lamellae anchors itself to the cortical bone that 
exists on the rim of the vertebral body 7.  Even though the disc tissues are attached to the 
endplates, the endplates are only weakly attached to the vertebral bodies.  For this reason, 
the  endplates are considered part of the disc, instead of part of the vertebral body 18.   
 
The mature human intervertebral disc has a very low density cell population compared to 
other tissues in the body.  Cells occupy approximately 0.25-0.5% of the tissue volume in 
the disc.  The cells in the nucleus and inner annulus are chondrocyte-like and round 19.  
On the other hand, the cells in the outer annulus are thin and extend along the collagen 
fibrils 20.  In the endplates, chrondocytes are aligned along the collagen fibrils, too 8.  The 
chondrocytic cells are responsible for the synthesis of proteoglycans and collagen in the 
disc, as well as proteases, which degrade old proteoglycans and collagen 8.  The health of 
these cells is vital to the disc because degeneration will ultimately occur if the rate of 
tissue breakdown increases over the matrix synthesis rates 21.  
 
Cell activity requires oxygen, glucose, and other substrates necessary for tissue synthesis.  
However, the disc is the largest avascular tissue in the body, since cells are located 6-8 
mm from the nearest blood supply.  Nutrients are supplied to the outer annulus via blood 
vessels at its periphery 22.  The inner annulus relies on nutrients supplied from capillary 
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beds in the vertebral body, which terminate at the vertebral endplate 23.  Small solutes 
such as oxygen, glucose, and lactate diffuse through the endplate in order to enter the 
center of the disc 22.   
 
One key feature of the disc is its ability to maintain a high water content, even under 
compressive loads.  This ability is attributed to the high osmotic pressure exerted by the 
proteoglycans in the tissue 24.  The osmotic pressure of the proteoglycans is mainly 
attributed to the ionic carboxyl and sulfate radicals on the GAG chains, which impart a 
high negative fixed charge to the tissue matrix.  Positively charged molecules are 
attracted into the tissue to balance the negative charge of the GAGs.  The osmotic 
pressure generated by this ion flux is responsible for the ability of disc tissue to attract 
and retain water.  The size of the GAG chains has little effect on the osmotic pressure of 
the disc tissues.  In fact, the water binding capacity of the proteoglycans has been shown 
to be proportional to their concentration, which increases from the outer to inner annulus 
8
, and is highest in the nucleus pulposus 21 .   
 
The water content of the disc not only depends on proteoglycan concentration, but the 
pressure applied on it under loading 21.  In human lumbar discs, the pressure inside the 
nucleus is lowest when laying prone, at 0.1-0.2 MPa, and increases by 5-8 times when 
standing or sitting 25.  The disc fluid is expressed as pressure increases and under 
sustained loads, however this fluid loss occurs very slowly.  The proteoglycans account 
for the fine pore size of the disc tissues, which restricts fluid flow under compression 26.  
Thus, the disc water content rarely achieves equilibrium 21.  Approximately 20-25% of 
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the disc water is expressed during daily loading, but this water is regained during a 
night’s rest 27.   
 
2.2 Intervertebral Disc Biomechanics 
 
It has been shown experimentally that the annulus can support briefly applied 
compressive loads and transmit them to adjacent vertebrae without the nucleus pulposus 
10,28
.  Its densely packed collagen lamellae make the annulus a relatively stiff body, and 
the collagen fibres are prevented from buckling due the presence of the proteoglycan gel.  
However, if the annulus is subjected to sustained loads, the proteoglycan gel will not be 
strong enough to prevent deformation.  The fibres will start to buckle and annulus will be 
slowly squashed 8.   
 
The primary function of the nucleus pulposus is to provide a bracing mechanism for the 
annulus under sustained loads.  Because of its low hydraulic permeability, the nucleus 
volume initially will not be compressed under vertical loading.  Instead, it deforms by 
expanding radially, exerting a hydrostatic pressure on the annulus, and pushing its 
collagen lamellae outwards.  The annulus fibres resist this stretch, and exert an opposing 
force on the nucleus.  Vertical loads are then transferred to the annulus by the nucleus in 
circumferential tension, preventing the fibers from buckling under sustained loads. 2,8.  In 
addition, because the annulus is stiff enough to resist bulging, nucleus deformation in the 
radial direction is limited.  This results in increased vertical pressure against the 
endplates.  This pressure serves to transmit part of the applied load to the adjacent 
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vertebral bodies, lessening the weight on the annulus.  Ultimately, however, the load is 
fully transmitted to the adjacent vertebrae 8.  
 
Another characteristic of the healthy disc is its elasticity. It has the capacity to store 
energy.  When the expanding nucleus pushes the fibres in the annulus outwards, they 
stretch like springs due to the elasticity of the collagen.  Once the load is released, the 
elastic recoil of the collagen fibers allows the energy stored in them to be transferred the 
nucleus, aiding it to restore any deformations caused by the loading 8.   
 
Together, the nucleus and annulus also act as a shock absorbing system for the vertebrae.  
When a compressive force is rapidly applied to the disc, it is first transferred to the 
annulus in the tension, before being transmitted to the vertebral bodies.  While this does 
not lessen the magnitude of the force, slowing the rate at which it is transferred to the 
vertebrae will help protect the bones 8.  The shock absorbing capacity of the disc lessens 
when the same disc is loaded repetitively.  Movements such as jumping or subtle 
bouncing, which may be experience during driving, are associated with disc injury 7.   
 
The fluid property of the nucleus pulposus is essential for maintaining synergy between 
itself and the annulus fibrosis.  Its high swelling pressure is the basis for the healthy 
biomechanical function of the disc.  The normal mechanical function of the disc will 
depend on the ability of the nucleus to attract and maintain water.  Any changes in the 
proteoglycan concentration or water content of the disc tissues will alter the mechanical 
properties of the disc 8.   
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In traction, sliding, and twisting movements the annulus acts as a ligament, helping to 
stabilize the spine by restraining movement.  During traction, the collagen fibres in the 
annulus are all pulled an equal vertical distance from the vertebral body.  The annulus 
resists this strain.  The capacity of the disc to resist this strain is illustrated by how well 
the spine can sustain the load of the trunk and legs when one is hanging by the hands 8.  
Even under traction, however, the spine is still under some compressive load due to 
muscle action 7.  In slide movements, the fibres that line parallel to the direction of 
movement will be strained and thus provide resistance to movement.  Twisting is also  
only resisted by the collagen fibres inclined in the direction of movement.  Movements 
such as these, which cause half of the annulus fibers to be stretched while the other half 
stays relaxed, are most likely to cause injury to the disc 8.   
 
2.3 Intervertebral Disc Degeneration 
 
Decreases in nutritional supply to the disc due to structural changes in the vertebral 
endplates are thought to be a major cause of disc degeneration 29.  As a result of aging, 
the blood vessels in the vertebral bodies become gradually occluded 30, resulting in a 
decrease in nutrients delivery to the disc.  Nutrient transport may also be inhibited by 
endplate calcification, which also naturally occurs in aging discs 29, as well smoking and 
vibration 31.  This impaired nutrition to the cells in the disc may be the underlying cause 
for biochemical changes seen as the result of degeneration 8  
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With aging, the rate of proteoglycan synthesis decreases.  In early adulthood, 
proteoglycans comprise approximately 65% of the dry weight of the nucleus 14, but this 
drops to 30% by age 60 32.  The proteoglycans that are synthesized are generally lower in 
molecular weight 33.  In addition to their molecular weight, the chemical nature of the 
proteoglycans changes with age.  The concentration of chondroitin sulphate GAGs falls, 
while keratin sulphate content stays the same.  Because chondroitin sulfate possesses 
both sulphate and carboxyl radicals, it has twice the water binding capacity of keratin 
sulfate, which only carries one sulphate radical.  The water binding capacity of the tissue 
therefore decreases with the drop in chondroitin sulphate content 34.  In addition, the 
frequency of collagen-proteoglycan binding increases 35, leaving fewer ionic groups on 
the proteoglycans available to attract water 36.  Because of these biochemical changes, the 
disc tissues dehydrate with age.  In fact, by age 75, the water content of the nucleus can 
drop to as low as 65% 14.  Added to this fluid loss, the disc tissues exhibit increasing 
hydraulic permeability with age, so water loss will occur more quickly under loading 37. 
 
The overall collagen content of the disc also increases with age 38.  Type X collagen is 
found in aged discs, and may be connected to calcification of the disc tissues 39.  The 
fibre diameter of the type II collagen in the nucleus pulposus increases, making it 
resemble the type I collagen in the annulus 38.  The collagen fibre diameter in the annulus 
decreases, making it resemble the type II collagen in the nucleus 40.  This may be one 
reason that the boundary between the nucleus and the annulus become indistinguishable 
with age.  Also, the annular rings thicken and become more disorganized 18.  The tensile 
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strength of the collagen decreases as well 41, making the disc tissues more susceptible to 
injuries associated with daily movements.   
 
These fundamental biochemical changes alter the biomechanical behavior of the disc and 
can initiate a degenerative cascade, ultimately leading to back pain.  The dehydration of 
the nucleus results in an overall volume loss, making it less able to exert a fluid pressure 
on the annulus when it is compressed 42.  In other words, the nucleus loses its ability to 
transmit weight directly to the annulus 8, altering the uniform load distribution 
characteristic of healthy discs 43.  The annulus then bears a greater portion of any load 
placed on the disc 8,43.  Repeated stresses cause the lamellae to buckle 8 and annular 
fissures to form 2,8,21.  These defects reduce the weight bearing capacity of the annulus, 
leading to further tearing and loss of tissue integrity 44.  Some finite element models have 
shown that loss of nucleus volume can lead to inward bulging of the annulus during 
compression 45.  This increases the shear stresses between the lamellae 46 and tears the 
layers apart 47.  
 
The nucleus may then migrate from the center of the disc, and perhaps eventually through 
all layers of the annulus, resulting in disc herniation. Consequently, the nucleus is no 
longer sheltered from the immune system, causing an inflammatory response from the 
body.  Studies on human patients have shown that herniations attract macrophages, 
fibroblasts, and lymphocytes 48.  A variety of inflammatory chemicals are also produced, 
such as phospholipase A2 49 and interleukin 12 50.  The presence of chemical pain 
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mediators activates nociceptors, which send the signals to the spinal cord and brain to 
cause back pain 51. 
 
In the healthy human disc, nerves extend into the outer third of the annulus.  However, 
degenerated discs often exhibit innervation that penetrates much deeper into the annulus, 
and in some extreme cases into the nucleus pulposus 52,53.  The migrating nucleus also 
may impinge on nerve roots, leading to additional pain 3.  Therefore, pain can occur even 
in discs where there is no protrusion of nuclear material into or beyond the periphery of 
the annulus fibrosis.  Typically, fissures reaching into the inner third of the annulus are 
not painful, but 70% of fissures extending into the outer third of the annulus cause pain 
for the patients 54.   
 
With age, there is also an overall decrease in the bone density of the vertebral bodies and 
a corresponding decrease in bone strength 7,55-57.  With ageing, the horizontal trabeculae 
are absorbed and not replaced 57.  This phenomenon occurs most dramatically in the 
central region of the vertebral body, directly above or below the nucleus pulposus 8.  The 
vertebral endplates then must share a greater portion of every load because it lacks 
support from the weakened underlying bone 58.  Repeated loading causes microfractures 
to occur in the endplate and a gradual bow into the vertebral body 57.  If the fracture in the 
endplate is large enough, nuclear material may migrate into the vertebral body, forming a 
Schmorl’s node.  The incidence of these is highest in the thoracic region of the spine 59.  
The fracture of an endplate can also lead to the introduction of inflammatory cytokines 
into the nucleus.  The presence of these chemical mediators actually slow metabolic and 
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reparative processes in the disc and lead to further degradation 60.  Cytokines can also be 
a direct source of pain 61. 
 
2.4 Treatment for Lower Back Pain 
2.4.1 Conservative Treatments 
 
Current treatment for lower back pain begins with conservative interventions, the goal 
being to relieve pain and restore function quickly 62.  Conservative treatment consists of 
rest, medication, and physical therapy 63.  In a study on 71 athletes with disc herniation, it 
was found that conservative treatment was satisfactory in controlling symptoms.  
Approximately 79% of the athletes were able to resume their sporting activities an 
average of 4.7 months after the start of treatment.  Resumption of activity occurred when 
the subjective symptoms were reduced by at least 80% 64.  Overall, however, the relative 
effectiveness of common conservative treatment strategies is not well understood 65.   
 
The most common initial treatment for lower back pain is rest.  Two days of total bed rest 
is often prescribed after a back injury.  This can help to reduce inflammation, relax 
muscles, and allow healing to occur.  Once healing has begun, a patient may resume light 
activity.  Although activity can increase the risk of relapse, periods of prolonged rest can 
lead to weakness and depression 63.  Four days or longer of bed rest has been reported to 
be detrimental to recovery 66.  Therefore, proper modifications to normal activities should 
be made to avoid recurrence of the injury 62.   
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The benefit a patient gains from bed rest may depend on the type of low back pain being 
treated.  Hagen et al. 67 performed a randomized trial comparing the effect of two days of 
bed rest on the symptoms of acute lower back pain (without neurological deficits) and 
sciatica (nerve root compression) 8.  For patients with acute lower back pain, staying 
active was slightly more effective than staying in bed.  For patients with sciatic back 
pain, there were no differences between staying active and bed resting 67.   
 
There is substantial evidence that exercise helps in the management of lower back pain 
62,65,67-70
.  Exercises can help regain range of motion 62,  strengthen abdominal muscles to 
help compensate for injured spinal tissues, and increase endurance of spinal 
muscles62,70,71.  Exercise may also help prevent future episodes of chronic pain and 
modify pain perception 72.   
 
There are several different modes of exercise and physical therapy.  Cold therapy can 
reduce inflammation and pain, whereas hot therapy can aid in muscle relaxation and 
improve circulation 62.   Transcutaneous electrical stimulation can block nerve impulses 
from being sent to the cerebral cortex that are interpreted as pain 73.  Traction, where 
systems of weights, cables, and pulleys are used to reduce pressure on the vertebrae, is 
used by 41% of 1239 physical therapists interviewed in the United Kingdom 74.  Clarke et 
al. 75 reported results of a randomized trial of 2177 patients, approximately half of which 
received traction.  There were no significant differences in the short or long-term 
outcomes of continuous or intermittent traction and placebo, with or without sciatica. 
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Many questions still remain regarding the exact application of exercise.  Mannion 
maintains that an exercise program must target the special needs of the patient and be 
balanced with the healthcare budget of the provider 76.  Hayden et al. 70 demonstrated that 
individually designed exercise programs improved outcomes for non-specific chronic 
lower back pain patients over a 12 week period.  Hurwitz et al. 65 followed 681 patients 
with lower back pain for 18 months and found that focusing on recreational physical 
activity rather than specific lower back exercises was more effective at reducing pain and 
increasing psychological health.  Linton et al. 77 studied the effects of combining physical 
therapy with cognitive behavioral therapy on back pain related sick leave.  They reported 
no significant differences in the recovery of patients who received cognitive behavioral 
therapy in addition to physical therapy compared to patients who received physical 
therapy alone.  
 
If symptoms do not improve over 4 to 6 weeks, pharmacologic pain control can be 
considered based on symptoms and history 66.  Muscle relaxants and oral nonsteriodal 
anti-inflammatory drugs are often prescribed.  The nonsteriodal anti-inflammatory drugs 
are prescribed at a much higher frequency, however 78. They block prostaglandin 
production and reduce inflammation, effectively relieving pain.  Epidural anesthetic 
injections are also used to minimize nerve irritation.  A series of injections several weeks 
apart may be needed 79.  The relief may last up to a few months.  However, a risk 
associated with this procedure is accidental puncture of the dural sac, leading to the 
leakage of cerebral spinal fluid 62.   
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Only after exhaustive conservative treatments should surgical interventions be employed.  
In addition, surgery can only provide relief when the correct source of the pain is 
identified.  For this reason, unresolved persistent back pain requires repeated, in depth 
evaluation.  There are several diagnostic tests which can supplement a physical 
examination.  Radiographs can be used to identify breaks in the vertebral body or 
posterior elements.  They can also be used to detect spondylolisthesis, which is the 
slippage of one vertebral body over the other.  Computed topography (CT) scans and 
magnetic resonance imaging (MRI) can be used to identify fractures, herniated discs, 
tumors, and infections.  Discography can allow for the identification of a painful disc by 
following the injection of a contrast medium into the nucleus pulposus.  Radiographic 
imaging will show leakage during a herniation.  In addition, low injection pressures will 
invoke intense pain in degenerated discs 61.  Despite these tools, in 80% of patients, no 
obvious cause of back pain can be found 80.   
 
2.4.2 Current Surgical Interventions 
 
Many current surgical interventions for back pain fall under one of two categories: 
decompression or stabilization procedures.  Laminotomy, laminectomy, and discectomy 
are decompression procedures 62.  They involve relieving pressure on the nerve elements 
by excision of disc, bone, or ligament material 2.  In a laminotomy, the surgeon will 
attempt to relieve nerve compression by making a small hole in the disc material to free 
the nerve root.  However, if this is not sufficient to free the nerve, a laminectomy can be 
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performed.  This is the removal of a small part of the disc tissue, facet joints, or any 
portions of the disc impinging on nerves.  This procedure will provide relief as soon as 
the inflammation subsides 79. 
 
A discectomy is used in cases where complete herniation has occurred.  The portion of 
the nucleus pulposus which is causing pressure on the nerve root is removed.  
Discectomy is sometimes performed in conjunction with laminectomy.  Discectomy can 
be done via open, micro, or percutaneous routes or using a laser.  In open discectomy, an 
incision over the posterior midline is made, and the ligaments and muscles are moved in 
order to access the affected disc.  In microdiscectomy, this is done with a small incision.  
Percutaneous discectomy involves the use of a cannula to suction out the offending 
tissue, and the surgery is monitored with a fluoroscope 62.  Laser discectomy is similar to 
percutaneous discectomy, however the tissue is removed with a laser, which burns the 
tissue for its removal 81.   
 
To date, however, microdiscectomy has been used as the gold standard because no other 
discectomy technique has been able to match or exceed its outcomes 66.  One popular 
microdiscectomy system is the METRx™ (Medtronic Sofamor Danek, Memphis, TN).  
The necessary incision with this system is less than one inch long and damage to muscles 
is minimal compared to open discectomy.  The surgery is made minimally invasive by 
accessing the surgical area with a series of tubes, called dilators, which increase in 
diameter.  The tubes are sequentially inserted though the muscle to split the fibers, 
creating an opening large enough through which the disc tissue can be removed 66.   
 23 
 
A review was performed on 873 consecutive patients who were treated for lumbar disc 
herniation with the METRx system.  The Oswestry disability index was used to quantify 
pain.  At 28 months post surgery, significant improvements were seen in the mean 
preoperative and postoperative score.  The average hospital stay was 4.8 days and it took 
an average of 15 days to return to work.  The average blood loss during the surgery was 
44 mL 82.   
 
Wu et al. 83 performed one of the only studies which compares the outcome of 
percutaneous discectomy to that of conservative treatment.  Surgery was performed on 
patients with herniations which were symptomatic for 6-12 weeks.  At a 2 year follow up, 
there were no clinically significant differences in pain intensity and quality of life 
between the two groups.  However, the discectomy group was associated with a more 
rapid initial recovery.  
 
Another study involved a 25 year or longer follow-up on patients who received 
discectomy for lumber herniation.  Patients who underwent surgery reported a higher 
quality of life and less pain than non-surgically treated patients 84.  Despite these results, 
there has been little other research into the long term effects of discectomy 85, making 
long term outcomes of the treatment questionable 86.  While the procedure is successful in 
relieving pain after surgery due to nerve root decompression, it does not restore the 
healthy biomechanics to the disc.  The degenerative cascade can therefore continue, and 
has been reported to be accelerated due to alterations made to the disc 87-89.   
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Vertebroplasty, kyphoplasty, and spinal fusion are stabilization procedures.  
Vertebroplasty was developed in France in the 1980s, but it was not used in the United 
States until 1994 90.  It involves the injection of bone cement into an area of vertebral 
compression facture.  By filling in a bone defect in the vertebral body, the vertebral body 
is stabilized because mechanical support is rapidly regained.  A CT scan is used to verify 
that the void is completely filled 62.   
 
Generally, curing poly(methylmethacrylate) is used as the augmentation material 62,91.  
The bone will not bond with the polymer and it will remain a foreign body in the 
vertebral body 91.  Consequently, the patient may experience fever and increased pain 
from the inflammatory response 62.  It is also possible to sustain tissue damage due to the 
exothermic polymerization reaction 91.  Calcium phosphates have also been investigated 
as a bone replacement material because it is biocompatible, osteoconductive, 
nonexothermic and injectable 92.  However, a bone substitute in the vertebral body must 
be able to withstand cyclic loading, so there are concerns over the brittleness of calcium 
phosphate cements 93.  Wilke et al. 91 investigated the fatigue behavior of calcium 
phosphate cement and poly(methylmethacrylate) in intact human osteoporotic specimens 
over 100,000 loading cycles.  Both of the cements exhibited decreases in height with 
increasing number of load cycles.  The poly(methylmethacrylate) lost 2.8 mm, while the 
calcium phosphate ceramic lost 4.2 mm.  Cryosections revealed the presence of small 
cracks in the calcium phosphate, but there were no signs of fatigue for the 
poly(methylmethacrylate).   
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After vertebroplasty, patients have reported a decrease in pain and increase in function 
90,94
.  However, for patients with malignancies, vertebroplasty has been shown to offer 
adequate vertebral stabilization, but inadequate pain relief 90.  In addition, Berlemann and 
Polikeit et al. both found that vertebroplasty increases stress in adjacent vertebrae, 
leading to fracture 95,96.  Another drawback to vertebroplasty is that vertebral height is not 
completely restored 62.  Kyphoplasty involves the percutaneous insertion of a balloon into 
a vertebral defect.  The balloon is inflated to compress the cancellous bone in order to 
create a cavity into which bone cement can be injected, thereby restoring height to the 
vertebral body 97,98.  Kyphoplasty and vertebroplasty have been shown to provide similar 
pain relief. 99.  A correlation between vertebral body height restoration and pain relief 
was not found by Kasperk et al. 99  However, a higher rate of cement leakage was 
reported for vertebroplasty.  The rate of other adverse events, such as pulmonary 
embolism or neurological injury, was low for both procedures 99.   
 
Spinal fusion, another stabilization procedure, is one of the most rapidly increasing forms 
of inpatient surgery in the United States.  Currently, it is recognized as a treatment for 
degenerated discs and segmental instability 100.  Between 1979 and 1990, the rate of 
lumbar spinal fusion doubled 101.  Then, in the 1990s, the rate tripled 102.  Possible 
reasons for this are changes in population, technological advances in the surgical 
methods, uncertainty about the indications, and financial incentives for doctors and 
hospitals 103.   
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The basic idea behind fusion is to use arthrodesis to prevent motion across the pain 
generating disc.  The disc material of the affected segment is removed, and the surface of 
the two opposing vertebral bodies are roughened and packed with bone material.  This 
fills the gap between bones, allowing them to grow into a single segment.  3,103,104.   
 
Today, metal implants are often used to stabilize the vertebrae until the fusion solidifies 
62
.  However, uninstrumented fusions have been performed, and are indicated for spine 
conditions where there is no instability 104.  In these fusions, bone grafts are place on the 
laminae, spinous processes, or transverse processes in order to eliminate motion.  The 
patient would be required to wear a brace to provide additional stabilization to the 
segment 104.   
 
Reported rates of internal fixation with instrumentation doubled from the 1980s to the 
1990s 105.  The most popular implants for internal fixation are metal pedicle screws 103.  
Using pedicle screws to stabilize the vertebral body provides significant immobilization, 
allowing for complete arthrodesis to occur 106-108.  Wood et al. concluded that patients 
with degenerative discs who undergo uninstrumented fusion are 24 times more likely to 
have pseudoarthrosis 109, or incomplete fusions.  The screws also provide continued 
support after the maturation of the fusion 110.  One disadvantage of pedicle screws is that 
less space is made available for the bone graft material 104.  An alternative method is to 
use facet screws for fixation.  Here a screw is used to transverse the facet joints.  While 
the procedure for using facet screws is more technically challenging than pedicle screws, 
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there is less need for soft tissue dissection.  High fusion rates have also been reported for 
facet screws111. 
 
There has been some debate about the clinical value of internal fixation with screws.  
There have been several studies indicating that, while it may help accelerate fusion rates, 
there has been little impact on the clinical results of fusion 112-115.  For instance, Thomsen 
et al conducted a randomized clinical trial which showed no significant differences in the 
functional outcomes of patients who received fusions with or without pedicle screw 
supplements 114  Moller et al. showed that the level of pain between the two groups 2 
years after surgery was very similar 112.  On the other hand, there have been other studies 
which showed a close relation between fusion rate and clinical outcome.  One group 
reported an 80% clinical success rate and 80% successful fusion 116.  Another group 
reported a 73% successful fusion rate and a 74% clinical success rate 117.   
 
Fusion rates in the United States rose 77% between 1996 and 2001.  This is because in 
1996 the Food and Drug Administration (FDA) approved intervertebral fusion cages 
(Figure 2.5) 102.  Fusion cages are another alternative to providing stabilization to the 
fused segment.  The advent of fusion cages reduced the incidence of graft collapse 
because they provide mechanical support while the bone matures 100.  The bone graft is 
placed inside the cage 3,118.  Cages are also associated with improved fusion rates over 
screw fixation and uninstrumented fusions 119,120.  The high stiffness of some metal cages 
can cause endplate subsidence 3, therefore titanium or carbon cages have been 
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recommended 100,118.  Carbon cages have an advantage over metal cages because they do 
not interfere with radiographs, tomography scans, or MRI 100.   
 
 
Spinal segments can be fused anteriorly, posteriorly, or circumferentially (360º fusion)..  
The method employed will depend on the area of the defect.  In anterior lumbar fusions, 
the surgeon retracts the abdominal contents and pulls the aorta and vena cava to the right 
side of the spine in order to access the anterior spinal area.  The anterior approach is 
advantageous because the back muscles and nerves remain undisturbed, resulting in 
lower recovery time.  In addition, Brady et al. maintain that fusing the anterior spine 
produces better results when the anterior portion of the disc is compressed 118.  Still, the 
posterior approach has also gained wide acceptance as a method for lumbar fusion.  It 
allows for the decompression of neural elements via a posterior midline incision 118.  
While both of these approaches have had clinical success 122-125, there is still debate 
regarding the effectiveness of an isolated arthrodesis because it may not totally eliminate 
motion through the segment 126.  Posterior lumbar fusion can be supplemented by the 
addition of a posterolateral fusion, creating a 360º circumferential fusion 100.  All of these 
techniques may or may not be assisted with internal fixation implants 100. 
 
The bone graft used in spinal fusions can either be an autograft or allograft.  Autografts 
are bone that is usually removed from the patient’s iliac crest, either requiring an 
additional incision or tunneling under the skin to reach the patient’s hip.  Allograft is 
obtained from a donor cadaver.  The bone is ground and applied over the area to be fused.  
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Autografts are generally considered the “golden standard” because of the availability and 
minimal risk of rejection.  However, many patients elect to use bone from a donor 
because of the pain associated with an autograft 127.  Patients have reported donor site 
pain to be greater than that of the spinal incision 62 and it can persist for years after the 
surgery 127.  It takes between three months and two years for the fusion to become solid 
127
. 
 
The usage of osteoinductive agents can enhance clinical outcomes for patients.  Bone 
morphogenic protein (BMP) can be mixed with the bone in order to induce bone growth 
127
.  Usage of these materials can also eliminate the need for autogenous bone harvesting 
all together 104.  Recombinant BMP (rh-BMP) has been reported to give superior results 
to autogenous bone grafts and more rapid clinical improvement 121,128,129.  Berkus et al. 
followed 46 patients who received spinal fusions with rh-BMP-2 threaded with cortical 
allograft.  Clinical results were compared to patients who received autograft from the 
iliac crest.  At 12 and 24 months, patients in the investigation group had higher rates of 
fusion and there were no unanticipated adverse events related to the rh-BMP-2.   
 
While spinal fusion undoubtedly provides pain relief for some patients, its efficacy for 
treating degenerative disc disease remains unclear 103.  Mofidi et al. 100 surveyed 65 
patients who received posterior lumbar fusion with carbon cages between 1993 and 2000.  
Clinical outcomes were assessed by measuring the postoperative Oswestry Disability 
Index, return to work, and overall satisfaction with the outcome.  Approximately four 
years after the surgery, there was an 84% satisfaction rate and 61% of the patients were 
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able to return to pre-disease activity level, and there was a significant improvement in the 
Oswestry Disability Index.  In another prospective assessment, 35 patients who received 
360º fusion with screw fixation were asked about their outcome approximately 31 months 
after surgery.  There was 71% overall satisfaction rate, but only 28.6% rated their 
outcome good or excellent. There was also a 75% reduction in medication usage 130.   
 
The UK Medical Research Council followed 349 patients with a 12 month history of 
chronic low back pain.  Approximately half of the patients received a fusion, though the 
surgical approach and instrumentation varied among patients.  The other half received an 
intensive rehabilitation program for three weeks in addition to cognitive behavioral 
therapy.  At 24 months after the surgery, the patients who received fusion had slightly 
better Oswestry scores than patients who participated in the rehabilitation program, but 
the groups did not differ in any other outcomes (anxiety, depression, or any adverse 
effects) 131. In Norway, a similar study was done where 64 patients were studied after 
either receiving 360º fusion with pedicle screws or 3 weeks of physical exercises and 
cognitive behavioral treatment for lumbar degeneration.  No differences were found 
between the Oswestry Disability Index for both groups one year after the surgery 132.   
 
The Swedish lumbar Spine Study Group did a similar study where they followed 249 
patients with chronic lower back pain and radiological evidence of lumbar degeneration.  
A 2 year study was done on a non surgical group, who received a variety of conservative 
treatments such as physical therapy, acupuncture, electrical nerve stimulation, and 
cognitive behavioral therapy, and a surgical group, who received three different fusion 
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techniques (posterior, anterior, and circumferential).  Initially, the surgical group reported 
more pain relief and a quicker return to work.  Pain and functioning improved by 33% for 
the surgical group, versus 7% for the non-surgical group.  At the 2 year follow-up, 
however, the improvement gradually deteriorated for the surgical group and only 63% of 
the patients who received fusions considered themselves “better” or “much better” 133. 
 
Spinal fusion is also associated with several surgical complications such as infection 100, 
nerve injury 114, and high blood loss 124.  Complications at the donor site and vascular 
complications have also been reported 134.  In addition, a Cochrane review of randomized 
controlled trials on the surgical treatment of lumbar disc degeneration concluded that 
there is no evidence for the efficacy of fusion for the treatment of spinal “instability” 135.   
 
Like with discectomy, the long term results of fusion are questionable.  Several 
biomechanical studies have shown that fusion causes increased stress to be experienced 
by spinal segments adjacent to the fusion site 126,136-139.  This promotes degeneration of 
these segments and the cycle leading to back pain begins again.  Miyakoshi et al. 139 
found that all intervertebral disc heights adjacent to the site of fusion decreased.  Chen et 
al. 140 used finite element modeling to confirm that the largest stress after fusion is placed 
on the disc adjacent to the surgical site.  Then, Chosa et al. 141 showed specifically that 
the stress increase in these discs is concentrated on the vertebral endplate and annulus 
during flexion and extension loadings.  They also showed that firm fusions increased the 
stress imposed on adjacent vertebral segments.  This has also been seen experimentally 
by other researchers 142. 
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Theoretically, replacing the diseased disc with a prosthesis would have an advantage over 
fusion because it could more closely mimic the loading and motion characteristics of a 
healthy spine 143.  It is hypothesized that motion preservation will decrease stress on 
adjacent segments, leading to favorable long term results 142,144.  Total disc replacement is 
therefore emerging as a viable alternative to fusion since it can be used to treat the same 
symptomatic pathology as fusion.  In addition to allowing for the removal of the painful 
disc, restoring disc height, and improving stability, proponents of this method say a 
prosthetic disc may help restore a healthy pattern of load bearing to the spine 144. 
 
The artificial disc with the longest clinical history is the Charité artificial disc.  The 
prosthesis was developed in the early 1980s and it consisted of a polyethylene core 
sandwiched between to metal endplates.  Since then, there have been three revisions to 
the implant, in order to minimize complications such as subsidence and fatigue failure.  
The current generation of the product is called the Type III SB Charité or the LINK SB 
Charité (Depuy Spine, Johnson & Johnson, Raynham, MA) (Figure 2.6) 145.  This version 
of the Charité was the first total disc implant for the lumbar spine to gain approval from 
the FDA 144.  It is indicated for patients between the ages of 18-60 with symptomatic 
single-level degeneration and failure to achieve pain relief for at least six months.  
Patients who have spinal fracture, bone disease, or spinal tumors should not receive the 
implant 143. 
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The implant consists of two concave metal endplates made from a cobalt chromium 
molybdenum alloy.  The surfaces of the endplates facing the vertebral endplate are 
covered in porous titanium and coated with calcium phosphate to encourage bonding with 
the bone.  In addition, the endplate surfaces also contain six teeth which are used to 
physically anchor the implant into the vertebral body.  Encased between the two 
endplates, there is a free-floating biconvex sliding core made of ultra-high-molecular-
weight polyethylene (Figure 2.7).  The mechanical behavior of the core mimics the major 
movements of the intervertebral segment: flexion, extension, and translation 146.   
 
The technique for the surgical implantation of all artificial discs is very similar to anterior 
lumbar fusion 144.  An anterior midline incision, approximately 5 cm in length, is made in 
order to access the spine and remove the diseased disc tissue.  A spreader instrument is 
used to distract the disc space.  The surfaces of the vertebral endplates are smoothed in 
order to maximize contact area with the prosthesis.  The artificial endplates are then 
positioned so that the inner surfaces of the plates are parallel and then they are implanted 
with the aid of a mallet to secure the teeth in the bone.  The polyethylene core is then 
inserted in place between the endplates 143.   
 
An FDA regulated prospective, randomized study was performed for the purpose of 
gaining FDA approval for the Charité.  The objective of the study was to compare the 
safety and effectiveness of the Charité artificial disc to anterior lumbar fusion for the 
treatment of single level lumbar degeneration and determine if there exists a correlation 
between implant placement and clinical outcome.  A total of 304 patients were followed 
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over 24 months, 205 being in the investigational group, and the remainder receiving 
fusion with a BAK cage and an iliac crest bone graft 147,148.  Overall, patients in both 
groups improved significantly after surgery.  However, patients who received the Charité 
recovered faster, had lower disability levels, and statistically lower pain scores.  The 
hospital stay was also significantly shorter for the disc replacement group 147.  Patients in 
the investigational group had a 13.6% mean increase in mean flexion/extension ROM, 
while the fusion group had an 82.5% decrease.  The investigational group also had 
significantly better restoration of disc height and less subsidence.  The flexion/extension 
ROM and prosthesis function improved with surgical technical accuracy of placement.  
At the 24 month follow up, no implant wear and creep was found 148. 
 
The study has received major criticism because the reference procedure, fusion with the 
BAK cage, has a very poor clinical history and is rarely used by surgeons due to its high 
failure rate 149.  This control was chosen because it was the only FDA approved anterior 
cage at the time of the study.  Currently there are other cages available that could have 
produced better scores for the fusion group 150.  It has also been suggested that the claim 
that the Charité disc produces less subsidence is not a valid argument for the superiority 
of disc replacement.  The BAK cage rests on the vertebral endplate, and because the area 
of the cage is small, this produces a stress point that leads to subsidence.  The Charité 
endplates are much larger, so it is only logical that less subsidence would occur 150.  In 
addition, despite the improvements in pain scores for both groups, 64% of the people in 
the investigational group and 80% of the people in the fusion group remained on 
narcotics 2 years after the surgery 147. 
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While the purported advantage of disc replacement technology is the preservation of 
adjacent vertebral segments, there was no conclusive evidence presented in the FDA 
regulated study to support this hypothesis.  Van Ooij et al. 142 reported on 27 patients who 
received the Charité disc replacement and were suffering from complications.  At the 53 
month follow-up, 7 patients exhibited degeneration at another spinal level that was not 
present prior to surgery, despite accurate placement of the prosthesis.  The authors 
conjecture that it is unlikely that this degeneration was simply caused by the degenerative 
disease itself.  They maintain that it is highly unlikely that the Charité or other disc 
replacements can completely mimic the normal movement of the disc, making adjacent 
segment degeneration inevitable.  Physiologically, the center of rotation in normally 
functioning segments is positioned posteriorly in the disc, and in the Charité this is 
centrally or anteriorly located 142.  In addition, the authors claim that the metal and 
polyethylene do not possess the same shock absorbing capacity as the healthy disc.   
 
Van Ooij et al. 142 also reported 16 cases of subsidence into the vertebral bone.  Because 
the central endplate is weaker than the outer rim, the metal plates of the implant must be 
large enough to rest on the periphery of the endplate.  Several of the patients who 
experienced subsidence had too small of a prosthesis inserted.  However, a disadvantage 
to larger plates is that there is a greater chance of nerve impingement. Because a great 
many blood vessels must be mobilized for correct insertion of the implant, this poses 
bleeding and thromboembolic risks 151, which increase with implant size 142.  Van Ooij et 
al. also reported anterior migration of the implant, causing iliac vein compression 142. 
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The ProDisc-L (Synthes Spine, West Chester, PA) (Figure 2.8) was developed in the late 
1980s and the second generation, the Prodisc, has been available since 1999 144.  The 
implant consists of two metal endplates made from cobalt chromium molybdenum alloy, 
the surface of which is coated with porous titanium.  Implant stability is achieved by a 
spike located on each endplate, called a keel 144.  During surgery, keel cuts in the bone are 
made with a chisel.  The ultra-high-molecular-weight polyethylene core is snapped into 
the lower endplate during the operation after endplate distraction152.  Unlike the Charité, 
which has a free floating biconvex sliding core, the Prodisc inlay does not move, thus the 
center of rotation is fixed 153.  In 2006, the FDA approved the ProDisc-L for lumbar disc 
replacement in skeletally mature patients with discogenic back pain and degeneration.   
 
Chung et al. 154 reported positive clinical outcomes for 36 patients who received a lumbar 
total disc replacement with the ProDisc.  The mean score for lower back pain improved 
significantly and 7 out of 10 preoperatively unemployed patients were able to return to 
work.  The Oswestry disability index scores also improved.  Mean range of motion and 
disc height also significantly increased.  There were no significant complications in this 
study.  Similar results were reported by Bertagnoli et al. 152.  At 3 months 
postoperatively, statistical improvements were reported in Oswestry scores and patient 
satisfaction, which were maintained at 24 months.  There were increases in disc height 
and range of motion.  There were no significant complications or the need for any 
surgical revisions.  Mayer et. al. 155 followed 37 patients postoperatively after receiving 
the ProDisc prosthesis.  After an average of 5.8 months, 76% of the patients had no low 
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back pain.  In addition, 61% of the patients were “completely satisfied” and 21.7% were 
“satisfied”.  Radiographs showed no changes in function of the implant over time and 
there were no incidences of subsidence.  
 
Zigler et al. 156 report the early results of an ongoing FDA trial at 19 US centers.  One 
report concerns 39 patients at a center in Plano, TX who received either the Prodisc or a 
360º lumbar fusion.  The fusion was a more substantial operation involving anterior 
fusion with femoral allograft followed by posterior fixation with pedicle screws and an 
iliac bone graft.  It is not surprising, then, that lower blood loss, shorter operating times, 
and briefer hospital stays were reported for the disc replacement group.  Zigler et al. also 
reports that, at three months postoperatively, the Oswestry disability scores were 
significantly lower for the disc replacement group and they exhibited significantly 
improved range of motion. 
 
Delamarter et al. reported 30 month follow-up data on 78 patients in Santa Monica, CA, 
who were participating in the same FDA trial.  Early results were similar to those 
described above; the disc replacement group had an early advantage in pain and recovery.  
However, at 12, 18, and 24 months, there were no significant differences in the pain, 
disability or mobility for the two groups 157.   
 
The complications associated with surgical implantation of the ProDisc appear similar to 
those associated with the Charité. Those include nerve root impingement 155, endplate 
subsidence 158, malpositioning158, dislodgement of the polyethylene core 155,156, and iliac 
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vein laceration 156.  Shim et al. 159 reported a split fracture of the vertebral body, which 
was attributed to the keel design of the ProDisc.  In the author’s opinion, the need for 
chiseling increases the risk of vertebral fracture, and the height of the keel is 
unnecessarily high, especially for Asian people who have smaller vertebral bodies than 
Caucasians.   
 
There are other total disc replacements besides the Charité and ProDisc under 
investigation, though the literature data concerning them is sparser.  The Maverick disc 
(Medtronic, Minneapolis, MN) (Figure 2.9) has similar design to the ProDisc, but is a 
metal-on-metal implant.  It consists of two flat metal endplates with a ball and socket-
joint sandwiched between them.  The center of rotation is fixed in the posterior of the 
disc space.  Stabilization in the vertebral bones is achieved by two large keels, similar to 
those on the Prodisc.  Due to the height of the keels, usage of the disc may be limited to 
larger vertebral bodies 144.  Barzilay et al. 160 reported 1 year follow-up results on the first 
30 consecutive patients to receive single level Maverick discs.  At 6 months and 1 year, 
patients experienced an improvement in back pain and achieved a normal range of 
motion.  There were no major device related complications.  The Flexicore disc (Stryker 
Corp, Kalamazoo, MI), is also a metal-on-metal implant with a ball-and-socket joint.  
The endplates are dome-shaped to adapt to the concavity of the endplates.  Because of 
this shape, the implant can be implanted either anteriorly or anterolaterally.  Also, the 
device is implanted as one single unit 144.   
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2.4.3 Nucleus Pulposus Replacement 
 
Based on the clinical outcomes of spinal fusion and total disc replacement, it appears that 
re-establishing the healthy biomechanics of the degenerated spine is still a challenge that 
needs to be realized by spine medicine.  Other than total disc replacement, another non-
fusion alternative being investigated is the replacement of the nucleus pulposus alone.  A 
synthetic nucleus replacement could be designed to recreate the biomechanical function 
of the healthy nucleus pulposus by applying tension to the annulus under compressive 
loads 161,162.  In doing so, a nucleus replacement would restore stability to the spinal 
segment 162.  In addition, motion could be preserved and disc height could also be 
restored 161-163, the latter helping to lessen compressive forces on the facet joints 163,164.  
Further tearing and nerve irritation could be prevented or postponed by the nucleus 
replacement relieving or lessening the shear forces on the annulus 165.  In addition, the 
implantation procedure for a nucleus replacement has the potential to be less invasive 
than a total disc replacement or spinal fusion 166, so the morbidity associated with those 
surgeries can be avoided.   
 
There are no clear standards establishing the degree of degeneration for which nucleus 
replacement is acceptable 167.  Some propose that nucleus replacement be intended for 
people in the earlier stages of degeneration, when the annulus is still intact 168 and there 
have been no previous operations 167.  Proponents of this philosophy view nucleus 
replacement as an early therapy, rather than a replacement for spinal fusion or a 
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prosthetic disc 161.  An intact annulus would be better able to contain the implant, 
reducing the risk of migration 163.  This is especially important for in situ forming nucleus 
replacement materials, which are injected as liquid and form a solid in the body.  A 
competent annulus is necessary to prevent the spread of liquid beyond its periphery 169.   
 
The problem with this approach is that by the time discogenic symptoms occur, the 
annulus may already be in the later stages of degeneration 167.  Nucleus replacement has 
also been proposed as an adjunct to discectomy or nucleotomy.  Removing offending disc 
material and filling the space with a synthetic material could help to restore function to 
the disrupted disc 168.  The nucleus replacement would lessen the load on the remaining 
disc tissues and transfer compressive forces to the annulus in tension again, preventing or 
postponing future degeneration.  However, the disc height must still be sufficient to allow 
insertion of the implant 163.  One major consideration to be taken into account when using 
nucleus replacements for this indication is that, by the time the patient becomes 
symptomatic, nerve impingement may not be the only cause of back pain.  Pain can be 
generated by inflammatory mediators which can access and stimulate the nociceptors in 
the tears of the outer annulus.  Mayer et al. maintains that replacing the nucleus in these 
situations would not bring relief to the patient, because the annulus fibrosis will remain 
insufficient 167.  However, if a soft tissue adhesive were used to close the annular fissures, 
and no vertebral fractures are present, the patient theoretically should not feel this pain 
anymore, because inflammatory chemical mediators would not be able to reach the 
nociceptors in the outer annulus.   
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There are several material requirements for a synthetic nucleus replacement.  First, it 
must be able to endure cyclic fatigue without failure or formation of significant particle 
debris 163,166,169.  An implant is expected to withstand approximately 100 million cycles 
over 40 years 170.  It must also possess elastic characteristics which would allow for shape 
memory under repetitive loading.  The stiffness of the material must be such that the load 
distribution on the endplates and vertebral bodies will not cause subsidence or stress 
shielding, leading to bone resorption 47,169.  The material should completely fill the disc 
space in order to avoid excessive movement of the implant 169.  In addition, intimate 
contact between a nucleus replacement and the inner annulus is necessary for the full 
restoration of biomechanical function 171.   Furthermore, the implant should be delivered 
to disc non-invasively, with minimal tissue trauma, which would reduce the risk of 
implant migration or expulsion 166,169.   
 
Currently, the most widely studied material candidates for nucleus replacement are 
hydrogels.  Hydrogel-based materials have been investigated for this application for over 
15 years 168.  In the literature, these three dimensional hydrated polymer networks have 
been favored for nucleus replacement because they have the ability to exude water under 
loads and re-imbibe it when the load the released 161,172.  Authors often note that this 
behavior is similar to the healthy nucleus pulposus 161,166,169.  Under sustained loading, 
however, the nucleus only undergoes a gradual fluid loss 173.  To more closely mimic the 
mechanical behavior of the disc, it may be favorable to design a material with a low 
hydraulic permeability, which would allow it to maintain a hydrostatic pressure on the 
annulus under sustained loading.   
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Currently, hydrogel materials for nucleus pulposus replacement can be categorized as 
either preformed or in situ curing.  Preformed hydrogels are of a predetermined size and 
shape.  In order to minimize the invasiveness of the implantation procedure, preformed 
hydrogels are often implanted in a dehydrated or partially dehydrated state.  They then 
expand in the nuclear cavity due to the presence of physiological fluids.  The main 
challenge associated with using preformed materials is matching the final size and shape 
of the implant to the cavity in the disc 169.   
 
The largest clinical experience with a preformed hydrogel nucleus replacement comes 
from the Prosthetic Disc Nucleus (PDN) (Raymedica, Inc., Bloomington, MN).  This 
copolymer hydrogel is composed of polyacrylamide and polyacrylonitrile, encased in a 
polyethylene jacket which constrains the swelling of the hydrogel pellet, reducing risk of 
endplate fracture 174.  Earlier versions of the device were implanted as two separate units; 
a tapered anterior unit and a rectangular posterior unit.  The two-unit system allowed the 
device to be implanted less invasively than a larger single unit.  The two units are 
connected with a tethering suture in the disc 162 (Figure 2.10).  Currently, the 
invasiveness of the implantation is thought to fall between a discectomy and fusion or 
total disc replacement 162.  The product is indicated for patients with degenerative disc 
disease and at least 5mm residual disc height.  Patients with annular defects are excluded 
as candidates for receiving the PDN 162.   
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Biocompatibility testing of the device revealed no systemic toxicity, carcinogenicity, or 
genotoxicity 175.  Scanning and transmission electron microscope examinations 
demonstrate no evidence of a giant-cell reaction or evidence of wear debris 176.  Fatigue 
testing revealed that the device is able to continue functioning as designed after 50 
million cycles 175.  In addition, Eysel et al. 177  implanted the PDN in nucleotomized 
cadaveric lumbar spinal segments and found that the device restored disc height and 
stabilized the motion segment to the intact pre-nucleotomized condition.   
 
In 1996, the first feasibility study for the PDN device was conducted.  Twenty four 
patients received the implant.  With the hydrogel pillow positioned perpendicular to the 
anteroposterior dimension of the disc, a success rate of 83% was seen.  Then, a second 
series of studies were performed on 17 additional patients in 1997 and 1998.  They tested 
an angle shaped hydrogel which was meant to conform better to the concavity of the 
endplates.  They also used a softer polymer to reduce stress on the endplates.  
Unfortunately, this version only produced a 62% success rate.  There was a high rate of 
device expulsion and several revision surgeries to remove the implant and perform a 
fusion.  In 1998-1999, a new trapezoid shaped model, designed to reduce the migration 
rate, was implanted in 26 patients.  The success rate improved to 79% 162.   
 
In 1999, surgical instrumentation was modified to facilitate implantation of the device.  A 
series of dilators were developed to help stretch the annulus fibers, rather than cut them.  
Fluoroscopic imaging was used to ensure proper placement of the device.  A more 
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restrictive post-operative procedure was developed which required patients to wear a 
brace for 6 weeks.  With these changes in place, the success rate increased to 91% 162.   
 
The clinical results have been encouraging.  After four years, patients report significant 
improvements in Oswestry scores.  Disc heights increased and implanted segments were 
stabilized 162.  However, there was still problems with device migration, the average 
migration rate being 12 percent178.  For this reason, a new surgical technique was 
introduced.  While the device was traditionally implanted via a posterior approach, 
similar to discectomy, Bertagnoli et al. 179 developed an anterolateral transpsoatic 
approach. An incision is made in the lateral region overlaying the disc, and the 
lateroabdominal muscles are dissected.  The disc can be accessed without disrupting the 
posterior structures of the spine.  A small study group of 8 patients were implanted with 
this approach.  While the Oswestry scores improved and disc heights increased, there was 
an increase in the migration rate.  The magnitude of the increase was not disclosed in the 
report, but the authors note that it may have been an artifact of the small patient 
population.  
 
The Newcleus Spiral Implant (Centerpulse Orthopedics, Winterthur, Switzerland) has 
also been implanted in humans as a treatment for the degenerative disc 163.  The implant 
is a polycarbonate urethane having the shape of a memory coiling spiral (Figure 2.11).  
The device is intended to be implanted into the disc after a discectomy, performed via a 
microsurgical posterior approach.  During the discectomy, the nucleus material is 
removed to create space for the implant.  The spiral can then be inserted into the disc 
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space through the same opening in the annulus created by the discectomy.  The spiral is 
loaded into a special insertion instrument and pressure is applied to advance it into the 
disc.  Gradually, a spiral forms in the disc space.  The volume of the implant is not fixed.  
When the cavity is filled, the surgeon can cut the spiral and close the wound 163. 
 
Fatigue tests were run up to 50 million cycles with no significant wear observed.  The 
device was also implanted into human cadaveric specimens.  Flexion and extension were 
measured in the intact condition, after the nucleotomy, and after insertion of the spiral.  
After the nucleotomy, an increase in rotation and facet joint translation was seen 
(decrease in spinal stability).  After implantation, a return to the intact condition was seen 
163
. 
 
Five patients have been implanted with the Newcleus thus far.  Low back pain decreased 
postoperatively in all the patients.  Four out the five people were able to return to 
employment and there were no intraoperative or postoperative complications that 
occurred.  MRI pictures show no abnormal displacements.  Five years post-implantation, 
disc height and rotational mobility were maintained.  Long term clinical studies are now 
under way 163. 
 
The Aquarelle (Stryker Spine, Allendale, NJ) is another preformed nucleus pulposus 
replacement.  It is primarily composed of poly(vinyl alcohol).  The implant is inserted 
laterally or posteriorly through an annulotomy using a 4 to 5mm tapered cannula.  The 
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implanted hydrogel contains approximately 80% water.  It has shown good 
biocompatibility in animal models and mechanical durability up to 40 million cycles 166. 
 
In situ forming hydrogels are injectable materials which can be delivered into the disc 
space as a liquid through a cannula or needle and harden in the body 166.  This minimally 
invasive approach reduces the risk of implant migration or expulsion 166,169.  These 
materials can conform to the shape of the cavity, completely filling the disc space, 
allowing for better stability of the vertebral segment 166.  The most common injectable 
nucleus replacements are self-curing elastomers.  The drawback to these systems is the 
potential for leakage of unreacted monomer into the physiological environment.  It is 
critical that the polymerization reaches completion, eliminating the presence of toxic 
leachables 180.  In addition, the concentration of unreacted monomer necessary to achieve 
the mechanical strength necessary for a nucleus replacement is quite high 181.   
 
The DASCOR Disc Arthroplasty Device (Disc Dynamics, Inc., Eden Prairie, MN) is a 
nucleus replacement consisting of self curing polyurethane.  An 18ºC monomer mixture 
is injected into the disc via a catheter and cures in 12-15 minutes to form an elastomer168.  
The reaction mixture is contained in a polyurethane balloon166.  The balloon also serves 
to create a space in the disc to accommodate the injectable material 168.  The device has 
been implanted in 16 patients in Europe, but the clinical results have not been published 
yet 166.   
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Also being developed is the Biodisc (Cryolife, Kennesaw, GA).  It is an injectable protein 
hydrogel based on Cryolife’s surgical adhesive BioGlue.  The Biodisc material, the 
detailed components of which have not been reported, is injected into the disc space and 
cures within 2 minutes.  The polymerization process occurs with negligible exothermic 
heat production.  This produces a solid with properties similar to the natural nucleus 
pulposus.  Cadaver tests on calf lumbar segments showed that the posterior injection of 
the hydrogels restored denucleated disc height and segment stability.  Minimal reduction 
in height was seen after 10 million loading cycles 182. 
 
Another injectable nucleus replacement device is the IDN (Injectable Disc Nucleus) 
(Spine Wave, Shelton, CT).  The hydrogel is composed of a synthetic silk-elastin 
copolymer created through DNA bacterial synthesis fermentation.  It is injected through a 
needle and forms a gel within a few minutes with no measurable exotherm.  Preliminary 
testing indicates that the IDN is able to restore disc height under loads, and cadaveric 
tests have shown no evidence of extrusion 168. 
 
2.5 Poly(N-isopropylacrylamide) 
2.5.1 Thermodynamics of the Phase Transition 
 
It is common for the miscibility of a polymer-solvent system to increase with increasing 
temperature.  Complete miscibility is reached at an upper critical solution temperature 
(UCST).  This phase behavior can be used to describe several binary mixtures, often in 
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systems composed of a polar liquid and paraffin hydrocarbon 183.  The miscibility of such 
a system can be explained in terms of fundamental thermodynamics.  A system tends to 
minimize its free energy, which can be described by Equation 2.1.  At low temperatures, 
a system minimizes its free energy by minimizing its enthalpy.  However, at high 
temperatures, increasing the entropy by a small amount can result in a large decrease of 
free energy of the system.  At high temperatures, binary systems with a UCST tend to 
maximize their compositional entropy by distributing the molecules randomly, therefore 
forming a miscible mixture 184. 
 
G H T S∆ = ∆ − ∆                                                                                                                     Equation 2.1 
 
There are some polymer-solvent mixtures, however, which exhibit increased solubility 
with decreasing temperature.  This phase equilibrium results in a lower critical solution 
temperature (LCST), below which complete miscibility occurs.  LCST behavior occurs in 
systems where both components have polar groups which interact through hydrogen 
bonding at lower temperatures.  This hydrogen bonding lowers the enthalpy of the 
system, since molecules that are bound together are at a lower energy state than free 
molecules.  However, hydrogen bonds have very low orientational entropy because the 
bonds between the polar groups on the polymer and the solvent can only be formed when 
the molecules are in specific orientations.  Hydrogen bonds have an angular spread of 10 
degrees, so if the orientation of the molecules relative to one another changes by more 
than 10 degrees, the bond will break.  At increased temperatures, the hydrogen bonds are 
not thermodynamically favored because of the high losses in orientational entropy.  The 
increase in molecular rotations caused by the temperature increase will break the 
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hydrogen bonds between the water and polymer.  It will be replaced by van der Waals 
attractions between like polymer chains. The solute then segregates itself from the 
solvent, forming an immiscible phase.  The enthalpy of the system is minimized by the 
aggregation of like molecules, and this loss in enthalpy outweighs associated gains in 
orientational entropy associated with this conformation.  Some systems exhibit both 
LCST and UCST behavior, meaning that the miscible phase may once again reappear at 
higher temperatures.  This is because the high orientational entropy associated with the 
randomly distributed molecules minimizes the free energy of the system, causing 
miscibility to be thermodynamically favored 184.   
 
Aqueous solutions of poly(N-isopropylacrylamide) (PNIPAAm) exhibit an LCST, 
typically occurring around 32-34ºC 185,186.  The chemical structure of PNIPAAm is shown 
in Figure 2.12.  Below the LCST, water hydrates PNIPAAm chains by forming hydrogen 
bonds with its polar amide and carbonyl groups.  Above the transition temperature, the 
polymer becomes hydrophobic, so its behavior is dominated by the isopropyl group and 
backbone, resulting in a dramatic phase separation 187-189.  In linear PNIPAAm systems 
which are soluble in water below the LCST, the phase transition will result in a sol to gel 
transition.  In crosslinked systems, hydrated PNIPAAm networks exhibit a swelling-
shrinking transition at the LCST 190.  It has also been observed that the phase transition of 
PNIPAAm is reversible 191-193. 
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2.5.2 LCST Determination 
 
The first reported value of the LCST of PNIPAAm was in 1967 by Scarpa et al 194.  They 
reported a dramatic precipitation of the polymer when a 2% solution was heated to 31ºC.  
This temperature was determined by simple visual observation of the phase separation 
upon heating. Because this method is simple and convenient, other researchers have 
employed this method of LCST determination 195-197, and it has become known as the 
cloud point method 198.  Since then, efforts have been directed at developing more 
quantitative techniques for cloud point determination, such as UV-Vis 
spectrophotometry.  Fundueanu et al. 199 measured the temperature dependence of the 
absorbance at 450nm using a UV-Vis coupled to a temperature controller.  The group 
used 1 w/v% aqueous solutions of poly(N-isopropylacrylamide-co-methyl methacrylate-
co-methacrylic acid) and heated the solutions at 0.2ºC/min and 0.02ºC/min in the vicinity 
of the LCST.  The cloud point, found to be 36ºC, was taken as the temperature at the 
inflection point of the absorbance versus temperature curve.  This method of analysis is 
consistent with that of Feil et al 200. 
 
Differential scanning calorimetry (DSC) is another very common method of LCST 
determination.  Heskins and Guillet 195 first reported that the transition temperature can 
be detected on a DSC thermogram by an endothermic peak.  The heat of phase 
separation, H, can also be determined from the thermogram.  This is the energy required 
to break the hydrogen bonds formed between water and the amide and carbonyl groups 
on PNIPAAm 198,201.  Schild and Tirrell 187 reported a value of 6.3 kJ/mol for the 
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enthalpy, which is consistent with those found from other researchers 200,202,203 and in the 
typical range for hydrogen bonded interactions 198.  The entropy changes associated with 
the transition can also be calculated using Equation 2.1, where G is taken as zero at the 
transition 204. 
 
Schild and Tirrell 187 determined that LCST of aqueous PNIPAAm solutions determined 
with DSC is consistent with results from cloud point measurements.  Transition 
temperatures were found to be independent of heating rate in the range below 30ºC/hr.  
While the shape of the endotherm varied with molecular weight of the PNIPAAm, it was 
independent of polymer concentration in water in range 0.4-4.0mg/mL.  These results are 
in contrast to those of Boutris et al. 201, who varied the polymer concentration in water 
between 0.5 and 22 wt%.  There was a significant dependence of transition temperature 
on polymer weight fraction in the range below 5 wt%; however the phase diagram tended 
to plateau in the range of 15-20%.  This group also compared the phase transition 
temperatures obtained from DSC and cloud point measurements with UV.  They reported 
that the techniques yielded similar values, but those obtained from DSC were slightly 
lower.  This was attributed to the fact that DSC detects the energy change associated with 
the destabilization of hydrogen bonds, which is the initial step in the phase separation 
process.  Cloud point techniques only detect the macroscopic phase separation which 
follows. 
 
In the literature, when DSC is used to detect the LCST of PNIPAAm, the temperature has 
been defined as either the onset of the endotherm 200,205 or the temperature at the peak 
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minimum 187,200.  Boutris et al. reported that the peak minimum can shift to higher 
temperatures with increasing sample mass, while the peak onset is not affected by this 
variable.  However, the peak onset can depend on the polydispersity of the polymer.  For 
these reasons, the group defined the transition temperature as the temperature 
corresponding to the maximum of the first derivative of the thermogram 201.   
 
The LCST of PNIPAAm has also been studied through light scattering techniques.  This 
route may be considered advantageous over DSC and cloud point techniques because it 
reveals information about the size of the polymer chains 206.  Light scattering will detect 
the change in chain conformation from coil to globule as the polymer is heated above its 
LCST 206,207.  Dilute solutions must be used in order to accurately measure the radius of 
gyration of a single coil.  Because the phase transition begins with the collapse of 
individual chains, followed by chain aggregation, decreasing the concentration in solution 
will decrease interchain aggregation, making the measured size changes for a single 
polymer chain more precise 207.  Kubota et al. measured changes in the hydrodynamic 
radius and radius of gyration of linear PNIPAAm chains of varying molecular weights 
between 1.63E6 and 2.52E7 g/mol 206.  They found a sharp decrease in the dimensions of 
the polymer at the LCST.  They were also one of the first groups to report a 
polydispersity for the polymers, 1.3-1.4, making the measured changes in chain 
dimensions more reliable.  Longer chains will precipitate first, perturbing experimental 
results 207. 
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There are a variety of other LCST characterization techniques that have been used in the 
literature.  The changes in solution viscosity associated with PNIPAAm chain 
aggregation have been studied.  Heskins and Guillet have reported a decrease in viscosity 
with increasing temperature for dilute solutions 195.  IR spectroscopy has also been used 
to detect changes in inter- and intramolecular bonding that occur at the LCST.  A study 
on aqueous PNIPAAm solutions using Fourier Transform Infrared Spectroscopy (FTIR) 
revealed that the peak associated with the polymer hydrogen bond with water (C=O··HO-
H) at 1625cm-1 decreases as temperature increases.  In addition, a peak at 1650cm-1, 
representing intersegment hydrogen bonding (C=O··H-N) appears at temperatures above 
the LCST.  This group also reported that the intersegmental hydrogen bonds act as 
crosslinking points, allowing the chain aggregates to swell like a gel 208.  
 
2.5.3 LCST Modulation 
 
Many studies have focused on modulating the LCST by modifying PNIPAAm with 
hydrophilic, hydrophobic, or ionic comonomers. Acrylic acid is one of the most 
commonly used comonomers for increasing the LCST of PNIPAAm.  The LCST of 
random block copolymers of PNIPAAm and acrylic acid were characterized by DSC and 
cloud point techniques.  The copolymers composed of 2 mol% acrylic acid exhibited a 
3.6ºC increase in transition temperature compared to the PNIPAAm homopolymer.  
Furthermore, the LCST of the copolymer composed of 7 mol% acrylic acid was found to 
be approximately 60ºC 209.  The group asserts that this increase in transition temperature 
is tied to increase in hydrophilicity of the copolymers due to the presence of acrylic acid.  
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As the temperature is raised, the hydrogen bonds between the water and polymer are 
weakened, and eventually broken, when the polymer precipitates.  When the hydrophilic 
acrylic acid chains are present, these losses in hydrogen bonding are offset by the 
hydrogen bonds between the acrylic acid units and the water.  This results in an increase 
in the LCST.   
 
The above hypothesis was  also put forth by Feil et al, who synthesized  poly(NIPAAm-
co-butyl methacrylate) copolymers with butyl methacrylate (hydrophobic), acrylamide  
(hydrophilic), and acrylic acid (anionic) 200.  It was found that the changes in LCST were 
proportional to comonomer content.  The increase in LCST was largest for the anionic 
comonomer, followed by the cationic and hydrophilic comonomers.  The group also 
varied the charge density on the anionic and cationic copolymers by changing the pH of 
the swelling medium.  They reported an increase in LCST with increasing charge density, 
and attributed this to the same mechanism by which hydrophilic components increase the 
transition temperature.   
 
Hoffman et al. reported similar increases in the LCST of PNIPAAm as a result of 
copolymerization with acrylic acid 210.  In addition, Brazel et al. reported increases in the 
LCST of  PNIPAAm as a result of copolymerization with methacrylic acid 211.  David et. 
al. created block copolymers of PNIPAAm and poly(n-acetylimino)ethylene. They 
showed that increasing the chain length and frequency of the hydrophilic blocks 
increased the LCST 212.   
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By the same token, incorporating hydrophobic comonomers into PNIPAAm networks 
decreases the LCST.  Ma et al. showed that creating PNIPAAm copolymers with the 
hydrophobic isopropyl methacrylate lowered the transition temperature. The 
experimental results showed a linear correlation between the LCST and the amount (mol 
%) of isopropyl methacrylate 213.  Xue et al. prepared hydrogels composed of PNIPAAm 
with hydrophobic di-n-propylacrylamide, di-n-octylacrylamide, or di-dodecylacrylamide.  
The group hypothesized that use of comonomers containing two alkyl chains would 
impart stronger hydrophobic interactions to the polymer network.  It was found that the 
incorporation of the comonomers lowered the LCST of the PNIPAAm.  However, the 
temperature was independent of hydrophobic comonomer.  Also characterized was the 
transition temperature of gels formed from aqueous solutions containing the anionic 
surfactant sodium dodecyl sulfate.  The surfactant causes an appreciable increase in the 
LCST of the polymer, this being attributed to electrostatic repulsions between polymer 
chains due to the binding of the sodium dodecyl sulfate to the PNIPAAm chains 192.    
 
Shin et al. observed anomalous swelling behavior for an interpenetrating network of 
PNIPAAm and hydrophilic poly(acrylic acid).  They observed a decrease in the LCST of 
PNIPAAm as a result of the formation of the interpenetrating network and hypothesized 
that the free carbonyl groups on the PNIPAAm hydrogen bonded with the acid group on 
the poly(acrylic acid), leaving less polar groups on the PNIPAAm available for hydrogen 
bonding with water.  This increased the overall hydrophobicity of the PNIPAAm, 
lowering its LCST 214.   
 
 56 
Han and Bae 215 performed an extensive study on the precipitation of a high molecular 
weight PNIPAAm block copolymer with 2 mol% acrylic acid  The LCST of the 
copolymer, determined by cloud point measurements, was 32ºC.  Solutions composed of 
5 wt% polymer were dissolved in phosphate-buffered saline (pH 7.4). The solutions, 
which were initially clear, turned cloudy when heated to 27ºC. When the temperature was 
increased to 35ºC, an immobile, bulk phase appeared.  Upon heating to 43ºC, the solid 
began to shrink due to the expulsion of water from the network.  The authors noted that 
this gel deformed without shape memory.  In other words, it exhibited very poor elastic 
properties.  Based on these visual observations, it was speculated that polymer chains 
with lower acrylic acid contents precipitated first, forming globules, but those with higher 
acrylic acid contents remain in a partially collapsed conformation.  The globules become 
entangled with the partially collapsed chains, forming hydrophobic regions with physical 
junctions 215. 
 
2.5.4 PNIPAAm-based Hydrogels 
 
In the past several years, temperature sensitive and in situ-forming hydrogel systems have 
gained extensive interest for biomedical and pharmaceutical applications.  PNIPAAm-
based systems have been one of the most commonly proposed thermosensitive materials, 
not only because its phase transition conveniently occurs between ambient and body 
temperature, but because copolymers of NIPAAm with different types of monomers can 
result in materials with a range of different properties.  For instance, copolymers of 
thermosensitive N-isopropylacrylamide and gelatin were prepared which form an elastic 
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hydrogel above 34ºC or below 10ºC 216.  In another study, functionalized PNIPAAm 
chains were grafted onto alginate to form a comb-like polymeric structure which, when 
heated above the LCST, formed extremely porous hydrogels, allowing for rapid 
deswelling kinetics.  These materials were investigated as a rapid stimuli-responsive drug 
delivery system 217.   
 
Some researchers have investigated copolymeric hydrogels of NIPAAm with a 
hydrophobic comonomer by characterizing the effect that the hydrophobic component 
has on the swelling and mechanical properties of the hydrogels.  Hydrogels composed of 
PNIPAAm and hydrophobic comonomers 2,2,3,3,4,4,5,5-octafluoropentyl methacrylate 
and n-butyl methacrylate were evaluated by Lee et al.  It was hypothesized that the 
presence of the hydrophobic comonomer would increase the deswelling kinetics of 
hydrogel system, decrease the swelling capacity of the gel network, and increase the 
mechanical properties.  The group found that the gel swelling ratio decreased and the 
stiffness increased with increasing content of the hydrophobic comonomer.  This effect 
was more pronounced in the hydrogels composed of NIPAAm and 2,2,3,3,4,4,5,5-
octafluoropentyl methacrylate, attributing this to the fact that the atomic size of the 
fluorine is much larger than hydrogen, causing the molecular chain packing in these gels 
to be much denser than that of the n-butyl methacrylate gels 218.  
 
Conversely, the incorporation of hydrophilic comonomers tends to increase the swelling 
capacity of PNIPAAm networks. For example, PNIPAAm copolymers with dextran were 
synthesized by free radical polymerization of NIPAAm and a dextran macromer 
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containing multiple hydrolytically degradable oligolactate-2-hydroxyethyl methacrylate 
units.   It was found that the swelling capacity of the gels was strongly dependent on 
temperature and copolymer composition.  While all of the copolymers exhibited 
decreases in water content as the temperature was raised above the LCST, the swelling 
ratios increased with increasing dextran content.  This was attributed to overall increase 
in hydrophilicity of the network due to the presence of the dextran.  After six days 
immersion in PBS, the gels began de-swelling at a higher rate, due to the degradation of 
the dextran within the gel work, resulting in an overall increase in the hydrophobicity of 
the polymer 219.   
 
In addition, Lin et al. investigated the structure-property relationship of block or star 
copolymers of PNIPAAm and poly(ethylene glycol) (PEG) hydrogels. The PEG lengths 
used in this study were approximately 2000 Da. These copolymers formed injectable 
solutions at 5ºC and at physiological temperatures formed strongly associated networks.  
The group reported that these networks were stabilized by either crosslinking, in the case 
of the networks formed from multiple armed PEG, or micellar packing and 
entanglements in the case of the linear block copolymers.  The gelation kinetics of the 
hydrogel system were rapid, occurring in less than one minute, and there was no 
significant syneresis after 2 months.  The networks formed from the four-armed PEG 
exhibited the highest strength and deformability.  These materials are being investigated 
for use as a drug delivery or cell encapsulation system 193.  
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The incorporation of ionizable groups into PNIPAAm hydrogels can improve the 
swelling of the network more effectively than non-electrolyte hydrophilic components 
190
.   For instance, Shin et al. synthesized interpenetrating networks of PNIPAAm and 
poly(acrylic acid).  They found the swelling behavior to be highest above pH 5.3, 
conditions under which poly(acrylic acid) is charged.  They also found that the 
compressive stiffness of the networks was directly related to the swelling of the network, 
and therefore pH of the immersion media.  Gels swelled at lower pH, such as 3, were 
stiffer than those swelled at pH 4.6 and 5.3 214.   
 
In another study, block copolymers of PNIPAAm and acrylic acid were loosely 
crosslinked with N-N’-methylenebis(acrylamide), forming a transparent, pliable solution 
at ambient temperatures.  These gels possessed improved volume retention capabilities 
compared to gel networks composed of the PNIPAAm homopolymer.  This was 
attributed to the fact that the acrylic acid containing networks exhibited 75% water 
retention after 6 days immersion in phosphate buffered saline, whereas the homopolymer 
network lost half of its water during that time period.  The authors postulated that the 
improved swelling properties of the acrylic acid containing networks were due to 
repulsions of the –COO- groups, whereas the homopolymer chains can collapse 
substantially and expel pore water above the transition temperature 220.  
 
PNIPAAm-based hydrogels have also been investigated as three dimensional matrices for 
cell encapsulation.  The acrylic acid copolymers described above 220 were shown to 
support chondrocyte viability, resulting in the formation of cartilage-like tissue inside the 
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matrix.  Consequently, the hydrogels are a viable material for the repair of cartilage 
defects.  Cho et al. encapsulated human mesenchymal stem cells in a PNIPAAm matrix 
grafted with chitosan.  The cell-thermosensitive gel complex was injected into the 
submucosal layer of the bladder of a rabbit, resulting in cartilage growth.  This system 
could be used as a treatment for vesicoureteral reflux or reflux esophagitis  221.  
 
Solutions of PNIPAAm were also proposed as an extracellular matrix for an artificial 
pancreas.  It has been shown that islets of Langerhans, groups of pancreatic cells that 
produce and secrete hormones, need to be repeatedly replaced after implantation to avoid 
malfunction.  Solutions of PNIPAAm loaded with islets can be placed in a pouch and 
implanted into diabetic patients.  The PNIPAAm gel, formed at body temperature, has 
been shown to immobilize islets in rats without impairing insulin secretion.  Periodically, 
the pouches can be cooled, allowing the solutions to be withdrawn, and refilled with a 
fresh polymer/cell suspension 222-224.   
 
2.5.5 PNIPAAm-based Systems for Drug Delivery 
 
PNIPAAm-based hydrogels can also be used to immobilize drugs, enzymes, antibodies, 
and other biomolecules. The LCST phase transition can be used as trigger for drug 
release.   In many of these cases, therapeutics are loaded inside a swollen matrix at T< 
LCST and is released when placed in a medium with T>LCST 225.  An initial burst 
release of surface drug, or other biologically active agent, can occur.  This is followed by 
the formation of a dense skin on the outside of the hydrogel as a result of the temperature 
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gradient across the gel.  Drug from within the matrix is squeezed out due to a buildup of 
hydrostatic pressure inside the gel.  Lastly, as PNIPAAm chains throughout the entire 
network collapse, drug release can occur via a diffusion process through the newly 
formed gel 225. 
 
Interestingly, the LCST phase transition can be used as an on or off switch for drug 
release. Hoffman et al. have studied the release rate of methylene blue from copolymers 
of NIPAAm and methacrylic acid, as well as from PNIPAAm homopolymer gels.  In 
both cases, above the LCST, there were two distinct regions of release where the amount 
of methylene blue liberated was proportional to the square root of time.  The first region 
was the initial rapid release and it was followed by a slow Fickian diffusion through the 
network at long times 225.  Gutowska et al. 226 synthesized PNIPAAm copolymers with 
acrylic acid which were crosslinked with ethylene glycol dimethacrylate.  They reported 
a zero order release profile for acetaminophen  at pH of 7.4, which was dictated by the 
des-welling kinetics of the gel network.  This release occurred as a response to heating 
the polymer above its LCST, in contrast to the NIPAAm copolymer system with butyl 
methacrylate studied by Bae et al 227.  They reported that the release of indomethacin 
occurred at temperatures lower than the gel LCST.  Above the LCST, the release was 
inhibited by the formation of a dense outer layer on the polymer surface.  The formation 
of this layer was found to be controlled by the concentration of hydrophobic comonomer.  
The presence of the hydrophilic component in the PNIPAAm copolymers with acrylic 
acid prevented the dense skin formation and allowed for release above the phase 
transition of the gel 226.   
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Drug loading into, and release from, a hydrogel network will be controlled by pore 
volume fraction, pore size and their interconnections, the size of the drug, interactions 
between the polymer and the drug, among other factors  228.  Some research efforts have 
focused controlling the release rate of certain drugs from PNIPAAM systems.  
Specifically, efforts have been directed into understand how to reduce a burst release of 
drug, which could lead to toxic levels of drug in the blood plasma 229, as well as 
modifying the system to prolong dosing of the drug.   
 
For instance, Zhang et al. 230 prepared hydroxyl-functionalized glycerol poly(-
caprolactone) based microspheres loaded with ovalbumin and physically entrapped them 
within a crosslinked PNIPAAm hydrogel.  At physiological temperature,  the PNIPAAm 
hydrogel alone release 90% of the ovalbumin within 24 hours, but only 40% of the model 
drug was released after 60 days from the combined microsphere/hydrogel delivery 
system.  The release curve for the latter had a typical biphasic pattern, with an initial 
burst release followed by a slow sustained release.  Release from the combined system 
was also examined at 22ºC, and the release characteristics were similar to those at 37ºC, 
but the burst release was smaller in magnitude.  This was attributed to the collapse of the 
PNIPAAm chains extruding ovalbumin from the network.  A more sustained release was 
achieved at 37ºC because the collapsed PNIPAAm matrix slowed the release of the drug. 
 
In another study, interpenetrating networks of temperature sensitive PNIPAAm and 
hydrophobic poly(ethylene acrylate) were investigated for the release of hydrophobic 
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drug daidzein.  The release profiles were compared to those from interpenetrating 
networks composed of the PNIPAAm homopolymer.  The poly(ethylene acrylate) created 
hydrophobic reservoirs, present even below the LCST when the gel is in the hydrated 
state.  This increased the diffusion resistance of the drug through the network and slowed 
its release rate, thereby avoiding the burst release seen with the homopolymer network 
231
.   
 
Wu et al. 228 evaluated the release of bovine serum albumin (BSA) and insulin from a 
crosslinked PNIPAAm network.  Drug loading was achieved by soaking the crosslinked 
gels in aqueous solutions of the proteins for 4 days, and it was found that loading 
decreased with increased network density, which limited the adsorption of the protein.  It 
was found that the insulin was released in its entirety within 48 hours, while the release 
of the encapsulated bovine serum albumin was incomplete at the end of the study.  The 
group hypothesized that the release of the BSA was slowed by a strong protein-gel 
interaction due to hydrogen bonding or hydrophobic interactions.  Other researchers have 
also reported an association between PNIPAAm and BSA whichcan be described as an 
intramolecular complex of a PNIPAAm chain with several bound albumin molecules 232.  
Zhang et al. demonstrated that release bovine serum albumin from interpenetrating 
polymer networks of PNIPAAm lowered the burst release compared to non-
interpenetrating PNIPAAm networks.  This is due to the higher polymer density in the 
interpenetrating network, inhibiting protein diffusion and increasing its interaction with 
the BSA.  In addition, they also noted an incomplete release of the albumin 233.   
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Other studies on drug release from PNIPAAm networks have focused on the use of micro 
or nanosized PNIPAAm-based gel carriers.  Microgels composed of PNIPAAm 
copolymers with acrylic acid were prepared.  BSA was loaded into the microgels by 
incubating them in a solution of BSA and phosphate buffered saline for 12 hours, 
allowing the albumin to adsorb onto the particles.  It was found that without the acrylic 
acid component in the copolymer, albumin adsorption did occur, though in small 
quantities.  The authors maintain that the driving force for the adsorption was the 
hydrogen bonding interaction occurring between the carboxyl groups on the albumin and 
the amide groups on the PNIPAAm.  However, adsorption was enhanced considerably by 
the presence of acrylic acid, due to the affinity between the carboxyl groups on the 
acrylic acid and the –CONH- groups on the protein.  BSA loading was maximum at pH 
between 4 and 5, since the acrylic acid dissociates, initiating an electrostatic attraction 
with the positive charges on the protein molecule 234.   
 
Another group studied the potential for using PNIPAAm-based nanogels to prevent 
proteins against denaturation agents.  Their studies demonstrated that nanospheres of 
various sizes between 765 and 1146 nm composed of PNIPAAm crosslinked with PEG 
dimethacrylate 400 and 1000 had the ability to protect insulin against high temperature.  
After 12 hours at 80ºC, 25% of the insulin loaded into the nanoparticles could still be 
detected by reverse phase high pressure liquid chromatography, compared to 0% for the 
control, which was an insulin solution in phosphate buffered saline 235. 
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Nanoparticles consisting of interpenetrating polymer networks of poly(acrylic acid) and 
PNIPAAm were also investigated as a potential drug delivery system 236.  The 
nanoparticles, loaded with dextran markers of various molecular weights, can be 
dispersed in an aqueous medium at ambient temperatures and injected into the body, 
where the dispersion becomes a gel as a result of the phase transition of PNIPAAm.  The 
resulting gel was described by the authors as a physically crosslinked system of 
nanoparticles.  The bonding between nanoparticles can be turned on or off using the 
gelation characteristics of PNIPAAm.  The release studies, conducted at 37ºC, indicated 
that lower molecular weight dextrans were released from the network much faster than 
the higher molecular weight markers.  Decreasing the particle radius did not have a 
significant impact on release..  Additionally, decreasing the weight percent of copolymer 
in the particles increased the release rate due to the formation of pores through which the 
model drug molecules could diffuse.   
 
Hsieu et al. 237 studied two PNIPAAM-based systems designed for the controlled release 
of ophthalmic agents for drug release.  The first system was composed of linear 
PNIPAAm chains, which formed an entangled network above 32ºC through which the 
drug could diffuse.  The second was a mixture of linear PNIPAAm chains combined with 
physically entrapped crosslinked PNIPAAm nanoparticles.  The intraocular pressure-
lowering effect was measured in order to evaluate the release characteristics of the 
systems.  It was found that the composite system produced a longer, sustained release.  
The intraocular pressure drop lasted 32 hours for the composite system, compared to 24 
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for the linear PNIPAAm network.  Both delivery systems produced an improved effect 
over traditional eye drops, the pressure drop duration of which only lasts 6 hours. 
 
One of the most interesting applications for nano and microscale PNIPAAm delivery 
systems is targeted cancer treatment based on magnetic particles.  Magnetite 
nanoparticles were conjugated to functionalized PNIPAAm chains 238.  Because the 
magnetite particles generate heat in response to an alternating magnetic field, the system 
exhibited a temperature-induced aggregation in response to the magnetic field.  In 
addition, the nanoparticles also possessed free carboxyl groups, which could be used as a 
conjugation point for drugs.   
 
Muller-Schulte et al. 239 studied the release characteristics of a similar system. Magnetic 
colloids and model drugs rhodamine B or methylene blue were encapsulated together 
inside spherical micro and nanoparticles composed of crosslinked PNIPAAm.  Those 
model drugs were chosen due to similarities in molecular mass and structure to the 
anticancer drug doxorubicin.  When an alternating magnetic field was applied, the 
particles were heated above the transition temperature of the PNIPAAm, due to heat 
transfer between the magnetic colloid and the polymer matrix, resulting in the complete 
release of the model drugs within 16 minutes, in concentrations that would be adequate 
for cancer therapy.  Methylene blue had a slightly slower release, attributed to an 
interaction between the positive charge on the methylene blue and the negative charge on 
the magnetite.   
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Nanoscale delivery systems composed on polymeric micelles have gained significant 
importance in biomaterials over the last two decades 240.  In an aqueous environment, 
amphiphilic block copolymers can form micelles, with the hydrophobic block becoming 
the hydrophobic corona of the micelle, and they hydrophilic forming the outer shell, or 
corona..  The highly hydrated corona of the micelle reduces recognition of the particle by 
phagocytic cells, increasing circulation time in the bloodstream 241.  In addition, the 
hydrophobic core can serve an environment for the incorporation hydrophobic drugs 241, 
which protected against external stresses by the outer shell.  These hydrophobic drugs 
would otherwise have a very low bioavailability in the body 240.  
 
Temperature-sensitive PNIPAAm copolymer-based micelles all function by a similar 
mechanism. At ambient temperatures, hydrated PNIPAAm chains for the micelle corona, 
while a hydrophobic comonomer, conjugated the PNIPAAm, stabilizes a hydrophobic 
drug in the core.  Drug release occurs as a result of increasing temperature, which causes 
the PNIPAAm to become hydrophobic, causing structural changes in the polymeric 
micelles.  For instance, amphiphilic graft polyphosphazene, constructed with hydrophilic 
PNIPAAm oligomers and hydrophobic ethyl 4-aminobenzoate side groups can assemble 
into micelles at 25ºC.  Above the LCST of PNIPAAm, occurring at 32.6 ºC, the micelles 
aggregate due to interactions with neighboring PNPAAm chains, resulting in an abrupt 
increase in the measured particle size 242.   
 
Temperature and pH responsive micelles were constructed from a diblock copolymer of 
poly(t-butyl acrylate-co-acrylic acid) and PNIPAAm.  At room temperature and pH 5.8, 
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the copolymers form micelles with the t-butyl acrylate as the core, and the hydrophilic 
acrylic acid and PNIPAAm chains stretched out to form a two component shell.  When 
the temperature is raised from 25ºC to 32.4ºC, the LCST of the PNIPAAm, water 
progressively becomes a poorer solvent for the PNIPAAm, so these chains collapse into 
the core and the acrylic acid composes the corona.  At this temperature, a significant 
decrease in the hydrodynamic size distribution of the particles could be measured.  As the 
temperature is raised further to 50ºC, the size of the particles reaches a constant value 
because the collapse of the PNIPAAm chains stop.  In addition, with the temperature held 
constant at 25ºC, and the pH lowered, the 3.0, the acrylic acid chains collapse to the core 
and PNIPAAm becomes the corona.  The solubility of the acrylic acid depends on the 
degree of ionization and is enhanced at increasing pH values 243.   
 
2.6 Poly(ethylene glycol) 
 
Poly(ethylene glycol) (PEG) is a hydrophilic, non-ionic, crystalline polymer.  Its 
chemical structure is shown in Figure 2.13.  It is soluble in water via hydrogen bonding 
interactions 244.  PEG is known for its biocompatibility.  It has been approved by the FDA 
for internal consumption 245.   
 
Because of its biocompatibility, PEG has received ample attention in the biomaterials 
community of recent years.  PEG is a component in several injectable biodegradable 
polymer systems intended for drug delivery, such as ABA or BAB block copolymers, 
where A is PEG and B is poly(DL-lactide-co-glycolide).  These systems are soluble in 
 69 
water just below room temperature due to the dominating behavior of hydrogen bonding 
that exists between the PEG and water.  At slightly higher temperatures, typically above 
30ºC, the behavior of the hydrophobic poly(DL-lactide-co-glycolide) dominates, 
allowing it to form associative physical crosslinks, causing a sol to gel transition.  These 
systems have been shown to be effective carriers for both hydrophilic and hydrophobic 
drugs, such as 5-fluorouracil and indomethacin 246.  Other PEG based sol to gel systems 
have also been investigated for biomedical applications, such as copolymers with 
polyglycolide, -caprolactone, sulfamethazine 247, poly(butylene oxide) 248, and 
poly(propylene oxide) 249.   
 
In many cases, research has been directed at using PEG-based materials for scaffolds that 
support cell growth and function.  For instance, Sims et al. 250 developed a technique for 
delivering a mixture of bovine chondrocytes and PEG subcutaneously into rats.  The cells 
were suspended in a 20 wt/vol% solution of PEG 100,000 g/mol.  It was hypothesized 
that the PEG could provide a biocompatible scaffold in which the chondrocytes could 
proliferate and secrete extracellular components.  The researchers saw an increase in the 
glycosaminoglycan content of the rat cartilage.  However, the PEG scaffold exhibited 
rapid dissolution and poor mechanical properties 251.   
 
Subsequent work showed that the properties of these networks can be enhanced by the 
preparation of crosslinked or interpenetrating PEG networks.  For example, PEG 
dimethacrylate-based hydrogels were prepared by UV photopolymerization.  By varying 
the crosslinking density of the network, hydrogels were prepared with shear moduli 
ranging from 10 kPa to 1 MPa.  In addition, supplementing the reaction mixture with a 
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small amount of glycidyl methacrylate comonomer created reactive sites within the 
network through which biomolecules could covalently bond with the PEG network.  
Textured surface topographies, in the form of parallel grooves, were created on the 
hydrogels by casting them on microstructured silicon wafers.  The cellular response to the 
surface topography and varying mechanical properties will be investigated 252.   
 
Crosslinked PEG scaffolds can also be rendered biodegradable by the incorporation of 
hydrolytically degradable components into the hydrogel matrix.  Crosslinked hydrogels 
were prepared from photopolymerization of PEG dimethacrylate.  Three degradable 
lactide units were grafted to each PEG molecule.  Additionally, neural cells were 
photoencapsulated into the network, which were shown to differentiate, proliferate, and 
generate neural tissue which penetrated through the open space in the network.  The 
distance between crosslinks in the network, or the mesh size, was shown to be a 
controlling factor in the rate of tissue ingrowth.  If the average mesh size was too narrow, 
neural growth was inhibited.  Because the network mesh size increased as the lactide 
units degraded, one way to control the rate of tissue ingrowth is to vary the lactide 
content of the network.  This work also demonstrated that the PEG-based material was 
well tolerated by the neural cells, making it a viable carrier for cell transplantation into 
the central nervous system 253. 
 
Conventional tissue engineering scaffolds which only provide a temporary, 3-D structural 
support are being replaced with scaffolds which are composed of more interactive 
biomaterials, such as biomolecules. which not only support cell migration and 
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proliferation, but initiate it 254.  In this new direction in tissue engineering, PEG still 
remains a major component in the hybrid biomaterials.  For instance, PEG-protein 
hydrogels have been studied for applications in tissue engineering because the protein 
sequences naturally possess cell signaling domains for adhesion and protease degradation 
254
.  Meanwhile, the PEG domains impart structural integrity to the scaffold.   
 
Benoit et al. created PEG hydrogels functionalized with heparin to use as a culture 
system for human mesenchymal stem cells 255.  Heparin has been shown to promote cell 
adhesion 256 and interact with proteins associated with osteoblast and osteoblast 
progenitor cell adhesion 257.  In this study, 94% of the stem cells survived over the five 
week study, compared to only 47% in previous studies with unfunctionalized PEG 
hydrogels 258.  This improvement was attributed to the ability of heparin to bind with 
fibronectin and bone morphogenic protein. 255.  Hwang et al. 259 incorporated 
glucosamine into embryonic stem cell-containing photocrosslinked PEG hydrogels.  
Glucosamine has been shown to play a role in enhancing the synthesis of cartilage, 
tendons, ligaments, bone, and other connective tissues 260.  The researchers found that the 
presence of glucosamine enhanced extracellular matrix production and, in doing so, 
helped improve the structural integrity of the scaffold. 
 
PEG has also been shown to be a beneficial component in mucoadhesive drug delivery 
systems.  Mucoadhesive devices can be applied to, and deliver drugs locally to, mucosal 
tissues, including the gastrointestinal, nasal, and buccal areas 261.  Mucoadhesion is the 
attachment of a natural or synthetic polymer to the mucosa 262.  This occurs via the 
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interpenetration, and subsequent hydrogen bonding, between the polymer chains in the 
chemical carrier with the glycoproteins present in the mucus 263.  Acrylic–based polymers 
have been extensively used in mucoadhesive applications due to their high adhesive bond 
strength with the tissue 264,265.  However, PEG can be used as a mucoadhesion promoter, 
though the polymer is not mucoadhesive itself.  PEG chains that are grafted onto the 
chemical carrier will enhance interpenetration of the material into the mucosa, increasing 
mucoadhesive strength 262,263,266-268.  For instance, Serra et al. 263 showed a 480% increase 
in the work of adhesion value for a poly(acrylic acid) copolymer with PEG 1000 g/mol 
tethers compared to pure poly(acrylic acid). 
 
Arguably, the most important and extensive use of PEG is in colloidal polymer systems 
for biological and pharmaceutical applications.  In fact, PEG is used universally as the 
hydrophilic block in polymeric micelles 241,269.  There are several reasons for its 
widespread use.  Firstly, PEG provides steric stabilization to colloidal particles such as 
liposomes or micelles 241.  The hydrated PEG chains create steric forces which compete 
with interparticle van der Waals attractive forces.  Particle coagulation is prevented 
because the repulsive forces overwhelm the attractive forces between particles 270.  The 
larger particle sizes caused by coagulation would increase the chances of the drug 
delivery vehicle being cleared by the immune system, reducing circulation time in the 
body 241. 
 
Secondly, PEG inhibits the surface adsorption of biological molecules 241, such as 
proteins, which typically occurs within the first few minutes of exposure to physiological 
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fluids.  As proteins approach a PEG surface, the PEG chains become compressed, 
reducing their conformational entropy and increasing their enthalpy, making protein 
adsorption thermodynamically unfavorable.  Also, the increase in particle concentration 
at the PEG surface due to the presence of proteins causes an influx of water caused by an 
osmotic pressure gradient, forcing the protein to separate from the surface 271.  Protein 
adsorption onto drug delivery vehicles could damage the particle or interfere in 
biochemical pathways 241.  Moreover, PEG chains prevent surface adsorption of proteins 
which belong to the reticuloendothelial system.  The adsorption of these proteins would 
attract phagocytic macrophages to ingest the drug delivery vehicle, clearing it from the 
body.  Grafting PEG onto particle surfaces will therefore impart “stealth” characteristics 
to the drug delivery system, increasing circulation time in the body 272.   
 
The work of Tobio et al. 273 is a prime example of how PEG can improve the stability and 
bioavailability of nanoparticle delivery systems.  The work investigated the influence of a 
PEG coating around poly(lactic acid) nanoparticles on their stability in GI fluids and their 
ability to transport proteins though the intestinal mucosa.  The authors hypothesized the 
PEG coating would help to overcome the challenges involved in oral application of drug 
carriers, specifically the instability of the particles in the GI tract and low intestinal 
uptake of the drugs.  PLA nanoparticles have been shown to degrade significantly in 
intestinal fluids 274,275, but the protein repellent properties of PEG could help overcome 
this.  In addition, the ability of PEG to improve mucoadhesion could increase transport 
through the intestinal mucosa.  Their studies revealed that, after four hours of incubation 
in digestive fluids the PEG coated particles were only slightly degraded (3% of the 
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poly(lactic acid) was converted to lactate, compared to 9% for the uncoated particles).  
Additionally, the levels of radioactive antigen in the blood stream, which was 
encapsulated in the nanoparticles, were higher for the coated system 273.   
 
Similarly, in another study, using a hydrophilic PEG corona in polymeric micelles (with 
cyanoacrylate-co-hexadecyl cyanoacrylate as the hydrophobic block) for the delivery of 
active therapeutic molecules increased the half life of the particles in the blood.  Results 
also showed a higher uptake of the drug by the target organs, the spleen and brain, 
compared to non-PEGylated micelles, the composition of which was not expressly stated 
276
.   
 
2.7 Poly(ethylene imine) 
 
Poly(ethylene imine) or PEI is a cationic polymer consisting of primary, secondary and 
tertiary amines.  Its chemical structure is shown in Figure 2.14.  It is available in a wide 
variety of molecular weights and degrees of branching.  It exhibits a very high charge 
density over a large range of pH values.  In fact, PEI exhibits one of the highest charge 
densities among organic molecules 277.  The pKa value of the primary amine is around 9, 
the secondary amine around 8 and the tertiary amine around 6–7 278.  At pH of 10, the 
amine groups are uncharged, and the swelling of PEI under these conditions can be 
mainly attributed to the hydrophilicity of the amine groups.  Lowering the pH results in 
protonation of the amine groups.  In salt solutions, swelling under these conditions is 
determined by a balance between the polymer network osmotic pressure and elasticity.  
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The osmotic pressure resulting from the high concentration of counterions in the interior 
of the PEI network causes an influx of water which swells the polymer.  If the PEI chains 
are crosslinked, they will oppose this expansion 279.   
 
At the present time, the biological properties of PEI are not completely understood 280, as 
there have been few investigations into the biocompatibility of PEI toward human cell 
lines.  Larkard et al. 281 coated semiconducting electrodes with polymer films and 
examined the adhesion, proliferation, and morphology of rat neuronal cell lines on the 
polymer surfaces.  After 8 hours in a cell culture medium, a high percentage of the cells 
were found to be attached to the PEI.  After 72 hours, the cells were found to proliferate 
faster on PEI than on the other polymers (polypropyleneimine and polypyrrole).  It was 
therefore determined by this group that PEI is a satisfactory coating for the cultivation of 
neuronal cells.  In another study, the adhesion and proliferation of human Schwann cells 
was compared on substrates composed of fibronectin, laminin, crosslinked gelatin, or 
PEI.  It was found that adhesion and proliferation was satisfactory on all coatings, but the 
relative performance of PEI was poor.  Cell proliferation was moderate compared to the 
other polyelectrolytes, and while choice of substrate was deemed not to be an important 
consideration in the culture of Schwann cells, PEI was not recommended.   
 
Based upon these studies, it may be inferred that the biocompatibility of PEI may depend 
on cell type.  However, the molecular weight of PEI used in the aforementioned research 
articles was not reported by the authors.  Morimoto et al. 282 reported the cytotoxicity of  
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PEI to be molecular weight dependent.  A comparison among the cytotoxicity of PEI 
1800, 10,000, and 70,000 Da showed increasing cytotoxicity with molecular weight.   
 
In another study, PEI 70,000 Da was deposited onto a titanium alloy surface, and it was 
found that osteoblasts and fibroblast proliferation and adhesion decreased over a 7 day 
period 280.  A group who studied PEI 750,000 Da as a potential coating for bone implants 
evaluated the response of human osteoblasts-like cells and periodontal ligament cells.  
While maximum adhesion occurred within twenty minutes for the coatings composed of 
poly(sodium 4-styrenesulfonate), poly(allylamine hydrochloride), poly(L-glutamic acid), 
or poly(L-lysine), cell adhesion to PEI was similar to that of glass or plastic.  In addition, 
no proliferation was seen for either cell type on the PEI substrate.  The cell nuclei became 
condensed or fragmented, and after 24 hours, cell apoptosis was observed.  These results 
are consistent with those of Moghimi et al. 283, who showed that branched PEI of 
molecular weight 25,000 and 750,000 Da induced necrotic changes within 30 minutes in 
human umbilical vein endothelial cells and hepatocyte-like cells.  Within 24 hours, cell 
apoptosis was initiated.  While the authors note that the molecular basis for the 
cytotoxicity is not understood, this property of PEI may have beneficial aspects when 
applied to tumor gene therapy.  
 
Despite its potential cytotoxicity, the presence of the ionizable groups on PEI has 
motivated researchers to investigate its potential in drug delivery.  Vinegradov’s group 
developed nanosized gel networks composed of crosslinked PEG and PEI.  While the 
PEG aids in the stabilization of the aqueous nanogel dispersions, the cationic PEI chains 
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allow for the immobilization of negatively charged biologically active molecules, such as 
indomethacin.  Prior to drug loading, the nanogels form expanded networks due to the 
osmotic pressure generated by the fixed positive charges on the PEI.  After drug loading 
occurs, due to the formation of an electrostatic complex with the charged drug molecule, 
the nanogels dehydrate, resulting in network collapse and decrease in particle size.  
Release studies showed that 17.5% of the indomethacin was released during the first 
hour, followed by an 82% release by 24 hours.  Interestingly, the release of the drug 
causes the nanogel to swell again, due to the increase in net ion concentration inside the 
network 279. 
 
Some researchers have diverged from using PEG as the hydrophilic corona for micellar 
structures in favor of using PEI.  The cationic nature of PEI allows the micelles to 
interact with negative charges on cell surfaces 284,285, helping to increase cell uptake.  
Tian et al. 284 synthesized novel amphiphilic biodegradable block copolymers based on 
PEG, hyperbranched PEI, and poly(-benzyl L-glutamate).  In aqueous solutions, these 
copolymers self-assembled to micellar structures.  Characterization studies on the 
micelles revealed that particle size was dependent on the ionic state of PEI.  As its charge 
density increased, the particle size decreased.  The authors attribute this change to an 
increase in macromolecular aggregation, which impeded hydrophobic block interactions.  
In addition, micellar solutions were added to plasmid DNA, which readily became 
immobilized on the micelles.   
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Another group prepared micelles composed of PEI and poly(D,L-lactide-co-glycolide).  
They also found that the micelle size depended on the charge density of the PEI, the size 
decreasing as charge density increased.  This was once again attributed to the inhibition 
of hydrophobic block interactions.  This group incubated micellar solutions with human 
keratinocyte cells and found that the particles not only adsorbed onto the cell membranes, 
but translocated into the nucleus.  PLGA nanoparticles were also studied as a control, and 
minimal adsorption and diffusion into the cell surface was exhibited 285.   
 
Based on the above findings, it is obvious why the most prominent application of PEI is 
gene delivery 286.  DNA is condensed with PEI due to its electrostatic interaction with the 
positive charges on PEI.  In the condensed form, DNA is protected against digestion of 
enzymes and can be delivered toward a targeted cell, and internalized via endocytosis 287.  
Polycations destabilize cell membranes, causing their rupture, releasing the PEI/DNA 
complex into the nucleus,  allowing it to be expressed 288,289.  It has been reported that the 
size of the PEI has a strongly affects the transfection efficiency.  Low molecular weight 
PEI (less than 2000 Da), though proven to be non-toxic, produces low transfection 
activity.  High molecular weight PEI (greater than 25 kDa) has shown high transfection 
activity combined with significant cytotoxicity 290,291.   
 
While the reason for its low transfection activity remains unclear 292, there have been 
some efforts to chemically modify low molecular PEI in order to increase its transfection 
efficiency while retaining its low cytotoxicity.  Peterson et al. created  PEI block 
copolymers with star-shaped PEG  molecules 292.  They hypothesized that chemically 
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modifying low molecular weight PEI to increase its size would increase the transfection 
efficiency, and that the charges on PEI do not critically contribute to condensation.  
Based on the obtained results, the authors maintain that low molecular weight PEI 
exhibits poor transfection efficiency because it only moderately condenses the DNA, 
insufficiently protecting it.  However, its condensation potential was enhanced by 
coupling it to star PEG molecules with branch sizes of 10 or 15 kDa.  These conjugates 
had similar size to high molecular PEI, and formed compact, stable complexes upon 
mixing with plasmid DNA.  The transfection activity and cytotoxicity of these complexes 
are still under investigation.   
 
Similar copolymers, based on linear copolymers of PEG 5 kDa and PEI 22 kDa, have 
been complexed with DNA to deliver genes to tumors which encode for the tumor 
necrosis factor 293.  Tumor growth inhibition was shown to occur in three murine tumor 
models.  It has also been demonstrated that the PEG molecules prevent non-specific 
interactions with the biological environment and prolong the circulation time of the DNA 
complex 294.   
 
2.8 Bioadhesive Polymers for Soft Tissue Repair 
 
Bioadhesive polymers are natural or synthetic materials that can be used for soft tissue 
repair, including wound closure, achieving hemostasis after a surgical procedure, or 
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fistula repair. Bioadhesive materials can supplement the use of sutures or replace them 
altogether 295.  
 
Cyanoacrylates are a widely used class of bioadhesive compounds.  The use of these 
adhesives in medicine began in the 1960s 296.  Cyanoacrylates are synthetic glues that 
polymerize in the presence of water or blood.  N-butyl-2-cyanoacrylate (Histoacryl, B 
Braun, Melsungen, Germany) and N-butyl-2-cyanoacrylate (Glubran, GEM S.r.l., 
Viareggio, Italy) were recently approved for endoscopic use in Europe. Although 
Histoacryl and Glubran are not commercially available in the United States, 2-octyl-
cyanoacrylate (Dermabond, Ethicon, Inc., Somerville, NJ) was approved by the FDA for 
superficial wound closure, but not for endoscopic applications 297. 
 
Cyanoacrylate sealants have had wide ranging clinical applications.  For example, 
injection therapy with cyanoacrylate adhesives has shown to be an effective treatment for 
gastric varices 298.  In one clinical study, this treatment was shown to be superior to band 
ligation, a widely accepted treatment for gastric variceal bleeding 299.  The use of 
cyanoacrylates for the treatment of gastric varices has been widely adopted outside of the 
United States 297.  In addition, N-butyl-2-cyanoacrylate  was used to repair esophageal 
variceal rupture, and this method was found to be superior to sclerotherapy with 
ethanolamine oleate solution 300.  The same adhesive was used to repair a peptic ulcer, 
and it was shown to be superior to using hypertonic saline.  While the two treatments 
showed similar initial bleeding rates, the re-bleeding rate was lower for the cyanoacrylate 
adhesive 301.  In another study, 8 out 12 pancreatic fistulas were successfully closed with 
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N-butyl-2-cyanoacrylate 302.  2-octyl-cyanoacrylate was used to close a corneal 
perforation, and the patient went on to full visual recovery 303. 
 
Mixing cyanoacrylates with lipid soluble contrast agent lipidol increases the radiopacity 
of the adhesive, enhancing imaging.  Lipidol also retards the polymerization process, 
allowing the adhesive to be applied endoscopically via needle, with less risk of premature 
solidification.  When closing superficial wounds, Chigira et al. recommends combining 
2-octyl-cyanoacrylate with reinforcing skin closure tape, which significantly increases its 
tensile strength.  Another group proposes preparing composites of 2-octyl-cyanoacrylate 
and poly(L-lactic-co-glycolic acid) to increase tensile strength.   
 
Cyanoacrylates form solid impermeable plastics in situ after polymerization is complete 
304
.  Therefore, possible complications include inflammatory response to a foreign body 
and local tissue necrosis 305.  Wippermann et al.296 created distal coronary anastomoses in 
porcine hearts and subsequently sealed with butyl cyanoacrylate.  Immediate hemostasis 
was obtained with the application of the cyanoacrylate adhesive.  Histological 
examinations were performed to determine the immunologic response to the adhesive.  
The inflammatory response to the adhesive was found to be moderate.  Microscopic 
evaluation revealed the presence of foreign body giant cells.  Three months after the 
surgery, evidence of an inflammatory response still existed and glue fragments were still 
present, though there was no scar tissue.  Another group used cyanoacrylate to close 
anastomotic blood vessels in adult dogs.  They reported necrosis rapidly occurring in the 
region surrounding the glue, which was later replaced by fibrous tissue.  They propose 
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that this was caused by thermal injury as a consequence of the heat generated from the 
exothermic polymerization 306. 
 
Fibrin adhesives have been investigated experimentally since the 1970s 307.  They act as a 
hemostatic plug by mimicking the last stage of blood clotting.  Fibrin sealants contain 
components such as fibrinogen, factor XIII, and thrombin.  Thrombin catalyzes the 
conversion of fibrinogen to fibrin, and factor XIII catalyzes the formation of crosslinks 
within fibrin to form an insoluble fibrin clot 308.  The clot is resorbed within days or 
weeks by macrophages and fibroblasts 309, allowing healing to occur at the site of 
adhesion.  Because they are natural materials, fibrin sealants are completely 
biocompatible 310.  
 
They are available commercially from Tisseel (Baxter, Westlake Village, CA) and 
Hemaseel (Hemacure, Sarasota, FL) 311.  They are approved for topical application and 
the closure of anastomoses in cardiovascular and colorectal surgery 297.  Tisseel is 
composed of four main components.  Fibrinogen, which is obtained from human donor 
plasma, is dissolved in bovine aprotinin.  Dry human thrombin is reconstituted in calcium 
chloride, and the two solutions are mixed and applied simultaneously 312.   
 
On the whole, studies comparing this fibrin adhesive to other hemostatic agents show 
fibrin to be equivalent or superior 297.  One such trial compared the use of the fibrin 
sealant to the injection of polidocanol for the repair of peptic ulcers.  Patients who 
received daily applications of the fibrin sealant had less re-bleeding and fewer acute 
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treatment failures.  However, patients who received only a single fibrin treatment did not 
experience significantly different outcomes than those in the control group 313.  In a 
randomized trial involving patients with esophageal variceal bleeding, the outcome of 
using sclerotherapy with ethanolamine in addition to human thrombin was compared to 
using sclerotherapy alone.  All clinically important outcomes were deemed to be 
equivalent 314. Fibrin adhesives have also been concluded to be effective sealants for 
corneal incisions, LASIK flaps, and conjunctival and skin grafts 304.  
 
Although fibrin sealants are not associated with inflammatory or foreign body reactions 
310
, some components in fibrin adhesives may present complications to patients.  Because 
the fibrinogen is obtained from human plasma, theoretically there is the risk of viral 
transmission.  Because aprotinin is extracted from bovines, there is risk or immunologic 
or allergic response when administered to humans 312.   
 
Glutaraldehyde (Figure 2.15) has achieved widespread acceptance as a successful 
chemical agent for tissue crosslinking 315.  Glutaraldehyde is inexpensive, can form 
miscible solutions with water, and reacts with tissue in a short period of time.  
Glutaraldehyde is an aliphatic organic molecule with aldehyde groups at each end. The 
di-aldehydes are able to react readily with the amines on proteins of the tissue 
extracellular matrix, via a Schiff’s base reaction 316, resulting in covalent crosslinks.  
Lower concentrations of glutaraldehyde, rather than high concentrations, have been 
shown to more effective for bulk tissue crosslinking.  High concentrations produce rapid 
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crosslinking of the tissue surface and inhibit diffusion of glutaraldehyde into the tissue 
317
. 
 
Because of its ability to rapidly react with tissues, a major group of tissue adhesives are 
based on glutaraldehyde.  BioGlue (CryoLife Europa Ltd, Hampshire, United Kingdom) 
is composed of BSA and glutaraldehyde.  The material does not become active until the 
two components are mixed at the point of application.  A rigid mechanical seal forms 
within seconds 318. The glutaraldehyde forms covalent crosslinks between the BSA 
molecules and also reacts with the tissue at the location of application, forming an 
adhesive bond at the repair site 319.  Currently, BioGlue is approved in the United States 
to repair aortic dissection 320.  However, in Australia, the Therapeutic Goods 
Administration has approved BioGlue for all surgical specialties, including cardiac care 
321
.  The glue exhibits very slow biodegradation, as remnants have been shown to exist in 
the body as long as two years after surgery 321,322.  The cohesive strength of BioGlue is 
higher than the fibrin glue Tisseel 321.  As a consequence of this strength, Bioglue is not 
recommended for use in children because it could inhibit growth when applied 
circumferentially 321.   
 
Passage et al. produced a large scale evaluation of 115 consecutive patients who 
underwent a range of cardiac procedures such as aortic root, aortic wall, or valve 
replacement, and coronary artery bypass grafting.  BioGlue was used for the achievement 
of hemostasis, tissue adherence, or tissue strengthening.  All of the surgeons believed that 
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BioGlue facilitated the operation.  However, they recommended more studies to assess 
the long term patient outcomes 321. 
 
BioGlue was also investigated for use after a thoracotomy to reduce alveolar air leaks.  
These air leaks could not be repaired by conventional tissue closure techniques.  It was 
found that BioGlue reduced air leak duration and resultant chest drainage, as well as 
hospital stay.  The surgeons recommended that the volume of BioGlue applied be kept to 
a minimum, while, of course, ensuring tight closure of the air leaks 323.  BioGlue was also 
applied for the achievement of hemostasis after a partial nephrectomy.  Adequate 
hemostasis was achieved, in addition to decreased blood loss and transfusion rate.   
 
The authors recommended investigation into using BioGlue in renal surgery 324.  The 
adhesive was also used to repair a dural tear which occurred during lumbar 
decompressive surgery.  Two years after application, during re-operation for an onset of 
sciatica, fragments of the glue were found adjacent to the dura.  They were not encased in 
fibrous tissue and there was no evidence of an inflammatory response.  Complete dural 
healing occurred 322. 
 
Despite its high adhesive strength, the potential toxicity of glutaraldehyde based 
adhesives needs to be considered 318.  Inflammatory responses have been associated with 
glutaraldehyde application and have been ascribed to its cytotoxicity 325.  Application of 
BioGlue to the bovine pericardium resulted in the presence of inflammatory cells 
surrounding the fixed tissue for as long as 26 weeks 326.  In another study, BioGlue was 
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used to repair bronchial anastomesis in sheep.  While tight closures were obtained with 
the adhesive, microscopic evaluation revealed the presence of polymorphonuclear 
neutrophils, macrophages, granulation tissue, and foreign body giant cells after two 
weeks.  This response did not occur in the sutured group 327. 
 
A valuable study was performed by Fürst et al 318.  The group cured portions of BioGlue 
and overlaid it with saline solution.  The supernatant was analyzed for glutaraldehyde 
content and applied to human embryo fibroblasts or mouse myoblasts, so the in vitro 
cytotoxic effects of the glue could be evaluated.  In addition, the in vivo toxicity of 
BioGlue was evaluated in the lung, liver, and aortic tissues of rabbits.  The application of 
the supernatant to both cell lines caused changes in the morphology and density of the 
cells.  Even diluted supernatants, which contained 10% of the initial concentration of 
glutaraldehyde, resulted in a complete loss of cell viability.  The in vivo studies revealed 
severe inflammatory responses in the lung and liver tissues, characterized by necrosis, 
edema, granulation tissue, and detected giant cells.  In contrast, the aortic model showed 
no significant differences between the tissue reactions to BioGlue and the biocompatible 
fibrin sealant 318. 
 
While several authors have demonstrated that inflammatory effects are a potential 
consequence of glutaraldehyde-based adhesives, this is the only study which 
systematically compares the physiological response of different tissues.  The results in 
this study indicate that the consequences of glutaraldehyde toxicity are strongly 
dependent on the location of application.  The authors postulate that the inflammatory 
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response was less severe in the aortic tissues than in the lung or liver because the aorta is 
contains larger amounts of extracellular matrix and fewer cellular components, rendering 
them less sensitive to the cytotoxicity 318.  In addition, Matsuda et al. 328 suggested that a 
lesser inflammatory response would be elicited by the adhesive if the aldehyde groups 
were immobilized on the surface of the implanted material.  This would prevent diffusion 
deep into the natural tissues, a scenario which could cause a large scale, persistent 
inflammatory response due to large scale damage and impairment.   
 
It is important to note that it is not clear whether the inflammatory responses to BioGlue 
have had any long term negative effects on the patient 329.  Herget et al. 327, who repaired 
bronchial anastomesis in sheep with BioGlue, noted that healing was not complicated by  
the foreign body reactions, and that the adhesive layer was eventually replaced by 
connective tissue.  However, another group reported tissue healing in glutaraldehyde 
treated tissues was retarded due to the microenvironment created by the inflammatory 
responses 325.   
 
A number of adhesive systems have been developed specifically for the repair of the 
damaged intervertebral disc tissues.  Repair of a defective annulus can be achieved by 
applying a curable material, which forms a solid that closes the defect.  Slivka et al. 330 
proposes the delivery of a crosslinking agent into a damaged intervertebral disc in order 
to stabilize the disc structure, help prevent prolapse of the disc material, and restore or 
retain biomechanical function.  If delivery of the crosslinking agent is targeted at the 
center of the disc, it would result in crosslinking of the native nucleus pulposus.  This 
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would shift its material properties from a viscous gel to a viscoelastic solid, reducing the 
risk of herniation.  The crosslinking agent can also be used to adhere the nucleus tissues 
to the surrounding annulus, further reducing its mobility in a degenerated disc. 
Furthermore, this technology could be used in conjugation with current surgical 
treatments for lower back pain, such as discectomy, to close the herniated portion of the 
annulus 330. 
 
Slivka et al. proposes using a range of crosslinkers, such as diepoxy compounds, 
diisocyanates, bis(sulfosuccinimidyl suberate), or glutaraldehyde.  The patent holders 
note that the crosslinker molecular weight should be over 100 Da, otherwise the agent 
can too easily diffuse into the tissues surrounding the disc.  They also propose modifying 
the polysaccharides or collagen in the native tissue with aldehyde groups using an 
oxidizing agent, then allowing spontaneous crosslinking to occur 330.  A similar method 
has also been proposed by Liu et al., who development a method for the oxidation of 
exogenous polysaccharides using  periodic acid or periodate 331.  The aldehyde 
functionalized polysaccharides will crosslink the collagen molecules in the tissue matrix.  
Growth factors can be incorporated into the system before or after crosslinking, providing 
a matrix for the therapeutic repair of the tissue. 
 
Tardy et al. 332 put forth a treatment method for collagen that should improve its stability 
and mechanical characteristics.  The tissues are heated via a laser, electrode, magnetic 
field, or heated aqueous solutions.  This shrinks the collagen in the tissue matrix, and then 
crosslinking is achieved with a solution of periodic acid or periodate.  This invention was 
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intended for the treatment of joint stability problems or the manipulation of skin structure 
and properties, but it could also be applied to repair of disc tissues.  However, heating 
could produce tissue damage or a non-uniform skin morphology 330. 
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Figure 2.1 Anterior view of the vertebral column showing the cervical, thoracic, lumbar, and sacral 
regions 7. 
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Figure 2.2 The division of the vertebrae into three regions 8. 
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Figure 2.3 (A) Lateral view, (B) superior view, (C) inferior view of the vertebra 7. 
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Figure 2.4 The structure of the intervertebral disc.  It consists of a nucleus pulposus (NP) surrounded 
by an annulus fibrosis (AF).  Both are sandwiched between two vertebral endplates (VE) 8. 
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Figure 2.5 A cylindrical interbody fusion cage. A, anterior; P, posterior 121. 
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Figure 2.6 Photograph of the Type III SB Charité 144. 
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Figure 2.7 The Charité artificial disc consists of a free-floating biconvex sliding core encased in 
concave endplates 146. 
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Figure 2.8 Photograph of the Prodisc-L 144. 
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Figure 2.9 Photograph showing the Maverick disc 144. 
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Figure 2.10 An implanted Prosthetic Disc Nucleus (PDN) device 162. 
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Figure 2.11 The Newcleus spiral implant 163. 
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Figure 2.12 The chemical structure of poly(N-isopropylacrylamide) (PNIPAAm). 
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Figure 2.13 The chemical structure of poly(ethylene glycol) (PEG). 
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Figure 2.14 The chemical structure of poly(ethyelene imine) (PEI). 
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Figure 2.15 The chemical structure of glutaraldehyde. 
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Chapter 3 - RESEARCH GOALS 
 
This work focuses on investigating the properties of a family of in situ forming 
PNIPAAm-based nucleus pulposus replacements.  The first objective in this work was to 
synthesize a class of hydrogels composed of PNIPAAm and PEG.  Because the 
PNIPAAm homopolymer holds little water and shows poor elastic recovery, the swelling 
and mechanical properties of PNIPAAm gels were tailored by the addition of the PEG.  
The molecular weight of the PEG chains and the relative proportions of NIPAAm and 
PEG units were varied.   
 
Then, the range of pertinent material behavior for the PNIPAAm-PEG family of 
copolymers, and how it varies with polymeric composition was examined.  These 
properties include lower critical solution temperatures, gel swelling, dissolution, stiffness, 
and elasticity.  Evaluation of the swelling and mechanical properties was carried out over 
long-term in vitro studies to determine the stability of the materials.  A material candidate 
from this class of materials was chosen for further evaluation as a synthetic nucleus 
pulposus replacement.  The copolymer formulation was then optimized to minimize 
water loss following implantation into the intradiscal environment, allowing the implant 
to remain space filling in the nuclear cavity.   
 
The last objective in this project was to impart bioadhesive properties to the injectable 
hydrogel system.  The PNIPAAm-PEG copolymer was blended with the amine 
containing polymer poly(ethylene imine) (PEI).  After gelation in the disc, the implant is 
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crosslinked with itself and with the surrounding tissues by the injection of a dialdehyde.  
This approach can help secure the implant in place, reducing the risk of implant 
migration or extrusion.  The material also has the potential to function as tissue adhesive 
for the repair of the degenerated intervertebral disc.  The specific aims in the project are 
as follows: 
 
Specific Aim 1:  Synthesize a class of polymers composed of PNIPAAm and PEG. 
Specific Aim 2:  Characterize the gelation, swelling and mechanical properties and long 
term stability of this family of hydrogels. 
Specific Aim 3:  Optimize the copolymer formulation to minimize water loss, and 
subsequent volume loss, due to the de-swelling of the polymer network following 
injection into the intradiscal environment. 
Specific Aim 4:  Modify the copolymer chemistry to impart bioadhesive properties to the 
hydrogel system and evaluate its capacity for tissue adhesion in vitro. 
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Chapter 4 - SYNTHESIS OF PNIPAAM-PEG BRANCHED 
COPOLYMERS 
 
4.1 Introduction 
 
The preparation of PNIPAAm-PEG branched copolymers begins with the synthesis of 
PEG dimethacrylate (PEGDM) from PEG diol and methacryloyl chloride (Figure 4.1).  
Synthesis was achieved using a modified procedure based on that of Bryant et al. 333.   
 
PNIPAAm-PEG branched copolymers are prepared by polymerizing the monomer 
NIPAAm in the presence of PEGDM, thereby creating a lightly crosslinked polymer 
network (Figure 4.2).  The PEGDM will be used in low enough quantities for the product 
to form a flowing solution in water below the LCST of PNIPAAm.  Most examples in the 
literature of crosslinked PNIPAAm systems form hydrated, insoluble polymer networks 
below the LCST of PNIPAAm 226,227,334.   
 
While PNIPAAm copolymerizations with methacrylate functionalized PEG chains have 
been reported before, most of these studies used short PEG chains.  Bae et al. 215 and 
Gutowska et al. 226 both prepared PNIPAAm networks that were crosslinked with 
ethylene glycol dimethacrylate (EGMDA).  Another group synthesized microspheres 
composed of PNIPAAm networks that were crosslinked with a combination of PEG (400 
and 1000 g/mol) dimethacrylate.  Still, there are some examples where researchers have 
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explored the use of higher molecular weight PEG chains.  PNIPAAm microgels, 
crosslinked with PEG (8000 g/mol) diacrylate 334 and PNIPAAm copolymers with star-
shaped PEGs with arms approximately 2000 g/mol 193 were both studied for drug 
delivery. 
 
Alava et al. studied the reactivity ratios of NIPAAm and PEG monomethacrylate.  The 
values were determined to be rNIPAAm=1.2 and rPEGM=0.13 335.  This indicates that 
NIPAAm is more reactive than PEG monomethacrylate to both propagating species.  
Copolymers of these two species would contain larger amounts of the more reactive 
monomer, NIPAAm, in random placement 336. 
 
In this work, a family of copolymers was synthesized by varying the molecular weight of 
the PEG blocks from 1000 to 10,000 g/mol and the relative amounts of NIPAAm and 
PEG.  Fourier transform infrared (FTIR) spectroscopy and nuclear magnetic resonance 
(NMR) spectroscopy were used to characterize the chemical nature of the polymers.  
Specifically, these analytical tools were used to verify the successful polymerization of 
NIPAAm, complete removal of residual monomer, and the covalent incorporation of 
PEG along the polymer backbone. 
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4.2 Experimental Section 
4.2.1 Materials 
 
N-isopropylacrylamide (NIPAAm) monomer (Sigma Aldrich) was recrystallized in n-
hexane before use.  Polyethylene glycol (PEG) diol (Mn = 2000, 4600, 8000, and 10000 
g/mol) (Sigma Aldrich), initiator 2,2’-Azobisisobutyronitrile (AIBN), 98% (Sigma 
Aldrich) poly(ethylene glycol) dimethacrylate (PEGDM) (n=1000) (Polysciences), and 
deuterium oxide (Sigma Aldrich) were all used as received. All solvents and other 
chemicals were of analytical grade. 
 
4.2.2 Methods 
4.2.2.1 Methacrylation of PEG 
 
PEGDM, with molecular weight between 2000 and 10,000 g/mol,  was synthesized from 
PEG diol333.  The diol was dissolved in methylene chloride and reacted with an excess of 
methacryloyl chloride and triethylamine under nitrogen atmosphere for 12 h at 4ºC and 
an additional 24 h at room temperature. The product was then precipitated in ether 
multiple times to ensure purification and the excess ether was removed in the vacuum 
oven.  The average methacrylation efficiency of the reaction was determined by 1H NMR 
(Varian 300, Palo Alto, CA) in deuterium oxide at 25ºC. 
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4.2.2.2 Copolymer Synthesis 
 
NIPAAm was polymerized in the presence of PEGDM to create PNIPAAm-PEG 
branched copolymers. Copolymers composed of five different block sizes were 
synthesized by using PEG 1000, 2000, 4600, 8000, or 10,000 g/mol dimethacrylate. For 
each PEG molecular weight, a high and low PEG content copolymer was produced by 
using a molar ratio of NIPAAm monomer units to PEG branches of 700:1 and 1600:1, 
respectively. The free radical polymerization, initiated by AIBN, took place in methanol 
at 65ºC for 48 hours. The methanol was evaporated from the reaction mixtures after 
polymerization was complete. The reaction product was purified by treatment with n-
hexane at 45ºC. The purified polymer was isolated by vacuum filtration and dried under 
vacuum overnight. It was subsequently ground into powder and analyzed with 1H NMR 
to verify the molar ratio of NIPAAm monomer units to PEG branches. 
 
Solutions containing 15 wt% polymer were prepared from the ground polymer and 
deionized water.  The polymer was dissolved overnight at 4ºC then centrifuged (Kendro 
Sorvall Legend Mach 1.6/R, Asheville, NC) at 15ºC and 10,000 rpm for 45 minutes to 
remove entrapped air from the viscous solutions.  
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4.3 Results and Discussion 
4.3.1 Methacrylation of PEG 
 
The 1H NMR spectrum for the PEGDM can be seen in Figure 4.3.  The signals 
corresponding to the functional groups are shown in the figure.  The average 
methacrylation efficiency of the reaction was tracked over a 12 month period and was 
found to be 90.8 ± 9.2 %.  This was calculated by comparing the area under the integral 
for the vinyl protons (=5.7 ppm, =6.1 ppm) to that of the PEG backbone (=3.5 ppm).   
 
4.3.2 Synthesis of PNIPAAm-PEG Branched Copolymers  
 
The extent of polymerization of the NIPAAm can be evaluated with FTIR 337.  Shown in 
Figure 4.4 is the FTIR spectra of the reaction mixture after 24 and 48 hours reaction time 
at 65ºC.  The time point t=0 refers to the FTIR spectrum of the reaction mixture prior to 
heating.  The peaks at 1650cm-1, 1543cm-1, and 1458cm-1 correspond to the Amide I 338-
340
, Amide II 338-340, and C-H bending 341 on the NIPAAm and PNIPAAm.  In addition, 
the peaks at 1368cm-1 , and 1387cm-1 correspond to the two isopropyl groups on the N-
isopropylacrylamide 338.  Therefore, these peaks are present at all time points.  At t=0, the 
peak at 1620cm-1 has been attributed to the C=C stretch on the NIPAAm monomer 341. In 
addition, the peaks at 984 cm-1 and 912 cm-1 correspond to out of plane C-H bending of 
an alkene with an RCH=CH2 structure, like the NIPAAm monomer.  The disappearance 
of these peaks over the course of the reaction confirms polymerization of the NIPAAm.   
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It is important to note that peaks for PEG or PEGDM are not seen in the FTIR spectra, 
likely because the instrument was not sensitive enough to detect the presence of PEG.  
The ether C-O stretch in PEG in typically seen around 1106 cm-1 and the C-H bending on 
an alkene with a methacrylate group structure (R2C=CH2) occurs between 880-900 cm-1 
341
.  Therefore, this FTIR analysis cannot be used to verify the covalent incorporation of 
PEG along the polymer backbone. 
 
A typical 1H NMR spectrum for PNIPAAm-PEG branched copolymers is shown in 
Figure 4.5.  The peak assignments have been previously described by Ma et al.342, 
however the group neglected to assign a peak to the methyl protons on the methacrylate 
group of the PEG (A), which were incorporated along the polymer backbone during 
polymerization.  The covalent incorporation of PEG along the polymer backbone can be 
verified by the presence of the characteristic peaks for PEG and PNIPAAm in the spectra, 
which are designated on the figure, and the absence of the sharp singlets at 5.7 and 6.1 
ppm, which represent the vinyl protons on the double bond of the NIPAAm monomer or 
PEG dimethacrylate.  To quantify the relative amounts of NIPAAm and PEG in the 
copolymer, the area of the peak at =3.5ppm, characteristic of the protons of the –
(CH2CH2O-)n- segment on the PEG, was compared to the area of the peak at =3.6 ppm 
for the CH protons adjacent to the isopropyl group of the NIPAAm.  Based on these 
calculations, all copolymers had molar ratios satisfactorily close to the targets of 700:1 
and 1600:1. 
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4.4 Conclusions 
 
The successful polymerization of NIPAAm was shown with FTIR.  This result was 
verified with 1H NMR.  In addition, 1H NMR was used to verify the covalent 
incorporation of PEG along the polymer backbone and quantify the molar ratio of 
NIPAAm monomer units to PEG blocks in each of the copolymers.  A family of 
copolymers was created by varying the PEG block molecular weight between 1000 and 
10,000 g/mol.  For each PEG block molecular weight, a high and low PEG content 
copolymer was synthesized by keeping the molar ratio of NIPAAm monomer units to 
PEG blocks at either 700:1 or 1600:1.  The material properties of this family of 
copolymers will be examined in subsequent chapters. 
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Figure 4.1 Schematic for the synthesis of PEGDM. 
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Figure 4.2 Schematic for the synthesis of PNIPAAm-PEG branched copolymers. 
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Figure 4.3 1H NMR spectrum for PEGDM in deuterium oxide at 25ºC. 
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Figure 4.4 The changes in spectra over reaction time for PNIPAAm-PEG branched copolymers.   
 
 118 
 
Figure 4.5.  NMR Spectra for purified PNIPAAm-PEG branched copolymers in deuterium oxide at 
at 25ºC.  
 119 
 
Chapter 5 - CHARACTERIZATION OF PNIPAAM-PEG 
BRANCHED COPOLYMERS 
 
5.1 Introduction 
 
There have been very few studies investigating PNIPAAm-based materials for orthopedic 
applications.  This may be because the polymer exhibits poor elastic properties and holds 
little water at physiological temperature due to its hydrophobic nature.  Ho et al. 343 
investigated PNIPAAm-PEG (1000 g/mol) copolymers for soft tissue fixation or repair.  
The authors found that by engineering a third component into the hydrogel system, 
trimethacryloxypropyltrimethoxysilane (MPS), the mechanical properties of the network 
could be tuned.  The MPS aided in network formation and increased the mechanical 
properties of the gels.  In addition, the authors note that by using different permutations 
of PNIPAAm, PEG, and MPS, the modulus of the hydrogels could also be tailored to 
match that of trabecular bone. 
 
This work focuses on tailoring the swelling and mechanical properties of PNIPAAm 
network by adding PEG blocks to the network.  It is proposed that lightly crosslinking 
PNIPAAm with a long chain, hydrophilic component will increase its water retention 
capability and elasticity.  PEG was chosen due to its biocompatibility, hydrophilicity, 
ease of functionalization, and availability in a range of molecular weights.  PNIPAAm-
PEG branched copolymers were synthesized by polymerizing the monomer NIPAAm in 
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the presence of PEG dimethacrylate (PEGDM).  In the previous chapter, it was shown 
that a family of copolymers was created by varying the molecular weight of the PEG 
chains between 1000 and 10,000 g/mol.  For each PEG block molecular weight, a high 
and low PEG content copolymer was synthesized by keeping the molar ratio constant at 
700:1 or 1600:1, respectively. 
 
In the following experiments, the structure-property relationship in these copolymers was 
studied.  Specifically, gel water content, stiffness, and elasticity were investigated as a 
function of PEG content and PEG block molecular weight.  It is hypothesized that a 
material candidate from the class of PNIPAAm-PEG branched copolymers can serve as a 
synthetic nucleus pulposus replacement exhibiting suitable, stable material properties 
over long term immersion in the physiological environment. 
 
5.2 Experimental Section 
5.2.1 Methods 
5.2.1.1 LCST Characterization 
 
The LCST and transition enthalpy of each copolymer was characterized using a DSC 
Model 2010 (TA Instruments, Wilmington, DE) by placing 7-10mg of solution in a 
hermetically sealed allodized aluminum pan, and heating from 10 to 60ºC at a rate of 
10ºC·min-1.  The phase transition of the polymer is detected as an endothermic peak on 
the DSC thermogram, with the temperature at the peak onset taken as the LCST.  The 
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area of the peak, normalized to the total mass of solution337, was taken as the transition 
enthalpy. 
 
5.2.1.2 Gel swelling and Dissolution 
 
To characterize gel swelling, approximately 2mL of each polymer solution was heated to 
37°C within a closed vial for 3 hours. The precipitated gels were then immersed in 
Dulbecco’s phosphate buffered saline (PBS) at 37°C.  A set of gels were evaluated at 0, 
7, 14, 30, 60, and 90 days, weighed, and subsequently dried under vacuum and weighed 
again.  Time 0 refers to a set of gels that were weighed immediately after precipitation 
and never immersed in PBS.  The gel water content was calculated according to Equation 
5.1, where mwet,37ºC(t) is the wet gel mass at 37ºC at time t and mdry is its dry mass. 
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                                                         Equation 5.1 
                                                        
For the dissolution studies, an identical procedure was used.  A set of gels were examined 
at 30, 60, and 90 days, dried under vacuum, and weighed. The mass retention of the gels 
at time t was calculated according to Equation 5.2, with mwet,25ºC(t=0) being the mass of 
polymer solution initially placed in the vial at 25ºC. 
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5.2.1.3 Mechanical Properties 
5.2.1.3.1 Compressive Studies 
 
Unconfined uniaxial compression tests were performed on gel samples after 7, 30, 60, 
and 90 days immersion in PBS.  The hydrogel samples were loaded in an Instron 
mechanical testing system (Instron Model 3362, Park Ridge, IL) and compressed at a 
strain rate of 100%·min-1 while submerged in a 37°C PBS bath. Load and displacement 
data were recorded with Instron Bluehill 1.2 software and converted to stress and strain 
values.  The compressive moduli at 10, 15, and 20% strain were approximated as the 
slope of the chord drawn between 5 and 15% strain, 10 and 20% strain, and 15 and 25% 
strain, respectively.   
 
5.2.1.3.2 Stress Relaxation Studies 
 
The gels’ ability for elastic recovery was evaluated using stress relaxation experiments, 
performed after 2, 7, 14, and 30 days immersion in PBS. Hydrogel samples were loaded 
in the Instron mechanical testing system and 20% compressive strain was applied and 
held for 1 hour while the gel was submerged in a 37°C PBS bath. Load versus time data 
was recorded with the Instron Series IX software.  Based on the Maxwell model, the 
stress of a polymer under constant strain will decay exponentially 344.  
σ σ
τ
( ) expt t= −




0                                                                                              Equation 5.3 
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Where (t) is the stress at some time t, and  is the relaxation time constant.  The 
relaxation time constant for each copolymer was computed as the time needed to lower 
the stress from its original value, oσ  to 
σ
o
e
.  The hydrogel height and diameter were also 
measured 0, 30, and 55 minutes after unloading.  
 
5.2.2. Statistical Analysis 
 
The sample sizes for each of the previously described tests were n=6.  Selected results 
were compared statistically using one way ANOVA with a 95% confidence level.   
 
5.3 Results 
5.3.1 LCST Characterization 
 
The LCSTs in the family of copolymers is shown in Figure 5.1 A.  The LCST of the 
PNIPAAm homopolymer was found to be 31.0 ± 0.1ºC. Every copolymer synthesized 
had a significant increase in LCST compared to the homopolymer (p<0.05).  No 
significant changes in LCST were made by varying the PEG molecular weight or the 
molar ratio of NIPAAm monomer units to PEG blocks (p>0.05).  All of the LCSTs in 
this family of copolymers were between 31.3ºC and 32.4ºC, which is in the range 
necessary for in situ gel formation.  Similarly, the homopolymer had a transition enthalpy 
of 4.35±0.24 J/g.  Every branched copolymer had a significant increase in transition 
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enthalpy compared to the homopolymer (p<0.05) (Figure 5.1 B).  There were no 
significant differences in the enthalpy values among the branched copolymers (p>0.05). 
The low PEG content PNIPAAm-PEG (8000 g/mol) and both the high and low PEG 
content PNIPAAm-PEG (10,000 g/mol) copolymers were not considered for further 
study because they only formed semisolid materials above their LCST, disqualifying 
them as candidate materials for nucleus replacement. 
 
5.3.2 Swelling and dissolution experiments 
 
All of the copolymers exhibited a dry mass retention of 97% or greater over 90 days 
immersion in vitro.  None of the copolymers had a significant change in mass retention 
between the 30 and 90 day time points except for the low PEG content PNIPAAm-PEG 
(2000 g/mol), which showed some statistically significant increase to 101.8% (p<0.05).  
This increase in the dry mass of the polymer could be attributed to ion uptake from the 
immersion media 345, but this was not confirmed.   
 
Holding PEG block molecular weight constant and varying the molar ratio of NIPAAm 
units to PEG blocks between 700:1 and 1600:1 produced no significant differences in 
equilibrium water content of PNIPAAm-PEG (1000, 2000, and 4600 g/mol) (p>0.05).  
Equilibrium water contents at 90 days immersion in vitro are shown in Table 5.1. 
 
The data in Figure 5.2 shows the water content for gels composed of block sizes varying 
between 1000 and 8000 g/mol.  The molar ratio of NIPAAm monomer units to PEG 
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blocks is held constant at approximately 700:1.  At the initial time point 0, the 
copolymers with PEG block sizes of 2000, 4600, and 8000 g/mol had significantly higher 
water contents (p<0.05) than the homopolymer and PNIPAAm-PEG (1000 g/mol).  
However, at 90 days immersion, only PNIPAAm-PEG (4600 and 8000 g/mol) had 
significantly higher equilibrium water contents (p<0.05) than the homopolymer control.  
 
All of the branched copolymers and the homopolymer had significant decreases in water 
content between the 0 and 7 day time points (p<0.05 in all cases). However, none of the 
copolymers exhibited significant changes in water content after the 7 day time point 
(p>0.05 in all cases).  
 
5.3.3 Compressive mechanical studies 
 
The compressive moduli at 15% for the family of copolymers at 7, 30, 60, and 90 days 
immersion in vitro are shown in Figure 5.3.  Equilibrium modulus values at 90 days are 
shown in Table 5.1.  All of the branched copolymers showed increasing trends in 
stiffness over 90 days immersion in vitro.  All of the copolymers reached an equilibrium 
stiffness by 30 days, except for PNIPAAm-PEG (8000 g/mol), which equilibrated by 60 
days immersion.  Both the high and low PEG content copolymers (Figures 5.3 A and B, 
respectively) exhibited decreasing stiffness as the PEG block molecular weight was 
increased.  However, there were no significant changes in the equilibrium compressive 
modulus as the molar ratio of NIPAAm monomer units to PEG blocks was varied 
(p>0.05).   
 126 
 
5.3.3.1 Network Analysis with Rubber Elasticity Theory 
 
Based on the theory of rubber elasticity, the compressive modulus of the hydrogels, G, 
can be expressed in terms of the compressive stress, c, the polymer volume fraction in 
the swollen gel 2,sυ , and the elongation, . (Equation 5.4) 336,346.  In tensile testing,  is 
defined as the length of the sample at any time divided by its initial length.  Because 
compressive testing was performed in this case,  was taken as the initial height of the 
sample divided by the height at any time. 
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The stress-strain behavior of the high PEG content copolymers, normalized to account for 
differences in swelling behavior, is shown in Figure 5.4.  The slope of the curves, or the 
modulus G, decreases with increasing PEG molecular weight.  The values for G at 90 
days immersion in PBS are illustrated in Figure 5.5.    
 
Using rubber elasticity theory, the effective molecular weight between crosslinks, Me, can 
also be calculated.  For a network crosslinked in the presence of a solvent, the following 
relationship holds 347: 
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Where 2,rυ  and 2,rρ are the polymer volume fraction and density in the relaxed state, 
respectively, and Mn is the number average molecular weight if no crosslinks were 
introduced.  The value for 2,rυ  is taken as 1, since the network is in its relaxed state when 
it is completely dry.  The density of the polymer in this state, 0.93 g/mL, was measured 
with the heptane density determination system.  The value of Mn for the PNIPAAm 
homopolymer was estimated based on the viscosity average molecular weight, Mv, 
(75,000 g/mol), determined previously for the same polymerization scheme by Thomas et 
al. using Ubbelohode capillary viscometry 337.  For a linear polymer in a theta () solvent 
which possesses the most probable molecular weight distribution, Mv can be related to Mn 
and the weight average molecular weight, Mw, through the following expression: 
 
Mn : Mv : Mw = 1: 1.67 : 2                                                                             Equation 5.6 
 
It has been shown previously that water is a  solvent for PNIPAAm 348.  Using the ratios 
in Equation 5.6, the estimated value of Mn for the PNIPAAm homopolymer was 44,910 
g/mol.  The calculated effective molecular weight between crosslinks, Me, was 
determined for the high PEG content copolymers (Figure 5.6).  The values for Me 
increased steadily  between PEG block molecular weight 2000 and 8000 g/mol.   
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5.3.4 Stress Relaxation Studies 
 
The relaxation time constants, as determined by Equation 4.3, over 30 days immersion 
time in vitro are shown in Figure 5.7.  All of the copolymers showed a significant 
increase in the value of the time constant compared to the homopolymer control (p<0.05).  
For the high PEG content copolymers (Figure 5.7 A), there was a significant increase in 
the time constant between PNIPAAm-PEG (2000 g/mol) and PNIPAAm-PEG (4600 
g/mol) (p<0.05).  However, varying the PEG block molecular weight did not produce any 
significant changes in the relaxation time constant for the low PEG content gels (Figure 
5.7 B) (p>0.05).  All materials recovered between 85 and 98% of their original height 
within 55 minutes after unloading. 
 
5.4  Discussion 
 
The PNIPAAm-PEG copolymers had higher LCSTs and transition enthalpies than the 
PNIPAAm homopolymer due to the presence of the hydrophilic PEG, which hinders the 
collapse and subsequent dehydration of the PNIPAAm chains 211.  However, there were 
no significant shifts in LCST or transition enthalpy as the copolymer structure was 
varied; signifying that the hydrophilic/hydrophobic balance was not impacted 
significantly by the range of PEG compositions studied.   
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It was investigated whether the water content of the precipitated phase is related to the 
weight percent of hydrophilic component in the gel.  If this were the case, the high PEG 
content PNIPAAm-PEG (2000 g/mol) would have the same water content as a low PEG 
content PNIPAAm-PEG (4600 g/mol) gel, since they contain approximately the same 
weight percent of PEG.  On the contrary, the PNIPAAm-PEG (4600 g/mol) held 
significantly more water at all time points.  This result suggests that overall water content 
of the precipitated phase is tied to network mesh size.  Since the PEG blocks do not 
collapse like the thermoresponsive PNIPAAm chains after the LCST transition, large 
spaces in the polymer network are created, allowing the gel to retain more water.  The 
low PEG content PNIPAAm-PEG (8000 g/mol) copolymers, as well as both PNIPAAm-
PEG (10000 g/mol) copolymers may have produced semi-solid gels because the high 
mesh sizes allowed the network to be overwhelmed with free water after the LCST 
transition.  Conversely, PNIPAAm-PEG 1000 g/mol did not hold significantly more 
water than the homopolymer, likely because of the tighter network structure.  
Furthermore, the increases in equilibrium gel water content seen experimentally between 
the high PEG content PNIPAAm-PEG (2000 g/mol) and PNIPAAm-PEG (8000 g/mol) 
correspond well with the steady increases in Me predicted by rubber elasticity theory.   
 
The gels exhibited an overall decreasing trend in compressive modulus as the PEG block 
molecular weight was increased.  This is likely due to the fact that the higher molecular 
weight PEG blocks caused increases in gel water content.  Water in hydrogels acts as a 
plasticizer, causing increased flexibility of the polymer chains, decreasing the mechanical 
properties as water content increases 349.  Additionally, varying the PEG content of the 
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gels produced no significant changes in equilibrium modulus.  This result was also 
consistent with the swelling results, which indicated that the molar ratio of NIPAAm 
monomer units to PEG blocks had no effect on gel water content.  The increases in gel 
stiffness seen during the 90 day study is attributed to the gradual de-swelling of the gels, 
which increases the polymer content, enhancing the mechanical properties.  The longer 
equilibration time for gels in the mechanical study compared to the swelling study is due 
to the gel geometry.  Water in the larger cylindrical samples used in the mechanical study 
took longer to diffuse out of the gel network than that in the flat discs used in the swelling 
study.   
 
In addition, Figures 5.4 and 5.5 illustrate the compressive mechanical behavior of the gels 
normalized to account for differences in swelling behavior.  The effect of network 
crosslinking density on the polymer modulus, G, can be determined from this data. 
Because G decreased with increasing PEG block molecular weight, it can be inferred that 
high molecular weight PEG blocks result in a looser network structure.   
 
Joshi et al. determined that a polymeric hydrogel implant with an unconfined 
compressive modulus of 50 kPa at 15% strain could successfully restore intervertebral 
disc stiffness 350.  The mechanical results presented here can therefore be used as an 
indication of whether or not there are suitable candidates in this family of copolymers to 
serve as a nucleus pulposus replacement.  The compressive mechanical results 
demonstrated that, after 7 days immersion in vitro, all of the high PEG content 
copolymers, except for PNIPAAm-PEG (8000 g/mol), and all of the low PEG content 
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copolymers, except for PNIPAAm-PEG (4600 g/mol), met this value of stiffness.  By 60 
days immersion, all of the copolymers met this value of stiffness. 
 
In addition to meeting this minimum stiffness, the material must be designed so that its 
elastic recovery is maximized.  In this analysis, the relaxation time constant is used as a 
measure of material elasticity. More elastic gels will exhibit a slower decrease in stress 
over time and hence have higher relaxation times. 
 
The elastic behavior of macromolecules can be linked to how their monomer units 
interact with one another and with surrounding solvent molecules.  Above the LCST of 
PNIPAAm, its polymer chains collapse into densely packed globular conformations due 
to the positive attractions between monomer units and between chains.  In other words, 
the energy of interaction between monomer-monomer molecules is lower than that of 
monomer-solvent molecules.  Compressing a PNIPAAm gel increases the frequency of 
monomer-monomer contacts.  Since this is the lowest free energy configuration for the 
chains, they do not a have a tendency to return to a more stretched out conformation after 
the external force is released.  On the contrary, PEG molecules swell in water because the 
monomer units prefer to be surrounded by the solvent molecules.  When the PEG chains 
are uniaxially compressed, the repulsive interactions between monomer units cause the 
free energy of confinement for PEG chains to be high 351.  This is manifested in a high 
elastic force compared to PNIPAAm chains.  For this reason, all PNIPAAm-PEG 
branched copolymers in this study had significantly higher relaxation time constants than 
the homopolymer. 
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The end-to-end distance, R, of a polymer chain increases with molecular weight.  The 
free energy of confining a real linear chain in a good solvent into a slit of spacing D or a 
cylinder with diameter D is proportional to R3/5 351.  Consequently, high molecular weight 
PEG chains exhibit high free energies of confinement.  This property accounts for the 
increase in elasticity between the high PEG content PNIPAAm-PEG (2000 g/mol) and 
PNIPAAm-PEG (4600 g/mol).  It is likely that the low PEG content copolymers showed 
no changes in time constant as the PEG block molecular weight was increased because 
there were not enough PEG chains in the system to impact the elasticity of the gel. 
 
5.5. Conclusions 
 
All of the copolymers had LCSTs in the range necessary for injectability and exhibited 
satisfactory mass retention over 90 days immersion in vitro.  PNIPAAm-PEG (4600 and 
8000 g/mol) had significantly higher mass swelling ratios than the PNIPAAm 
homopolymer, with the latter having the highest water content of all the copolymers.  
After 7 days immersion in vitro, the high PEG content PNIPAAm-PEG (1000, 2000, and 
4600 g/mol) and the low PEG content PNIPAAm-PEG (1000 and 2000 g/mol) met the 
minimum stiffness of 50 kPa for the restoration of intervertebral disc stiffness.  After 60 
days in vitro, all of the copolymers met the minimum stiffness.  The branched 
copolymers showed improved elasticity over the PNIPAAm homopolymer, but 
PNIPAAm-PEG (4600 and 8000 g/mol) had the highest relaxation time constants, 
indicating maximum elasticity.  Because of its high water content and suitable 
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mechanical properties, the high PEG content PNIPAAm-PEG (4600 g/mol) will be 
further assessed as a material candidate for nucleus pulposus replacement.  
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Table 5.1 Equilibrium water contents and compressive moduli for PNIPAAm-PEG after 90 days 
immersion in vitro. 
PEG molecular 
weight (g/mol) 
PEG 
content Water content 
Compressive modulus at 
15% strain at 90 days 
immersion in vitro (kPa) 
Low 0.35 ± 0.02 205 ± 54 1000 High 0.35 ± 0.03 127 ± 64 
Low 0.47 ± 0.11 115 ± 40 2000 High 0.41 ± 0.01 119 ± 38 
Low 0.51 ± 0.01 141 ± 36 4600 High 0.52 ± 0.02 90.3 ± 9.3 
8000 High 0.71 ± 0.00 52.3 ± 8.9 
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Figure 5.1 LCST and enthalpy of transition as a function of weight percent PEG in PNIPAAm-PEG 
branched copolymers.   
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Figure 5.2 Effect of PEG block molecular weight on gel water content.   
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Figure 5.3 Effect of PEG block size on the equilibrium compressive modulus of PNIPAAm-PEG 
branched copolymers.   
A 
B 
 138 
0
5
10
15
20
25
30
35
40
0 0.2 0.4 0.6 0.8 1 1.2
v2,s
-1/3(-1/2)

 
(kP
a)
PNIPAAm-PEG (2000 g/mol)
PNIPAAm-PEG (1000 g/mol)
PNIPAAm-PEG (4600 g/mol)
PNIPAAm-PEG (8000 g/mol)
 
Figure 5.4 Stress-strain behavior of PNIPAAm-PEG branched copolymers at 90 days immersion in 
PBS, normalized to account for the swelling of the gel. 
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Figure 5.5 Modulus, G, for the high PEG content PNIPAAm-PEG branched copolymers at 90 days 
immersion in PBS, normalized to account for differences in the swelling behavior of the gels. 
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Figure 5.6 The effective molecular weight between crosslinks, Me, for the high PEG content 
PNIPAAm-PEG branched copolymers at 90 days immersion in PBS.   
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Figure 5.7 Effect of immersion time in vitro on the compressive modulus at 15% strain of high PEG 
content (a) and low PEG content (b) PNIPAAm-PEG branched copolymers.   
A 
B 
Se
co
n
ds
 
 142 
 
Chapter 6 - OPTIMIZATION STUDIES TO PREVENT WATER 
LOSS IN VIVO 
 
6.1 Introduction 
 
This chapter describes a two part study that was conducted to better understand the 
dehydration behavior of the PNIPAAm-PEG (4600 g/mol) gels.  The in vitro 
characterization studies in Chapter 5 showed that the de-swelling behavior of the gels 
upon heating to 37ºC is characterized by an initial gradual water loss, followed by an 
equilibrium condition.  To predict the implant behavior in vivo, it is necessary to 
understand how the de-swelling rate and equilibrium water content change with osmotic 
pressure of the surrounding medium.  The disc tissues possess a high osmotic pressure 
due to the flux of ions into the tissues generated by the fixed negative charges on the 
proteoglycans 8.  J.P. Urban’s group performed studies on the osmotic pressure of lumbar 
disc tissues and reported the osmotic pressure of the healthy inner annulus and nucleus 
pulposus to be approximately the same, at 0.2 MPa 26.  The first part of the study will 
focus on analyzing the de-swelling behavior of PNIPAAm-PEG (4600 g/mol) gels over a 
range of physiologically pertinent osmotic pressures. 
 
PNIPAAm gels also exhibit a decrease in volume as a result of dehydration 352.  
Significant volume loss in vivo will prevent the implant from having intimate contact 
with the inner annulus.  It has been shown experimentally and through finite element 
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modeling that total nucleus replacements which are oversized, allowing for intimate 
contact with the inner annulus, were most effective at restoring the compressive stiffness 
of the intervertebral disc 171.  The second part of this dehydration study will focus on 
optimizing the copolymer formulation to minimize water loss and subsequent volume 
loss upon injection into the intradiscal environment.  Ideally, the volume of injected 
solution would equal that of the gel formed, allowing the implant to remain space filling 
after the thermal transition.  
 
6.2 Experimental Section 
6.2.1 Materials 
 
PEG diol (20,000 g/mol) (Serva), dialysis tubing (Spectrum Spectra/Por Biotech cellulose 
ester, 500 Dalton MWCO), and 55 mm dialysis clips (Fisher Scientific) were all used as 
received. 
 
6.2.2 Methods 
 
Gel swelling under a range osmotic pressures was evaluated using a modified version of 
the procedure developed by J.P. Urban 24,26.  Varied concentrations of aqueous solutions 
of PEG (20,000 g/mol) were prepared.  The osmotic pressure of a macromolecular 
solution is given by Equation 6.1, where Π  is osmotic pressure, R is the gas constant, T 
is absolute temperature, M2 is the molecular weight of the macromolecule, B and C are 
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the second and third virial coefficients, and c2 is the concentration of the macromolecule 
in solution 351. 
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The values used for the second and third viral coefficients were 2.59e10-3 and 1.35e10-2, 
respectively 353.  Approximately 2mL of 10, 15, or 25 wt% aqueous PNIPAAm-PEG 
(4600g/mol) solution were injected into dialysis tubing and sealed with dialysis clips.  
The dialysis bags were then immersed in aqueous PEG solution at 37ºC.  The volume of 
PEG solution used was approximately 100 times the volume of PNIPAAm-PEG solution.  
After 1, 2, 7, 14, and 30 days, the gels were removed from the dialysis bags, weighed, 
dried under vacuum, and weighed again.  Time 0 refers to solutions that were not 
immersed in PEG solution, but immediately weighed, dried under vacuum, and weighed 
again to determine water content prior to swelling.  The water content was calculated at 
each time point according to Equation 4.1.  
  
6.2.3 Statistical Analysis 
 
The sample sizes for each of the previously described tests were n=3.  Selected results 
were compared statistically with one way ANOVA and a 95% confidence level.   
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6.3 Results and Discussion 
6.3.1 Osmotic Swelling Studies 
 
The water content of PNIPAAm-PEG (4600 g/mol) gels over 30 days immersion in 37ºC 
aqueous PEG (20,000g/mol) solution, with an osmotic pressure of 0.2 MPa, is shown in 
Figure 6.1.  As a comparison, a set of gels were also swollen in 0.4 MPa and pure water.  
Between the 0 and 2 day time points, the gels swollen in 0.4 MPa dehydrated faster than 
those swollen in 0.2 MPa osmotic pressure and water. By 7 days immersion, there were 
no significant differences between the water contents of the gels swollen in 0.2 and 0.4 
MPa (p>0.05).  By 30 days, there were no significant differences in the water contents of 
all three sets of gels (p>0.05).  
 
These results indicate that the equilibrium gel water content for PNIPAAm-PEG (4600 
g/mol) is not significantly affected by varying osmotic pressures in the range studied.  
Osmotic pressure measurements are based on the use of a semi-permeable membrane 
through which solvent molecules pass freely and polymer molecules cannot pass 354.  It is 
possible that higher osmotic pressures did not appreciably affect equilibrium water 
contents of the gels because the remaining water in the gel is sufficiently associated with 
the polymer through hydrogen bonding such that the osmotic pressures studied did not 
generate enough thermodynamic drive to cause further dehydration.  
 
To ensure the implant remains space filling, it is necessary to eliminate the drastic water 
loss occurring between the 0 and 2 day time points in Figure 6.1.  The first avenue 
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explored was analyzing the relationship between the water content of the polymer 
solution at room temperature and that of the gel at equilibrium.  Figure 6.2 shows the 
water content of gels swelled for 30 days at 37ºC in aqueous solutions of PEG (20,000 
g/mol) with an osmotic pressure of 0.2 MPa.  The gels were formed from aqueous 10, 15, 
or 25 wt% PNIPAAm-PEG solutions at room temperature.  Initially, the gels swelled 
under the highest osmotic pressure dehydrated at the quickest rate.  However, by 30 days 
immersion, the water content of all three sets of gels was very similar, between 0.4 and 
0.5.   
 
Logically, it follows, that in order to minimize the magnitude of water loss after gelation, 
the solution from which the gels are formed must be more concentrated.  However, 
solutions above 25 wt% polymer cannot be prepared directly by combining dry polymer 
and water because they will not form uniformly.  
 
6.3.2 Thermal Cycling Studies 
 
Water loss upon gelation was minimized by thermal cycling.  Solutions composed of 15 
wt% PNIPAAm-PEG (4600 g/mol) were injected into dialysis bags at room temperature 
and allowed to equilibrate at 37ºC and 0.4 MPa for 48 hours.  When these gels were 
subsequently cooled to room temperature they formed concentrated, homogenous 
polymer solutions and the water content was measured.  The water content of the 
solutions before and after this 2 day cycle is indicated in Figure 6.3 as thermal cycles 0 
and 1.  As expected, there was significant water loss during this period (p<0.05), which 
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was large in magnitude.  These concentrated polymer solutions were subsequently 
injected into dialysis bags again at room temperature and re-immersed in the same 37ºC 
osmotic environment for an additional 48 hours.  The water content of the solutions after 
this second thermal cycle is shown in Figure 6.3 as thermal cycle 2.  There were no 
significant changes in water content (p>0.05) compared to cycle 1.  The cycle was 
performed an additional 3 times to ensure repeatability.  There were no significant 
changes in water content between cycles 1 and 3 (p>0.05).  However, there were slight 
decreases in water content between cycles 1 and 4 and 1 and 5, which were statistically 
significant (p<0.05), though small in magnitude.  During the initial 48 hours immersion, 
the solutions only retained approximately 25% of their initial volume.  However, there 
were no more significant changes in solution volume thereafter (p>0.05).  
 
While homogenous polymer solutions cannot be prepared from dry powder at these high 
concentrations, these results indicate that reversibility of the PNIPAAm’s phase transition 
can be exploited in order to form them.  Dilute polymer solutions can be thermally cycled 
by equilibration in a 37ºC osmotic environment.  These gels can then be cooled to room 
temperature, forming more concentrated solutions that should show minimal water loss 
once injected into the intradiscal environment. 
 
6.4 Conclusions 
 
The osmotic swelling studies revealed that while osmotic pressure influenced the rate of 
PNIPAAm-PEG (4600 g/mol) gel dehydration, the equilibrium water content was not 
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dependent on osmotic pressure of the immersion media.  Furthermore, equilibrium water 
content of the gels is not appreciably affected by the concentration of the polymer 
solution from which they were formed.  Significant implant water loss upon gelation can 
be prevented by equilibrating dilute polymer solutions in a 37 ºC environment.  Upon 
cooling to room temperature, the polymers will form uniform, concentrated solutions 
which should show minimal water loss when gelled again. 
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Figure 6.1 Effect of immersion media osmotic pressure on the water content of PNIPAAm-PEG 
(4600 g/mol). 
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Figure 6.2 Effect of solution concentration at room temperature on equilibrium water content of 
PNIPAAm-PEG (4600 g/mol) gels. 
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Figure 6.3  Effect of thermally cycling the polymer solution by equilibrating in a 37 ºC osmotic 
environment, followed by cooling to room temperature. 
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Chapter 7 - SYNTHESIS AND CHARACTERIZATION OF 
BIOADHESIVE PNIPAAM-PEG/PEI BLENDED 
COPOLYMERS 
 
7.1 Introduction 
 
Imparting bioadhesive properties to this hydrogel system will reduce the risk of implant 
migration or expulsion out of the annular defect created by injection of the nucleus 
replacement.  Additionally, bioadhesive properties will increase the potential for using 
this material as nucleus replacement in discs which are in the later stages of degeneration, 
which possess tears, cracks, and fissures that would normally increase the risk of implant 
migration or expulsion.   
 
Because of its injectable nature, this bioadhesive could be used as a closure material for 
the repair of a damaged annulus.  The technology could be used in conjunction with a 
discectomy, to close the herniated disc, or with a total nucleus replacement, to close the 
defect created by injection of the material and help anchor the implant in the center of the 
disc.  The bioadhesive could also repair annular tears associated with degeneration.  
Using a hydrogel material to close these annular defects would help stabilize the disc 
structure, prevent prolapse of disc material, and restore biomechanical function 330.  This 
strategy can also be used to address pain produced by cytokines and inflammatory 
mediators that can migrate through annular fissures and produce pain by stimulating the 
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nociceptors in the outer annulus 51.  Sealing annular fissures will prevent the diffusion of 
these molecules to the nerve roots in the outer annulus.   
 
The plan for imparting bioadhesive properties to the hydrogel system begins with the 
incorporation of a third component in the hydrogel system, poly(ethylene imine) (PEI).  
PEI is a highly branched polyamine 277.  The pKa value of the primary amine is around 9, 
the secondary amine around 8 and the tertiary amine around 6–7 278.  At or above a pH of 
10, the amine groups are uncharged 279.  In the pH range from 10 to 4, approximately 
60% of the total amount of amino groups are protonated 355. 
 
PEI will be incorporated in the PNIPAAm-PEG (4600 g/mol) network by physical 
blending.  The blends will be prepared by co-dissolving PNIPAAm-PEG and PEI in 
water at room temperature.  PEI will comprise approximately 4.25 wt% of the aqueous 
solution, while the PNIPAAm-PEG copolymer content will be fixed at 15 wt%.  This 
weight percent of PEI was chosen because it is approaching the maximum amount of PEI 
that can be co-dissolved with 15 wt% PNIPAAm-PEG.  Above the LCST of PNIPAAm, 
a collapsed network will form, physically entrapping the PEI chains within it.   
 
The three component system will be injected into the disc and allowed to thermally 
transition, forming a gel.  This will be followed by the injection of aqueous 
glutaraldehyde solution into the gel core.  The aldehyde groups of the glutaraldehyde will 
become covalently bonded with the primary amines of PEI, crosslinking PEI with itself.  
This reaction between amine and aldehyde functionality is known as a Schiff’s base 
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reaction 356 (Equation 7.1) and has been studied with Fourier Transform Infrared (FTIR) 
spectroscopy.  For this reason, FTIR will be used to verify the crosslinking chemistry in 
the PNIPAAm-PEG/PEI blends. 
 
NH2 + O=CH-  N=CH + H2O                                                     Equation 7.1 
 
In the disc, after the glutaraldehyde crosslinks the PEI, unreacted glutaraldehyde will 
continue to diffuse through the gel and crosslink it to the tissues in contact with the 
implant by reacting with the amine functions present in the proteins of the tissue 
extracellular matrix. Because only small amounts of the reacting dial will be injected 
directly into the gel, reaction with tissues not in immediate proximity to the gel should 
not occur.   
 
It is postulated that this system is feasible for use in the intervertebral disc despite the 
potential cytotoxicity of PEI 280,283,290,291,357 and glutaraldehyde 318,325,327,328,358.  Because 
the disc tissues contain large amounts of extracellular matrix proteins and fewer cellular 
components 19,318, they are less sensitive to the cytotoxicity, and the inflammatory 
response from the body can be minimized with a controlled release profile of 
glutaraldehyde.   
 
Preliminary work for this project has indicated that injecting larger volumes of dilute 
glutaraldehyde solutions results in a more uniform crosslinking than small volumes of 
highly concentrated solutions.  Therefore, the swelling, mechanical, and adhesive 
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properties of the hydrogels will be evaluated based on the injection of 0.62 mL of a 5 
wt% glutaraldehyde solution in water into the gel core.  As a comparison, the properties 
of the system were also evaluated using 10 and 20 wt% glutaraldehyde solutions. 
 
The overall objective of these studies is to successfully impart bioadhesive properties to 
the injectable PNIPAAm-PEG hydrogel system.  The basic synthesis and characterization 
techniques will be established, laying the foundation for future optimization of the 
adhesion system.   
 
7.2 Experimental Section 
7.2.1 Materials 
 
Poly(ethylene imine) (PEI) (Mn=10,000 g/mol, water-free), Copper(II) sulfate 
pentahydrate, Iron(III) chloride, 3-Methyl-2-benzothiazolinone hydrazone hydrochloride 
monohydrate (MBTH), and deuterium oxide (D2O) were obtained from Sigma Aldrich 
and used as received.  PEI (Mn=60,000 g/mol, 50 wt% in water) and glutaraldehyde (70 
wt% in water) were also obtained from Sigma Aldrich and diluted before use to the 
concentrations specified in the method descriptions.  Fresh porcine skin was obtained 
from a butcher. 
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7.2.2 Methods 
7.2.2.1 PNIPAAm-PEG/PEI Blend Preparation and Characterization 
 
A polymer solution was prepared at ambient temperatures composed of 15 wt% 
PNIPAAm-PEG (4600 g/mol), 4.25wt% PEI (Mn= 60,000 g/mol), and the balance water.  
The solutions were heated to 37ºC for gelation to occur. The precipitated gels were 
lyophilized overnight and re-dissolved in D2O. They were analyzed with 1H NMR 
(Varian 300, Palo Alto, CA) to verify and quantify the incorporation of PEI into the gel 
network.  
 
The chemical stability of the blends was evaluated by comparing the amount of PEI 
released from the network upon gelation to the amount dissolved in the room temperature 
solution.  Approximately 2 mL of the PNIPAAm-PEG/PEI (Mn=10,000) or (60,000 
g/mol) solutions were heated inside a closed vial for 10 minutes.  Then, 10 mL of 
deionized water, preheated to 37ºC, was added to each vial.  The vials were agitated at 40 
rpm for 2 minutes. Then 500 	L of each immersion media was added to 500 	L of 0.4 
wt% aqueous copper(II) sulfate pentahydrate.  Upon the addition of copper (II) ions, PEI 
forms a blue cuprammonium complex 359, allowing the PEI to be quantified 
spectrophotometrically.  The absorbance of these solutions was measured at 550 nm with 
a plate reader (BIO-TEK, model ELx800, Winooski, VT).  The concentration of PEI in 
the gel immersion media was determined using a standard curve of known PEI 
concentrations.  A linear relationship (r2=0.999 for PEI Mn=60,000 g/mol and r2=0.993 
for PEI Mn=10,000 g/mol) was found between the absorbance at 550 nm and the amount 
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of PEI in concentration range tested, which was 0.001 to 6.67 mg/mL.  Each optical 
density measurement was performed in triplicate and the sample size was n=3. 
 
7.2.2.2 PNIPAAm-PEG/PEI Crosslinking with Glutaraldehyde 
 
For this and all subsequent characterization studies, uniformly sized cylindrical gel 
samples were formed by injecting aqueous solutions of 15 wt% PNIPAAm-PEG (4600 
g/mol) and 4.25wt% PEI (Mn= 60,000 g/mol) into molds and heating to 37ºC for 10 
minutes.  The precipitated gels were removed from the molds and 0.62 mL of 5 wt% 
aqueous glutaraldehyde was injected into the gel core with a 26 gauge needle at rate of 40 
cc/hr, using a syringe pump (Autosyringe, model 5A, Hooksett, NH).  The gels were then 
lyophilized overnight and analyzed with FTIR (Nicolet Magna IR 560, Madison, WI) to 
verify the covalent crosslinking of the PEI with the glutaraldehyde. 
 
7.2.2.3 Free Glutaraldehyde Release 
 
Uniformly sized gel samples formed from aqueous solutions composed of 15 wt% 
PNIPAAm-PEG and 4.25 wt% PEI (Mn=60,000 g/mol) were injected with either 5, 10, or 
20 wt% glutaraldehyde.  Once again, 0.62 mL of glutaraldehyde solution was injected 
into the gel core with a 26 gauge needle at a rate of 40 cc/hr.  This process was carried 
out while the gels were fully immersed in 150 mL of deionized water.  The gels were 
swelled in this same immersion media throughout the study.  The amount of free 
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glutaraldehyde in the immersion media over time was then quantified with the MBTH 
method 360.  At t=10 mins, 3, 24, 48, and 96 hours, 300 	L of immersion media was 
combined with 300 	L of 0.4 wt% aqueous MBTH and 0.2 wt% Iron (III) chloride.  The 
reaction was allowed to stand for approximately 10 minutes, and then 2 mL of acetone 
was added.  The optical density of the solution at 405 nm was measured with the plate 
reader.  The concentration of glutaraldehyde in the immersion media was determined 
using the standard curve of known glutaraldehyde concentrations.  A linear relationship 
(r2=0.951) was found between the absorbance and the amount of glutaraldehyde in 
concentration range 0.0002 to 0.10 mg/mL.  The amount of glutaraldehyde released at 
each time point was compared to the total amount injected into the gel core.  Each optical 
density measurement was performed in triplicate and the sample size was n=3. 
 
7.2.2.4 PNIPAAm-PEG/PEI Gel Swelling 
 
To characterize the swelling properties of the blends, uniformly sized cylindrical gel 
samples composed of PNIPAAm-PEG/PEI (Mn=60,000 g/mol) were prepared using 
molds and immersed in PBS at 37ºC.  A set of gels were pulled at 0, 1, 7, 14, and 30 
days, weighed, and subsequently dried under vacuum and weighed again. Time 0 refers 
to solutions that were not heated to 37ºC or immersed in PBS, but weighed, dried under 
vacuum, and weighed again to determine water content prior to gel formation and 
swelling.  This procedure was repeated 3 additional times with a set of gels which were 
injected with 5, 10, or 20 wt% glutaraldehyde solutions, according to the procedure 
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described above prior to immersion in PBS.  The gel water content was calculated 
according to Equation 4.1. 
 
7.2.2.5 PNIPAAm-PEG/PEI Compressive Mechanical Properties 
 
Unconfined uniaxial compression tests were performed on gel samples injected with 5, 
10, or 20 wt% glutaraldehyde after 7 days immersion in PBS.  As a comparison, a set of 
gel samples which were not injected with glutaraldehyde were also tested.  The hydrogels 
were loaded in an Instron mechanical testing system (Instron Model 4442, Park Ridge, 
IL) and compressed to 50% strain at a rate of 100%·min-1 while submerged in a 37°C 
PBS bath. Load and displacement data were recorded with the Instron BlueHill 1.2 
software and converted to stress and strain values.  The compressive moduli at 10, 15, 
and 20% strain were approximated as the slope of the chord drawn between 5 and 15% 
strain, 10 and 20% strain, and 15 and 20% strain, respectively. 
 
7.2.2.6 Bioadhesive Force Studies 
 
The bioadhesive capacity of PNIPAAm-PEG/PEI (Mn=60,000 g/mol) blends was 
determined using an Instron mechanical testing system (Instron Model 4442, Park Ridge, 
IL).  Uniformly sized cylindrical gels were fixed to the upper support with cyanoacrylate 
adhesive.  Sections of fresh porcine skin were cut and cleaned to remove excess fat.  The 
substrate was fixed to the bottom support with cyanoacrylate adhesive.  The gel was 
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lowered slowly until full contact with the skin was achieved.  Subsequently, the gels were 
injected with 0.62 mL of 5, 10, or 20wt% glutaraldehyde at 40 cc/hr using a 26 gauge 
needle.  The gels were kept in contact with the substrate for 10 minutes.  The upper 
fixture was then withdrawn at a rate of 2mm·min-1 and the load-displacement data was 
recorded by the Instron BlueHill 1.2 software until the polymer became completely 
detached from the skin.  During the test, the skin and gel were submerged in a 37ºC PBS 
bath.  The sample size was n=3.  A fresh piece of tissue was used for each repeat.  
 
The load versus displacement data was converted to stress strain values and the 
maximum force required to detach the gels from the biological samples was read directly 
from this the curve.  In addition, the work of adhesion was calculated by fitting the stress 
strain curve for each sample to a sixth order polynomial, and calculating the area under 
the curve between the strain values of 0 and that after which complete detachment 
occurred.   
 
7.2.2.7 Statistical Analysis 
 
The sample sizes for each of the previously described tests were n=3.  Selected results 
were compared statistically with one way ANOVA and a 95% confidence level.   
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7.3 Results 
7.3.1 PNIPAAm-PEG/PEI Blend Characterization 
 
The successful physical incorporation of PEI (Mn=60,000 g/mol) in the PNIPAAm-PEG 
(4600 g/mol) network was verified with the 1H NMR.  The NMR spectrum for the blends 
is shown in Figure 7.1.  The incorporation of PEI was verified by the presence of the 
peak for the CH2 protons on the PEI at =2.2 ppm.  Additionally it was determined that 
approximately 10.3±4.2% of PEI (Mn=60,000 g/mol) that was dissolved in the solution at 
room temperature was released from the network upon gelation (Figure 7.2).  As a 
comparison, the same measurement was performed on blends composed of PEI 
(Mn=10,000 g/mol) and it was found that 56.7±4.0% was released.   
 
7.3.2 Gel Crosslinking with Glutaraldehyde 
 
The FTIR spectra for a dry PNIPAAm-PEG/PEI (Mn=60,000 g/mol) gel, 
glutaraldehyde/PEI mixture, and a gel injected with glutaraldehyde are shown in Figures 
7.3 A, B, and C, respectively.  As can be seen in 7.3 A, the spectrum for the blend is 
completely dominated by PNIPAAm, the characteristic peaks being the Amide I and II 
bands at 1649 and 1543 cm-1 338-340.  The peaks for PEI are not seen in this spectrum, 
likely because the FTIR is not sensitive enough to detect its presence.  The peak for free 
NH2 amines on the PEI should occur at 1596 cm-1 316,361, the C-H bending at 1456 cm-1 
361,362
, and C-C vibration and C-N stretch between 1300 and 1000 cm-1 341,361.   
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Illustrated in 7.3 B is the spectrum for a dried 1:1 mixture of PEI (Mn=60,000 g/mol) and 
5 wt% glutaraldehyde.  The spectrum is shown simply to indicate that the peak at 1661 
cm-1 represents the –C=N- covalent bond formed as a crosslink between the NH2 on PEI 
and the HC=O group on the glutaraldehyde 316,363.  In addition, the amide II band (HN=C-
) on the crosslinked PEI occurs at 1560 cm-1 316.  These peaks could not be detected in the 
spectrum of the PNIPAAm-PEG/PEI (Mn=10,000 g/mol) blend that was injected with 
glutaraldehyde (7.3 C) because PNIPAAm once again dominates the spectrum. 
 
When this overlap occurs, the spectrum of one component can be subtracted from the 
combined system in order to reveal the peaks of interest 364.  In this case, the spectrum for 
the PNIPAAm-PEG/PEI blend was subtracted from that of the same blend injected with 
5% glutaraldehyde.  The results of the spectral subtraction are shown in Figure 7.4.  
Peaks in the characteristic range for the –C=N- and HN=C- bonds occur at 1668 cm-1 and 
1540 cm-1.  The results of the FTIR difference spectroscopy indicated that covalent 
crosslinking of the PEI occurring in this system can be described as a Schiff’s base 
reaction. 
 
7.3.3 Free Glutaraldehyde Release 
 
Shown in Figure 7.5 are the release profiles of free glutaraldehyde from the gels.  
Initially, 10, 21, and 16% of the glutaraldehyde injected was released from the gels 
injected with 5, 10, and 20% glutaraldehyde, respectively.  This corresponds to a total of 
3.0±0.4, 13.3±7.4, and 20.2±10.0 mg of glutaraldehyde.  After 96 hours, 47, 83, and 59% 
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of the glutaraldehyde was released from the gels injected with 5, 10, and 20% 
glutaraldehyde, respectively.  This corresponds to a cumulative total of 14.5±3.9, 
51.5±3.4, 73.2±14.8 mg of glutaraldehyde, respectively.   
 
7.3.4 PNIPAAm-PEG/PEI Gel Swelling 
 
The water content of PNIPAAm-PEG/PEI (Mn=60,000 g/mol) blends with and without 
glutaraldehyde injection over a 30 day immersion in PBS is shown in Figure 7.6.  All of 
the PEI-containing gels, including those that were crosslinked with glutaraldehyde, held 
significantly more water than the PNIPAAm-PEG copolymer alone (p<0.05).  At 30 days 
immersion, only the gels crosslinked with 20% glutaraldehyde underwent a significant 
decrease in water content compared to the polymer solution from which it was formed 
(p<0.05).  Furthermore, the PNIPAAm-PEG/PEI blend alone exhibited a significant 
increase in water content between 0 and 30 days, from 78.2±0.0 to 83.7±1.2 % (p<0.05).  
Though varying the concentration of glutaraldehyde solution injected made no significant 
changes in gel water content (p>0.05), all of the crosslinked gels exhibited decreasing 
trends in water content compared to the PNIPAAm-PEG/PEI blend.  At 30 days 
immersion, the gels injected with 10 and 20% glutaraldehyde held significantly less water 
than the PNIPAAm-PEG/PEI alone(p<0.05). 
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7.3.5 PNIPAAm-PEG/PEI Compressive Mechanical Properties 
 
Shown in Figure 7.7 are changes in the compressive mechanical properties of PNIPAAm-
PEG/PEI as a result of glutaraldehyde injection.  The compressive modulus of the 
PNIPAAm-PEG/PEI blend at 15% strain was 6.3±2.6 kPa.  All of the blends exhibited 
significant increases in compressive modulus (p<0.05) with glutaraldehyde injection.  
However, there were no significant changes in the modulus value as the glutaraldehyde 
concentration was varied from 5 to 20 wt% (p>0.05).  
  
7.3.6 Bioadhesive Force Studies 
 
Figure 7.8 illustrates the typical stress-strain curve for the in vitro bioadhesive force 
studies.  The curves shown in shades of blue represent PNIPAAm-PEG and PNIPAAm-
PEG/PEI hydrogels which were never injected with glutaraldehyde, but fully contacted 
with the porcine skin and withdrawn at 2mm·min-1.  The curves for these samples show a 
gradual increase in stress followed by a plateau region.  The initial increase in load is 
likely caused by two factors.  First, as the gel loses contact with the skin, the upper 
fixture supports an increasingly greater portion of the weight of the gel itself.  Secondly, 
as the fixture moves up, it encounters resistance as it moves through water, contributing 
to the load. The plateau region represents full loss of gel contact with the substrate.  
 
The curves shown in red, orange, and pink represent samples that were injected with 
glutaraldehyde while in contact with the porcine skin and subsequently withdrawn.  
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These samples also exhibited an initial increase in load but they continue to a higher 
maximum value in the stress.  This is indicative of greater adherence to the substrate.  
The stress field caused by the withdrawal of the upper fixture will seek the most 
vulnerable point in the adhesive bond and failure is initiated there 365.  This initial failure 
is represented on the stress-strain curve as the first drop in stress.  The subsequent drops 
in stress represent the failure propagating.  Again, complete separation from the substrate 
is represented by the plateau region.  It is worth noting that failure can occur at any of the 
adhesive interfaces or by the fracture of the gel sample. In each of these cases, the 
separation occurred at the interface between the gel and the substrate.  
 
The mean maximum force required to detach PNIPAAm-PEG and PNIPAAm-PEG/PEI 
gels from the porcine skin was taken as the maximum in the stress-strain curve before 
complete detachment occurred. These values are shown in Table 7.1.  The mean 
maximum force of detachment for PNIPAAm-PEG and PNIPAAm-PEG/PEI without 
glutaraldehyde injection was 0.64±0.14 kPa and 0.71±0.24 kPa, respectively.  There were 
no significant differences between these two values (p>0.05).  All of the PNIPAAm-
PEG/PEI gels injected with glutaraldehyde exhibited significant increases in the mean 
maximum force of detachment (p<0.05).  Among the gels injected with glutaraldehyde, 
varying the concentration between 5 and 20% increased the adhesion strength by a factor 
of 1.6.  There were no significant differences in the mean maximum force of detachment 
for the gels injected with 10 and 20% glutaraldehyde (p>0.05), but both values were 
significantly higher than that of the gels injected with 5% glutaraldehyde (p<0.05).  The 
values for work of adhesion are shown also shown in Table 7.1.  While there were no 
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significant differences in work of adhesion for the PEI blends injected with 
glutaraldehyde (p>0.05), all of them had significantly higher values that the PNIPAAm-
PEG/PEI blend and the PNIPAAm-PEG copolymer alone (p<0.05).  
 
7.3 Discussion 
 
A chemically stable hydrogel blend will be defined in this context as one in which all of 
the PEI dissolved in the room temperature solution becomes physically entrapped in the 
gel network during the collapse of the PNIPAAm chains.  The blends composed of PEI 
(Mn=10,000 g/mol) released 5 times as much PEI as the blends composed of PEI 
(Mn=60,000 g/mol) immediately after gelation.  In other words, the blends prepared from 
the higher molecular PEI were more chemically stable.  It is likely that the higher 
molecular weight PEI allows for a greater degree of physical entanglements with the 
PNIPAAm-PEG upon network collapse, reducing the free PEI released.  A minimal 
release of free PEI is considered a positive scenario since PEI with molecular weight 
higher than 2000 Da has been shown to be cytotoxic 290,291..  It is for this reason that the 
PNIPAAm-PEG/PEI (Mn=60,000 g/mol) gels were further characterized in these studies.   
 
It is likely that the chemical stability of these blended networks will be further enhanced 
by the injection of the glutaraldehyde, which will crosslink the PEI to itself.  The amount 
of PEI released from the network post-injection of the glutaraldehyde cannot be 
quantified with the current method because the free glutaraldehyde and PEI in the 
immersion media will readily react before they can be quantified.  If histological studies 
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indicate a necessary decrease in the release of free PEI, a higher molecular weight PEI 
can be utilized in the blend.  Another option is to incorporate the PEI along the polymer 
backbone as grafts.  PEI chains can be functionalized with methacrylate groups and then 
polymerized in the presence of NIPAAm and PEG dimethacrylate 366.  It should be 
considered, however, that an increase in free PEI release could potentially increase the 
adhesive strength of the gels.  A thick coating of PEI on the gel surface could play an 
important role in stabilizing the adhesive bond between the material and the surrounding 
tissue.  
 
The incorporation of PEI into the PNIPAAm-PEG network increased the swelling 
capacity of the network appreciably.  The equilibrium water content of PNIPAAm-PEG 
increased significantly with the incorporation of PEI from 63.5±.1.2 to 83.7±1.2 %.  In 
addition, the PNIPAAm-PEG/PEI blend exhibited a significant increase in water content 
(p<0.05) between the 0 and 30 day time points.  At the pH of the PBS, approximately 7.4, 
several of the primary and secondary amine groups on the PEI are ionized.  In salt 
solutions, the charges on the PEI attract an influx of counterions into the polymer 
network.  The osmotic pressure created by this these ions causes the polymer to swell 279.  
The network expansion could also be due to the ionic repulsions between the positively 
charged PEI chains 220.  Overall, these results are consistent with the findings of Qui et 
al., who showed that incorporation of ionizable groups into PNIPAAm hydrogels can 
improve the swelling of the network more effectively than non-electrolyte hydrophilic 
components alone 190.   
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This increase in water content is responsible for decreasing the mechanical properties of 
the PNIPAAm-PEG.  While the previous characterization studies have shown the 
modulus of this copolymer after 7 days immersion in PBS to be over 50 kPa, the modulus 
of the PEI blend at this same strain level was 6.3±2.6 kPa.  The glutaraldehyde 
crosslinking did, however, cause an 8 to 12-fold increase in the compressive modulus of 
the gels, putting the moduli back above 50 kPa, indicating the potential of the material to 
function as a total nucleus replacement by restoring the compressive stiffness of 
intervertebral disc stiffness 171. 
 
Varying the concentration of glutaraldehyde injected did not produce significant changes 
in gel water content.  In addition, while the crosslinked gels exhibited a small increasing 
trend in stiffness with increased glutaraldehyde concentration, the differences were not 
significant (p>0.05).  These results indicate that the crosslinking density of the gels did 
not vary greatly with increasing glutaraldehyde concentration.  Furthermore, increasing 
glutaraldehyde concentration only produced modest gains in adhesive strength.  The 
adhesion tests were conducted 10 minutes after glutaraldehyde injection, corresponding 
to approximately 3.0±0.4, 13.3±7.4, and 20.2±10.0 mg of free glutaraldehyde release for 
the 5, 10, and 20% glutaraldehyde solutions, respectively.  The adhesive strength only 
increased by a factor of 1.6 in this range.   
 
The above results can be better understood by analyzing the release profile of free 
glutaraldehyde shown in Figure 7.6.  A sustained release of unreacted glutaraldehyde 
from the gel network occurred for 48 hours.  It is apparent that a large portion of the 
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glutaraldehyde diffused out of the network unreacted, and only a small portion of the 
glutaraldehyde is contributing to the crosslinking of the PEI and the adhesion to the 
tissue.  
 
Ideally, a much smaller portion of the glutaraldehyde should be released from the 
network, though the target amount will be a balance between the desired adhesive 
strength and minimization of large scale tissue damage.  A higher concentration of PEI 
inside the gel is one way to minimize the long term release of glutaraldehyde.  This 
would increase the likelihood of the amine-aldehyde reaction, so it could also potentially 
increase the crosslink density of the network, lower the water content and increase the 
stiffness.  Employing more dilute solutions of glutaraldehyde and a slower injection rate 
could also minimize the long term release of glutaraldehyde.  
 
Slivka et al. 330 conjectures that the crosslinker molecular weight should be at least 100 
Da, otherwise diffusion into the environment surrounding the disc would occur too easily.  
Using a high molecular weight dialdehyde, such as PEG dialdehyde, would slow the 
diffusion of the molecules through the network, also making reaction more likely.  
Perhaps the best option in terms of minimizing the diffusion of aldehydes into the tissue 
would be to immobilize the aldehyde groups on the surface of the implanted material 328.  
This could be achieved by conjugating an aldehyde group to one end of a PEG chain that 
possesses a methacrylate group on the other end.  The methacrylate group can be reacted 
in the presence of NIPAAm monomer to form a copolymer 366. 
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7.4 Conclusions 
 
In these studies, an injectable, bioadhesive hydrogel system was developed which has the 
potential to serve as a synthetic replacement for the nucleus pulposus of the intervertebral 
disc or as an annulus closure material.  Gel samples were formed at 37ºC from aqueous 
solutions at room temperature composed of 15 wt% PNIPAAm-PEG (4600 g/mol) and 
4.25 wt% PEI (Mn=60,000 g/mol).  1H NMR results indicated the successful physical 
incorporation of PEI into the PNIPAAm-PEG network by blending, though 10.3±4.2 % 
of the PEI that was dissolved in the room temperature solution was released from the 
network immediately upon gelation.  This value increases with decreasing PEI molecular 
weight.  The covalent crosslinking between the amine functionalities on the PEI and the 
aldehyde functionalities on the glutaraldehyde was verified using FTIR difference 
spectroscopy.  Mechanical characterization of these blends showed a significant increase 
in compressive modulus following glutaraldehyde injection, also an indication that 
crosslinking occurred.  Post-injection of the glutaraldehyde, all of the gels attained a 
modulus value of at least 50 kPa at 15% strain, indicating their potential for restoring the 
compressive intervertebral disc stiffness as a total nucleus replacement 171.  Varying the 
amount of glutaraldehyde injected into the gels at 40 cc/hr did not have an appreciable 
effect on the water content or mechanical stiffness of the gels.  
 
The bioadhesive force studies show a significant increase in the mean maximum force to 
the break the adhesive bond between the PNIPAAm-PEG and PNIPAAm-PEG/PEI gels 
and the porcine skin when 5, 10, or 20 wt% glutaraldehyde was injected into the gel core.  
The bioadhesive strength of the gels injected with 10 and 20 wt% glutaraldehyde was 
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significantly higher than that of the gels injected with 5 wt% glutaraldehyde (p<0.05).  
The results from this study indicate that the reactivity between amines and aldehyde 
functionalities can be exploited in order to impart bioadhesive properties to PNIPAAm-
PEG/PEI copolymers.   
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Table 7.1 The mean maximum force and work of adhesion required to detach the PNIPAAm-PEG 
and PNIPAAm-PEG/PEI gels from the biological substrates. 
 
Mean Maximum Force of 
Detachment (kPa) Work of Adhesion (kPa) 
5% glutaraldehyde 0.7±0.3 1.5±0.7 
10% glutaraldehyde 0.6±0.1 1.6±.08 
20% glutaraldehyde 1.4±0.0 1.7±1.1 
PNIPAAm-PEG/PEI 2.5±0.2 0.1±0.1 
PNIPAAm-PEG 2.2±0.1 0.0±0.0 
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Figure 7.1 The 1H NMR spectrum for PNIPAAm-PEG/PEI (Mn=60,000 g/mol) blend in deuterium 
oxide at 25ºC. 
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Figure 7.2 The chemical stability of PNIPAAm-PEG/PEI (Mn=10,000) and PNIPAAm-PEG/PEI 
(60,000 g/mol) blends. 
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Figure 7.3 The FTIR spectra for a dry (A) PNIPAAm-PEG/PEI gel, (B) glutaraldehyde/PEI mixture, 
(C) PNIPAAm-PEG/PEI  gel injected with glutaraldehyde. 
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Figure 7.4 FTIR difference spectroscopy for the analysis of PNIPAAm-PEG/PEI crosslinked gels. 
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Figure 7.5 Release profile of free glutaraldehyde from the PNIPAAm-PEG/PEI network. 
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Figure 7.6 The water content over a 30 day immersion in PBS for PNIPAAm-PEG/PEI blends with 
and without glutaraldehyde injection.   
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Figure 7.7 The compressive modulus of PNIPAAm-PEG/PEI gels at 15% strain with and without 
glutaraldehyde crosslinking at 7 days immersion in PBS. 
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Figure 7.8 Typical stress strain curves for the in vitro bioadhesive force studies. 
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Chapter 8 - CONCLUSIONS AND FUTURE 
RECOMMENDATIONS 
 
8.1 Conclusions 
 
The long term objective of this project was to develop an in situ forming nucleus 
pulposus replacement, which upon implantation, could prevent or postpone the annular 
degeneration process by restoring the healthy biomechanics of the intervertebral disc.  A 
class of PNIPAAm-PEG branched copolymers was characterized.  From this class, a 
material candidate which exhibited suitable, stable material properties over long term 
immersion in vitro was further optimized to minimize water loss upon gelation, therefore 
remaining space-filling in vivo.  Bioadhesive properties were then imparted to the 
hydrogel system, increasing its potential for use as a total nucleus replacement or tissue 
adhesive in discs with annular degeneration. 
 
First, the successful polymerization of NIPAAm was shown with FTIR.  This result was 
verified with 1H NMR.  In addition, 1H NMR was used to verify the covalent 
incorporation of PEG along the polymer backbone and quantify the molar ratio of 
NIPAAm monomer units to PEG blocks in each of the copolymers.  A family of 
copolymers was created by varying the PEG block molecular weight between 1000 and 
10,000 g/mol.  For each PEG block molecular weight, a high and low PEG content 
copolymer was synthesized by keeping the molar ratio of NIPAAm monomer units to 
PEG blocks at either 700:1 or 1600:1.   
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All of the copolymers had LCSTs in the range necessary for injectability and exhibited 
satisfactory mass retention over 90 days immersion in vitro.  PNIPAAm-PEG (4600 
g/mol) and PNIPAAm-PEG (8000 g/mol) had significantly higher water content than the 
PNIPAAm homopolymer, with the latter having the highest water content of all the 
copolymers.  After 7 days immersion in vitro, the high PEG content PNIPAAm-PEG 
(1000, 2000, and 4600 g/mol) and the low PEG content PNIPAAm-PEG (1000 and 2000 
g/mol) met the stiffness value of 50 kPa, indicating potential for the restoration of 
intervertebral disc stiffness. After 60 days in vitro, all of the copolymers met this value of 
stiffness. The branched copolymers showed improved elasticity over the PNIPAAm 
homopolymer, but PNIPAAm-PEG (4600) and PNIPAAm-PEG (8000 g/mol) had the 
highest relaxation time constants, indicating maximum elasticity.  Because of its high 
water content and suitable mechanical properties, the high PEG content PNIPAAm-PEG 
(4600 g/mol) was further assessed as a material candidate for nucleus pulposus 
replacement.  
 
The osmotic swelling studies revealed that while osmotic pressure influenced the rate of 
PNIPAAm-PEG (4600 g/mol) gel dehydration, the equilibrium water content was not 
dependent on osmotic pressure of the immersion media in the range tested.  Furthermore, 
equilibrium water content of the gels is not appreciably affected by the concentration of 
the polymer solution from which they were formed. Significant implant water loss due to 
de-swelling can be prevented by equilibrating 15 wt% polymer solutions in a 37 ºC 
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environment.  Upon cooling to room temperature, the polymers will form uniform, more 
concentrated solutions which should show minimal water loss when gelled again. 
 
In the last portion of this project, the hydrogel system was made bioadhesive.  Gel 
samples were formed at 37ºC from aqueous solutions composed of 15 wt% PNIPAAm-
PEG (4600 g/mol) and 4.25 wt% PEI (Mn=60,000 g/mol).  1H NMR results indicated the 
successful physical incorporation of PEI into the PNIPAAm-PEG network by blending.  
The chemical stability of the blended network decreased with decreasing PEI molecular 
weight.  The covalent crosslinking between the amine functionalities on the PEI and the 
aldehyde functionalities on the glutaraldehyde was verified using FTIR difference 
spectroscopy and can be described by Schiff’s base chemistry.  The swelling 
characterization revealed that PNIPAAm-PEG/PEI blends exhibit significantly better 
water retention than PNIPAAm-PEG alone (p<0.05) in PBS.  Mechanical 
characterization of these blends showed significant increases in compressive modulus 
following  the injection of 5, 10, or 20 wt% glutaraldehyde.  Post-injection of the 
glutaraldehyde, all of the gels attained a modulus value of at least 50 kPa at 15% strain, 
indicating their potential for restoring the compressive intervertebral disc stiffness as a 
total nucleus replacement.  Varying the concentration of glutaraldehyde injected into the 
gels at 40 cc/hr did not have an appreciable effect on the water content or mechanical 
stiffness of the gels.  The results from the bioadhesive force study indicate that the 
reactivity between amines and aldehyde functionalities can be exploited in order to 
impart bioadhesive properties to PNIPAAm-PEG/PEI copolymer blends.  A significant 
increase (p<0.05) was observed in the mean maximum force to break the adhesive bond 
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between the PNIPAAm-PEG and PNIPAAm-PEG/PEI gels and the porcine skin when 5, 
10, or 20 wt% glutaraldehyde was injected into the gel core.  The bioadhesive strength of 
the gels injected with 10 and 20 wt% glutaraldehyde was significantly higher than that of 
the gels injected with 5 wt% glutaraldehyde (p<0.05).   
 
8.2 Recommendations for Future Work 
 
More in-depth mechanical and biomechanical studies on the PNIPAAm-PEG (4600 
g/mol) base formulation and PNIPAAm-PEG/PEI adhesive formulation are warranted.  
Joshi et al. 350 evaluated solid polymer hydrogels formed from blends of poly(vinyl 
alcohol) and poly(vinyl pyrrolidone) for nucleus replacement.  The hydrogels were 
loaded dynamically at 10 million cycles for compression fatigue.  Fatigue testing has also 
been performed on a number of other material candidates being investigated for nucleus 
pulposus replacement 175,163,182.  Joshi et al. 350 also implanted the hydrogels in cadaveric 
specimens to evaluate the compressive behavior of the implanted discs.  The authors also 
recommended testing the implant under complex loading conditions.   
 
With the addition of PEI to the network, the swelling behavior of the copolymers in PBS 
improved dramatically.  The swelling behavior of PEI containing gels should also be 
evaluated within a range of physiologically pertinent osmotic pressures.  Furthermore, the 
need for thermal cycling to minimize water loss upon gelation needs to be re-evaluated.  
It is likely that the presence of PEI will increase the swelling capacity of the network 
such that minimal volume loss upon gelation will be achieved with more dilute polymer 
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solutions at room temperature.  The chemical stability of the blends post-glutaraldehyde 
injection should also be characterized over long term immersion in vitro and under 
repetitive loading conditions.   
 
A target adhesive strength needs to be established for the injectable, bioadhesive 
hydrogel system.  In order to do so, gels of varying adhesive capacities (determined by in 
vitro bioadhesive force studies)  should be implanted into the discs of cadaveric 
specimens, and subjected to static, cyclic, bending, and torsional loading to seek signs of 
implant migration or expulsion. An understanding can be gained about the minimum 
bioadhesive strength that is suitable for the application.  In addition, if the material were 
also used as an adhesive for the repair of annular defects, mechanical tests are warranted 
to determine if the requisite mechanical properties differ from that of a nucleus 
replacement. 
 
The work in the current studies has led to valuable insight into the parameters that can be 
varied in order to modify the properties of the material.  Slight increases in adhesive 
strength were seen with increasing free glutaraldehyde release into the porcine tissue.  
The release of free glutaraldehyde from the network can likely be tailored by using varied 
injection flow rates, glutaraldehyde solution volumes, or glutaraldehyde solution 
concentrations.  It is also recommended that other dialdehyde molecules such as PEG 
dialdehyde be studied.  Larger crosslinkers would likely diffuse through the network 
slower, making them more likely to react, and decreasing their release into the 
surrounding medium.  If the release profile indicates a prolonged dialdehyde release, 
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adhesion tests should be performed at time points following extended contact between the 
material and tissue.  To eliminate diffusion of aldehydes into the tissues all together, 
aldehyde groups can be immobilized on the surface of the implanted material 328.  This 
could be achieved by conjugating an aldehyde group to one end of a PEG chain that 
possesses a methacrylate group on the other end.  The methacrylate group can be reacted 
in the presence of NIPAAm monomer to form a copolymer 366. 
 
It is also proposed that blending PNIPAAm-PEG with lower molecular weight PEI will 
increase the adhesive capacity of the material.  The loss of chemical stability of the gel 
network, probably due to a lower frequency of molecular entanglements, causes a thick 
coating of PEI to form on the surface of newly formed gels which can enhance adhesion 
to the tissue.  Therefore, the adhesive capacity of blends composed of PEI (Mn=10,000 
and 800 g/mol) should be investigated.  The blend needs to be chemically stable enough, 
however, to retain enough PEI in the network for uniform crosslinking to occur following 
glutaraldehyde injection.  
 
It is likely that the adhesive capacity of the gels will have to be balanced with the 
cytotoxic effects of PEI 280,283,290,291,357 and glutaraldehyde 318,325,327,328,358.  Therefore, 
histological studies will be warranted to determine the in vivo inflammatory response to 
the system.  The inflammatory response to the optimized system should be minor and 
small in duration.  It is also recommended that the use of less cytotoxic crosslinkers, such 
as genipin 325, be evaluated.  Genipin is a naturally occurring compound, derived from 
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fruits of Gardenia jasminoides Ellis 367.  Genipin crosslinks molecules containing 
primary amines 368.   
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